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Abstract
Plasma membrane proteins are ideal therapeutic targets, being both easily accessible and
involved in mediating numerous cellular processes. However, the development of therapeutic
agents targeting these proteins has been hindered by the difficulties associated with their
identification and characterisation. Transcriptomic approaches are unreliable and previous
proteomic efforts have failed to sufficiently enrich for plasma membrane (PM) proteins or
were not quantitative. Plasma membrane profiling (PMP) is a novel proteomic technique that
overcomes previous limitations and enables the identification and quantification of hundreds
to thousands of PM proteins across multiple samples. We have adopted this technique to
characterise the whole cell surface proteome in myeloma and to identify a novel antibody-
drug conjugate (ADC) target.
Eight primary samples and ten human myeloma cell lines were profiled by mass spec-
trometry using PMP. A total of 2,077 proteins were identified with high confidence across all
samples of which at least 1,319 were PM proteins. This represents a substantial improve-
ment over other reported datasets, both in terms of total PM proteins identified and in the
number of primary samples quantitated. This dataset was validated by repeat profiling and
by comparing the relative PMP expression values against flow cytometry expression for six
different antigens. To identify a novel antibody-drug conjugate target, proteins were ranked
according to a combination of a) presence of a targetable extracellular domain b) high and
ubiquitous on-tumour expression and c) low off-tumour expression. High-ranking candidates
were screened for internalisation by flow cytometry and microscopy.
One target, SEMA4A, which was rapidly internalised and exhibited restricted healthy
tissue expression, was taken forward to test for in vitro killing activity. An anti-SEMA4A
ADC induced cell death exclusively in high SEMA4A-expressing cell lines in vitro and
demonstrated potent activity in an in vivo xenograft model of myeloma. We also observed
that the knock-down of SEMA4A using RNA-interference causes a competitive disadvantage,
suggesting that target-downregulation would not be a viable mechanism of tumour escape.
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1.1 Overview of Myeloma
Multiple Myeloma (MM) is a haematological malignancy characterised by the clonal expan-
sion of plasma cells within the bone marrow. It is the second most common blood cancer,
accounting for around 13% [1], and is considered to be a disease strongly associated with
age, with 43% of new cases between 2009 and 2011 occurring in people aged 75 or over [2].
Despite recent therapeutic advancements, myeloma is still typically considered ‘treatable’
rather than ’curable’ and it is expected that the majority of patients will relapse, with a 10
year survival rate of just 33% [2].
1.2 Pathophysiology
Preceding myeloma is a premalignant stage known as monoclonal gammopathy of unde-
termined significance (MGUS) [3]. This is an asymptomatic disorder characterised by the
presence of an abnormal immunoglobulin in an individual’s serum or urine that originates
from the proliferation of a single plasma cell clone. These patients, however, do not exhibit
myeloma or other lymphoproliferative disorder symptoms [4]. Although nearly all MM
cases are precceded by MGUS [3], not every MGUS will transform into myeloma. The
rate of progression is considered to be on average 0.5-1% per year [5], although this is
difficult to conclusively determine as MGUS is asymptomatic and therefore usually identified
incidentally. Furthermore, some risk factors may be associated with an enhanced rate of
progression [6]. Between MGUS and MM is an intermediate, more advanced stage known
as smouldering multiple myeloma (SMM). This is still considered an asymptomatic stage
but exhibits an increased rate of progression of around 10% [7]. Although there is limited
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evidence to suggest that early therapeutic intervention at this stage may convey a survival
benefit, MGUS and SMM are typically untreated and instead patients are monitored for
disease progression [8].
Active myeloma is diagnosed by the presence of >10% clonal bone marrow plasma cells;
biopsy-proven bony or extramedullary plasmacytoma; and any one or more of the classic
CRAB features and myeloma defining events (MDEs). CRAB features define the presence
of end-organ damage that includes hyperCalcaemia, Renal failure, Anaemia and lytic Bone
lesions. Renal dysfunction is commonly the result of the accumulation and precipitation of
light and heavy chains within the kidney, forming urinary casts that obstruct the renal tubules.
Renal failure may also be attributed to immunoglobulin light chain amyloidosis and light
chain deposition disease, as well as the direct toxicity of light chains on the renal tubules
and glomeruli [9]. Renal insufficiency may in turn contribute to the elevated serum calcium
levels. Tumour-mediated bone destruction also contributes to the observed hypercalaemia
[10]. Approximately 80 to 90% of myeloma patients suffer from osteolytic lesions that may
result in bone fractures, pain, spinal cord compression as well as reduced mobility [11]. The
observed anaemia may be attributed to several factors, including the crowding of the bone
marrow and functional impairment of the megakaryocyte-erythroid progenitors [12]. MDEs
include >60% clonal bone marrow plasma cells, a serum involved/uninvolved free light chain
ratio of >100 or >1 focal lesion as detected by MRI [13].
Typically, patients will initially respond well to the first line of treatment following diag-
nosis and enter a period of remission. Inevitably patients relapse, and although they may still
respond to additional lines of therapy, these periods of remission shorten and individuals may
become refractory to all currently available treatments, known as relapsed/refractory multiple
myeloma (RRMM) [14]. A subset of patients may subsequently develop extramedullary
disease (in which the malignant plasma cells escape the bone marrow [15]) or plasma cell
leukaemia (PCL) (a rare and aggressive gammopathy defined by the presence of >20% of
plasma cells in the peripheral blood) [16][17].
1.3 Molecular classification
Multiple myeloma is a highly heterogenous disease both at the genetic level, involving nu-
merous translocations (both primary and secondary), chromosomal abnormalities, mutations
and epigenetic modifications, but also at the clonal level. These genetic events can be broadly
grouped into primary and secondary events. Primary genetic events are observed in MGUS
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and are present in all clones within the tumour. These primary events are believed to play
a role in establishment of the disease but not in driving malignant progression. Secondary
genetic events, on the other hand, are considered to be the drivers of myeloma. Unlike
primary events which are present in the premalignant stage of MM, secondary events may
occur at any stage of the disease but typically occur more frequently in SMM and MM or are
associated with more advanced end-stage disease. Multiple secondary genetic events may
also occur within the same patient and can overlap within subclones [18]. The presence of
particular genetic events can heavily influence a patient’s prognosis, with some abnormalities
associated with rapid disease progression or a poor response to commonly used therapeutics
(table 1.1), although these are not the sole predictors of disease outcome and other criteria,
including age and co-morbidities, are also taken into account.




Median OS 2-3 years Median OS 4-5 years Median OS 8-10 years
Table 1.1 The mSMART risk stratification system for active MM. OS=Overall survival.
Adapted from [19]
Clonally, the myeloma tumour is also heterogenous. Recent studies have shown the
presence of multiple independent, yet related, subclones within a tumour that carry different
mutations. It was initially considered that myeloma tumours typically contain at least 5 such
subpopulations, however, recent evidence suggests that is most likely an under-estimation
[20][21]. Interestingly, it has recently been shown that this heterogenous subclonal structure
is present at all stages of disease, including MGUS [21]. As myeloma progresses, the genetic
complexity of the disease correspondingly increases, with an increase in the number of
non-synonymous mutations [21] . Contrary to the traditional dogma of a linear evolution,
events typically appear to accumulate in a branching evolutionary pattern known as the
Darwinian model (figure 1.1). The multiple steps involved in myeloma tumorigenesis result
in a changing pattern of subclones and increasing complexity as the disease progresses [22].
External selection pressures, such as treatment, also contribute to these changing patterns of
dominant subclones with previously minor drug-resistant subclones increasing in prominence
at relapse [23][24][25][26]. It is therefore of great importance to take into account this
clonal heterogeneity when identifying novel therapeutics to prevent the selection of a highly
resistant subclone.
4 Introduction
Fig. 1.1 A branching evolution of myeloma. Myeloma consists of a highly heterogenous
subclonal structure. Over the course of the disease the predominant clone changes as minor
subclones emerge or acquire further mutations that allow them to survive treatment. Differ-
ent subclones are represented by individual colours. MGUS=monoclonal gammopathy of
undetermined significance, SMM=smouldering multiple myeloma, MM=multiple myeloma,
EMD=extramedullary disease, PCL=plasma cell leukaemia. Adapted from [23][27].
Primary cytogenetic events are broadly classed into two groups: hyperdiploid or non-
hyperdiploid. Those with a hyperdiploid karyotype (approximately 40% of MM cases [13])
exhibit numerous trisomies of odd-numbered chromosomes (typically 3, 5, 7, 9, 11, 15, 19
and 21) with a low prevalence of immunoglobulin heavy chain (IgH) translocations (14q32)
[28]. Hyperdiploid myeloma is associated with a better prognosis, and some trisomies
may in fact overcome the poor prognosis conferred by other cytogenetic abnormalities [29].
Non-hyperdiploid myeloma includes hypodiploid, pseudodiploid and near-tetraploid; and is
associated with a high prevalence of IgH or immunoglobulin light chain translocations (κ ,
2p12 or λ , 22q11) and a less favourable outcome [28]. The five most recurrent translocations
are: t(11;14), t(4;14), t(14;16), t(14;20) and t(6;14).
1.3.1 Primary translocations
One of the most common translocations is the t(11;14)(q13;32) (15% of MM cases [28]),
resulting in the aberrant over-expression of Cyclin D1 (CCND1) [30]. Cyclin D1 belongs to
the cyclin protein family and is a critical for progression through the G1 phase of the cell
cycle. As such, amplification of CCND1 is associated with a release from the normal control
of cell cycle and subsequently, enhanced cellular proliferation [31]. Aside from cell cycle
dysregulation, amplification of CCND1 may also contribute to drug resistance in MM [32].
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Qiang et al observed an increased expression of multidrug resistant protein 1 (MDR1), a
cell membrane protein involved in the efflux of toxins (including therapeutics), in cyclin
D1-positive patients [33]. Although this translocation is considered to be a ’standard-risk’
cytogenetic, several studies have noted an increased prevalence in PCL [17]. Cyclin D3 is
also targeted by an IgH translocation (t(6;14)), although this is a much rarer event [28].
Interestingly, dysregulation of cell cycle progression appears to be a common event in
myeloma regardless of translocation status and cyclin D has been reported as dysregulated
in up to two-thirds of myeloma and highly expressed in many of the remaining samples
[34][30]. This includes the two cyclin D translocation subgroups but also the c-Maf subgroup
which is associated with cyclin D2 (CCND2) dysregulation [35]. Further CCND1 biallelic
dysregulation that appeared independent of a subgroup was observed in 40% of tumours. [34].
Another recurrent translocation (15% of cases [28]) is the t(4;14) translocation which
promotes the amplification of fibroblast growth factor receptor 3 (FGFR3) and multiple
myeloma SET domain (MMSET) [36]. Unlike the other translocations identified in MM, two
genes with oncogenic potential are dysregulated. However, it appears that MMSET is the
primary target and is overexpressed in all t(4;14) tumours, whilst FGFR3 is only expressed
in approximately 70% of cases [36].
MMSET is a member of the nuclear receptor binding SET domain (NSD) family and
possesses lysine methyltransferase activity. Amplification of MMSET is primarily associ-
ated with an increase in H3K36 dimethylation (associated with active transcription) and a
corresponding decrease in H3K27 trimethylation (a repressive mark) [37]. These alterations
result in the dysregulation of numerous signalling pathways including those regulating cell
cycle, apoptosis and adhesion [37][38]. MMSET overexpression is also associated with an
enhanced DNA damage repair. Shah et al observed that a loss of MMSET in a t(4;14) human
myeloma cell line (HMCL) (KMS11) reduced the efficiency of both non-homologous end
joining (NHEJ) and homologous recombination (HR), two pathways involved in the repair
of double strand breaks, with a corresponding enhanced sensitivity to the alkylating agent
melphalan [39]. Pei et al similarly reported a link between MMSET and DSB repair [40].
This is in concordance with the poor prognosis that was initially associated with the t(4;14)
subgroup prior to the introduction of novel agents when alkylating agents were the mainstay
of myeloma therapy. These patients, despite an initial response to melphalan, experienced
shorter periods of remission and quicker disease progression [41].
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Although FGFR3 may not be the direct target of the t(4;14) translocation, it may still play
a key role in oncogenic transformation. FGFR3 belongs to the FGFR family of tyrosine kinase
receptors that are involved in the activation of multiple pathways implicated in tumorigenesis
including the Mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase/protein
kinase B (PI3K/Akt) and Janus kinase/signal transducers and activators of transcription
(JAK/STAT) signalling pathways [42]. Because of the role that FGFR3 has in these critical
pathways, it is clear how genetic alterations of the receptor may have oncogenic potential
and the activation or over-expression of FGFR3 has been observed to promote proliferation
and cell survival as well as drug resistance [43][44][45]. Activating mutations, although
rare, have also been reported for FGFR3 and are acquired during tumour progression [44][46].
The two remaining common translocations (t(14;16) and t(14;20)) dysregulate the tran-
scription factors c-Maf and MafB respectively and are commonly grouped together as the
MAF subgroup. Aberrant Maf signalling dysregulates a number of genes, including CCND2,
C-C motif chemokine receptor type 1 (CCR1), NUAK Family Kinase 1 (NUAK1) and
integrin subunit beta 7 (ITGB7), increasing the rate of cell cycle progression and adhesion
of myeloma cells to the stroma [35][41]. This subgroup is relatively rare (5-7% [28]), but
is considered a ‘high-risk’ genetic event (table 1.1) and unlike the t(4;14) subgroup, the
introduction of bortezomib has had minimal impact on the prognosis of these patients [41].
This may be in part explained by the observed stabilisation of c-Maf and MafB by borte-
zomib, with t(14;20) cells exhibiting a reduced sensitivity to both bortezomib and carfilzomib
[41][33]. Similar to cyclin D, c-Maf is also frequently dysregulated in cells independent of
a t(14;16) translocation, with high c-Maf expression reported in up to 50% of patients and
HMCLs [35]
1.3.2 Secondary mutations
As previously mentioned, secondary genetic events are considered to drive the disease and
are typically associated with later disease. These genetic events may include additional
translocations (secondary translocations), chromosomal deletions/amplifications and muta-
tions in key signalling pathways.
Chromosome 13 abnormalities, either monosomy or deletion of the long arm (del(13q)),
are a common occurrence in MM and have been reported to occur in up to half of MM
tumours. These events are one of the earliest secondary events occurring in myeloma
progression, occurring as early as MGUS (albeit rarely) [47] and are indicative of an adverse
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prognosis for both progression-free survival (PFS) and overall survival (OS) [13]. The exact
target of the chromosome 13 deletion is currently unknown and there are several proposed
targets. One such target is the retinoblastoma protein (RB1), a tumour suppressor protein
involved in cell cycle regulation. The RB1 gene locus is at 13q14, a commonly deleted
region [48].
Chromosome 1 is also frequently dysregulated in MM, with either deletions of the short
arm (del(1p)) or amplifications of the long arm (dup(1q)). The prevalence of chromosome
1 aberrations highly depends on the disease stage and 1q gains are typically infrequent in
MGUS (0 to 29%). The incidence of chromosome 1 aberrations increases with disease
advancement, with a reported prevalence of 45 and 44% in SMM and newly diagnosed MM
respectively and up to 72% in RRMM [49][50]. This high frequency and association with
later disease suggests it plays a key role in driving disease progression. Subsequently, dup(1q)
is associated with a poor event-free survival (EFS) and OS [50]. Similar to chromosome
13, the exact targets of these deletions/amplifications are unknown, although 1p has been re-
ported to contain several putative tumour suppressor genes [51]. For dup(1q), two minimally
amplified regions have been identified: 1q21-23 and 1q31-q42 [52] and several potentially
oncogenic targets have been identified. This includes mucin 1 (MUC-1, 1q22) which acti-
vates MYC to dysregulate target genes including CCND2 [53], PDZ domain containing 1
(PDZK1, 1q21.1) involved in chemotherapeutic resistance [54], cyclin-dependent kinases
regulatory subunit 1 (CKS1B, 1q21.1) involved in cell cycle progression [52], myeloid cell
leukaemia sequence 1 protein (MCL-1, 1q21.2) that may be essential for HMCL survival
and is associated with relapse and shorter OS [55], as well as B cell lymphoma 9 (BCL9,
1q21.2), and FC receptor like 4 (FCRL4, 1q23.1) [52].
A third common chromosomal abnormality is del(17p), which is considered to target
the well known tumour suppressor p53 (17p13.1). p53 is also found mutated in myeloma,
although this is a rare event [56] and is typically associated with del(17p) [57]. DNA damage
stabilises p53, inducing cell cycle arrest, senescence, and if not resolved, apoptosis [58].
These mutations/deletions are likely to be key mediators in disease progression, occurring
rarely in MGUS and newly diagnosed MM (13%) but up to almost half of patients with
advanced-stage disease [49][59][60].
The Ras GTPase family members, KRAS and NRAS, are also targeted by activating
mutations in myeloma (≈30% of patients [61]). These GTPases mediate a number of sig-
nalling pathways, regulating many cellular processes including cell cycle progression, growth,
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migration, apoptosis and senescence [62]. Although NRAS mutations appear to be more
frequent, 17-18% and 6-7% for N- and K- Ras respectively in newly diagnosed MM, only
KRAS mutations are associated with a poorer prognosis and shorter OS [63].
The nuclear factor kappa B (NFkappaB) family of transcription factors are also implicated
in myeloma tumorigenesis. Genetic events targeting this signalling pathway have been
reported in 9-17% of patients, supporting myeloma survival, proliferation and drug-resistance
[64]. Other genetic events in myeloma include activating mutations in the PI3K/Akt signalling
pathway [65] and chromosomal rearrangements of the transcription factor MYC [66].
1.4 The Plasma Cell
1.4.1 Immunoglobulins
Myeloma is a cancer of the plasma cell (PC), which are terminally-differentiated B cells that
secrete high titres of a specific immunoglobulin (Ig). These secreted glycoproteins are one of
the major components of humoral immunity, specifically recognising and binding to antigens
to target pathogens for destruction. Immunoglobulins are comprised of two identical heavy
chains and two identical light chains (κ or λ ). Each heavy chain consists of one variable
domain and three to four constant domains, depending on the class of antibody. Meanwhile,
light chains are comprised of just one of each. The light chain variable region is encoded
by two gene segments: variable (VL) and joining (JL). A third gene segment (diversity
(DH)) encodes the heavy chain variable region, alongside VH and JH . The antigen binding
domain of the antibody is known as the Fab region (antibody-binding fragment) whilst the
Fc (fragment, crystallisable) domain is the primary recognition site for effector functions and
other antibodies (figure 1.2) [67].
Diversity within the antibody repertoire is achieved by three processes that occur during
B cell and plasma cell development. The first process is the combinatorial rearrangement
of the V, D and J gene segments to create a functional variable domain. Encoded within
the germline are multiple copies of each of the three gene segments. The selection of just
one segment for each type (V, D or J) and the different combinations of these provide initial
diversity [69] . Further diversification is provided by the introduction of point mutations to
the variable region by somatic hypermutation (SHM). Finally, antibodies may undergo class
switch recombination (CSR), in which the constant regions of the heavy chain are switched,
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Fig. 1.2 Structure of immunoglobulin. Immunoglobulins are comprised of two heavy and
two light chains that contain variable (VL or VH) and constant (CL or CH) domains. Target
antigen is bound by the Fab domain and effector functions mediated by the FC domain.
Adapted from [68]
changing the isotype of the antibody from IgM to another class [70]. There are five major
isotypes of Ig in humans: IgA, IgD, IgE, IgG and IgM. IgA and IgG are further divided into
two (IgA1 and IgA2) and four (IgG1, IgG2, IgG3, IgG4) subclasses respectively. These Igs
may be either surface bound or secreted [67].
Secreted Igs recognise and bind foreign antigens on the surface of pathogens, coating
the microbe or virus in a process termed opsonisation. These opsonised pathogens can then
be recognised and destroyed by the immune system by either activation of the complement
system (Complement-mediated cytotoxicity (CDC)) or immune effector cells. Binding of
the complement component 1q (C1q) to the Fc domain of the bound antibody triggers the
activation of the complement cascade, resulting in the formation of the membrane attack
complex (MAC) on the target cell. This disrupts the cell surface membrane and triggers cell
death by osmotic lysis [71]. Alternatively, the Fc domain of the antibody may be recognised
by one of the many Fc receptors expressed on immune effector cells, triggering antibody-
dependent cellular phagocytosis (ADCP) by phagocytic cells which engulf the target cell, or
triggering antibody-dependent cell-mediated cytotoxicity (ADCC) [71]. ADCC is primarily
mediated by natural killer (NK) cells, but may also be mediated by monocytes, macrophages,
neutrophils, eosinophils and a subset of T cells. Receptor binding triggers cell death by one
of the three mechanisms: 1) release of granules containing perforin which forms large pores
in the target cell membrane and enables the diffusion of the cytotoxic granzyme into the
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cytoplasm, 2) upregulation of Fas ligand on the effector cell to induce apoptosis in the target
cell or 3) the release of reactive oxygen species (ROS) [72][73].
1.4.2 Plasma cell development
Antibody-secreting cells (ASCs) are derived from the mutipotent, bone-marrow residing
haematopoietic stem cells (HSCs). HSCs differentiate through several rounds of progenitor
cells before emerging as a progenitor B (pro-B) cell that is committed to the B lineage.
Maturation of the pro-B cell continues in the bone marrow initially before cells migrate to the
spleen. As these cells differentiate into mature B cells, they undergo V(D)J recombination
to produce monomeric IgM. This is expressed on the cell surface in association with two
polypeptide chains (Cluster of differentiation (CD)79a and CD79b) to form a functional B
cell receptor (BCR). During this process auto-reactive B cells, cells expressing BCRs with
an affinity for self-antigens, or cells without a functional BCR are removed [74]. As B cells
mature, they also begin expressing IgD at the cell surface, in a process mediated by alternative
RNA splicing [75]. The majority of these naïve IgM+IgD+ mature B cells are recirculating
B cells known as follicular B cells. This subset of B cells localise to the blood and the B cell
follicles of secondary lymphoid organs. B cells may also reside within the marginal zone
(MZ) of the spleen and are therefore termed marginal zone B cells [74]. A third population,
B-1 cells, represent a very small but unique subclass of B cells that contribute to the innate
immune system. B-1 cells are responsible for the constitutive, spontaneous secretion of
resting Ig (natural Ig) that occurs in the absence of infection [76].
B cell activation occurs in response to the BCR recognition of their cognate antigen.
Antigens are broadly grouped into two types, those that require T cell assistance for full B
cell activation (T-dependent (TD)) and those that don’t (T-independent (TI)). Follicular B
cells appear to be more specialised for responding to TD antigens whilst MZ B cells are
specialised towards TI antigens, although these roles aren’t strictly enforced and both subsets
may respond to either antigen [77][78]. Activation of both subsets takes place in the lymph
nodes and spleen. These secondary lymphoid organs are comprised of several distinct regions
that are selectively enriched for particular immune cell subsets [79].
Follicular B cells and follicular dendritic cells (FDCs) reside within areas known as
follicles. Adjacent to these follicles are T-cell rich zones (the paracortex or periarteriolar
lymphoid sheath in the lymph node or spleen respectively). Also surrounding the follicles
are macrophages. The spleen also contains an additional structure, the marginal zone, which
contains both MZ B cells and macrophages [79]. This zone separates the follicle-containing
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white pulp from the red pulp of the spleen.
The temporal and spatial control of B and T lymphocytes within these regions is tightly
regulated by chemokines. Circulating naïve follicular B cells are recruited to the C-X-C
motif chemokine ligand 13 (CXCL13)-expressing follicle by high CXC Chemokine Receptor
5 (CXCR5) expression [80][81], where they may encounter their cognate antigen. Activation
of B cells following BCR recognition of the antigen results in the upregulation of C-C motif
chemokine receptor type 7 (CCR7) expression, promoting the migration of the activated B
cells to the border of the B and T cell zones along a C-C motif chemokine ligand 19 (CCL19)
and CCL21 gradient. Concurrently, naïve CD4+ T cells are primed by dendritic cells (DCs)
in the T cell zone and differentiate into follicular helper T cells (TF H). TF H cells upregulate
CXCR5, downregulate CCR7 and P-selectin glycoprotein ligand 1 (PSGL1) and migrate
towards the B cell follicle border [82]. At the border, activated B cells present the antigen on
their cell surface, which is recognised by the TFH cells and triggers TFH CD40L expression,
providing a co-stimulatory signal necessary for B cell survival [83].
Activated B cells may then either migrate to extrafollicular sites and differentiate into PCs
or return to the follicle with the TF H cells and undergo an intense period of proliferation to
form germinal centres. The plasma cells generated via the extrafollicular route are short-lived
and secrete typically low-affinity antibody, providing an early and rapid response to infection
[79]. Similarly to follicular B cells, MZ B cells may participate in either the extra-follicular
or GC response [84]. In the GC, B cells undergo affinity maturation, a process in which the
activated GC B cells undergo multiple rounds of proliferation and SHM to enhance antibody
affinity and avidity. This process is regulated by both the TF H cells and FDCs, promoting the
survival of high-affinity B cells as well as CSR [83][82]. Eventually, B cells enter one of two
fates: memory B cell or plasma cell. Memory B cells contribute to immunological memory;
repeat exposure to their cognate antigen triggers reactivation and the rapid differentiation
into plasma cells [85]. Emerging PCs leave the follicles of the secondary lymphoid organs
and migrate to specialised plasma cell niches, predominantly the bone marrow. Bone marrow
homing is primarily regulated by the upregulation of CXCR4. CXCR4 expression promotes
the migration of these cells towards the CXCL12-high bone marrow [86]. Within the bone
marrow, plasma cells may remain short-lived or fully mature into quiescent and sessile long-
lived plasma cells, providing Ig-mediated immunity for several decades [87][88]. Outside of
the bone marrow, PCs also reside in other sites including the gut and tonsils [89][90] or may
also be recruited to sites of inflammation, associated with an upregulation of CXCR3 [91].
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The mechanism regulating the decision to become a short-lived or long-lived plasma cell
is unclear. One proposed theory is the competition model, proposing that the total number of
PC niches is finite and that short-lived PCs entering the bone marrow must compete with
older, resident long-lived PCs to survive [92]. This model has been supported by the finding
that antigen-specific PCs in the bone marrow were replaced following subsequent repeat
immunisations with different antigens [93]. It is unlikely, however, that this model fully
explains the decision to become a long-lived plasma cell. Even in vitro, where survival factors
are not limited, only a fraction of the population become long-lived PCs [94]. Cell-intrinsic
factors may also be involved, such as a failure to cope with the metabolic stress caused by
secreting high Ig titres or a failure to express key survival receptors [95].
1.5 The bone marrow niche
Regardless of its role in determining the longevity of plasma cells, it is axiomatic that the bone
marrow niche plays a vital role in PC survival. This is evidenced by the rapid apoptosis of
plasma cells following their removal from the bone marrow [96][97]. The bone marrow niche
is a complex microenvironment and consists of both a cellular and non-cellular compartment.
During oncogenic transformation, myeloma cells alter this microenvironment to further
promote malignant cell survival, proliferation, metastasis and resistance to therapeutics.
1.5.1 Non-cellular compartment
Interleukin-6
Interleukin-6 (IL-6) is one of the quintessential plasma cell growth factors. Initially identified
in 1983 as human B-cell differentiation factor (BCDF) from T cell-conditioned media, IL-6
was shown to promote the terminal differentiation of B cells into ASCs [98]. The use of an
IL-6 targeted antibody subsequently demonstrated that the cytokine was also a potent growth
factor for myeloma cells and is secreted in both a paracrine and autocrine manner [99][100].
Additionally, IL-6 acts as an anti-apoptotic factor [101], protecting MM cells against both
spontaneous and dexamethasone-induced apoptosis [102]. Although the addition of IL-6
can support PC survival in vitro in the absence of stromal cells or growth factors, it does not
appear to be essential in vivo as IL-6 deficient mice do not appear to exhibit any impairments
in long-term immunity [97].
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Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) expression is dysregulated in a number of malig-
nancies, supporting the growing tumour by mediating the formation of new blood vessels to
provide additional oxygen and nutrients [103]. Equally in myeloma, angiogenesis is dysregu-
lated, with elevated VEGF production compared to normal donors [104] and a corresponding
increase in the bone marrow microvessel density that is associated with a poor prognosis
[105]. Both bone marrow stromal cells (BMSCs) and PCs secrete VEGF, which supports
normal and malignant PCs in an indirect manner by enhancing BMSC IL-6 production
[104][106]. VEGF also directly targets the myeloma cells, promoting proliferation, growth,
migration and survival through the upregulation of anti-apoptotic factors, including MCL-1
[107]. Aside from VEGF, BMSCs also secrete other pro-angiogenic factors such as basic
fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), osteopontin (OPN) and
metalloproteinase-1 (MMP-1) [103].
Transforming growth factor beta 1
Transforming growth factor beta 1 (TGF-β1), an anti-inflammatory cytokine secreted by
both BMSCs and PCs, is also upregulated in myeloma. Although it does not directly
stimulate myeloma cell growth or survival, it promotes the transcription and secretion of
IL-6 and VEGF from BMSCs [108][104]. As an anti-inflamamtory cytokine, TGF-β1 also
contributes to the immunosuppressive microenvironment of MM, preventing the expression
of pro-inflammatory cytokines, suppressing immune effector functions and promoting the
expansion and suppressive function of CD4+CD25+ regulatory T cells (Tregs) [109][110].
Additionally, TGF-β1 contributes to disease progression and exacerbates bone disease
through the suppression of osteoblast differentiation [111].
B-cell activating factor/A proliferation-inducing ligand
Other key growth factors that make up the non-cellular compartment of the bone marrow
niche include B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL).
BAFF and APRIL are both members of the tumour necrosis factor (TNF) superfamily and
share significant homology. Although both growth factors bind B-cell maturation antigen
(BCMA) and Transmembrane Activator and CAML Interactor (TACI), only BAFF binds
BAFF receptor (BAFF-R) [112].
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The role of these ligands in supporting the survival of long-term BMPCs was demon-
strated by O’Connor et al. Blockade of both APRIL and BAFF in vivo using TACI-Ig (the
extracellular domain of TACI fused to the Fc portion of human IgG1) caused a decay in
the long—lived ASC population [113]. Of the three receptors, the pro-survival functions of
APRIL/BAFF appear to be predominantly mediated by BCMA. Unlike TACI and BAFF-R,
which are heterogeneously expressed across MM patient samples, BCMA is both highly
and consistently expressed on myeloma cells [112]. Furthermore, although BCMA -/- mice
exhibit normal early humoral immunity, with no significant defects in peripheral B cell
frequencies or GC formation, they exhibit a substantial reduction in the number of long-lived
ASCs [113]. Interestingly, the antagonism of both APRIL and BAFF in vivo is required to
replicate this BM PC impairment, suggesting a certain level of redundancy [114]. Consider-
ing their role in supporting long-lived PCs, it is unsurprising that the serum levels of both
growth factors are elevated in myeloma compared to normal donors [112].
Both BAFF and APRIL are secreted by a multitude of cell types, primarily cells of the
myeloid lineage [115][116]. APRIL and BAFF promote cell cycle progression [117][118],
and protect MM cells from lenalidomide and dexamethasone induced cell death through
the upregulation of anti-apoptotic proteins such as B-cell lymphoma 2 (BCL-2) and MCL-1
[112][118]. Similarly to TGF-β , APRIL contributes to an immunosuppressive environment,
inducing Programmed death-ligand 1 (PD-L1) expression on MM cells and supporting Treg
survival and function [119][120].
1.5.2 Interactions between myeloma cells and the bone marrow cellu-
lar compartment
Bone marrow stromal cells
As already mentioned, the CXCR4/CXCL12 axis is involved in the homing of PCs from the
secondary lymphoid organs to the bone marrow. One of the primary sources of CXCL12
are the bone marrow stromal cells, which reside in close contact with the plasma cells [121].
BMSCs are considered one of the most vital constituents of the bone marrow niche and
the addition of stromal cells to in vitro plasma cell cultures prevents the rapid decline in
viability, maintaining a subpopulation of these cells for several weeks [96]. These CXCL12-
expressing cells also highly express vascular cell adhesion molecule 1 (VCAM1), an Ig-like
adhesion molecule that binds to the integrin very late antigen-4 (VLA-4) [121]. VLA-4 is
highly expressed on PCs [122] and the interactions between these two cell surface proteins
1.5 The bone marrow niche 15
mediates the adhesion of PCs to BMSCs [123]. Aside from PC homing, BMSCs are also
a rich source of cytokines and growth factors which promote both normal and malignant
PC survival, including IL-6, VEGF and TGF-β [100][108][106]. The co-culture of BMSCs
and plasma cells promotes the expression of these growth factors [96][106], but also, in the
context of myeloma, conveys therapeutic resistance (cell adhesion mediated drug resistance
(CAM-DR)). Several groups have demonstrated that the co-culture of BMSCs and HMCLs
significantly reduces the cytotoxic effects of several commonly used therapeutic agents.
This resistance is mediated in predominantly a contact-dependent manner, although soluble
factors also appear to play a role [124][125][126]. The use of RNA-mediated interference
(RNAi) or blocking antibodies has revealed that loss of integrins, such as VLA-4, reverses
this resistance. Interestingly, drug resistance was not conferred by stromal cell-conditioned
media alone, suggesting that this resistance is mediated by a dynamic interaction between
the two cell types [124].
In addition to the BMSCs, other cell types within the bone marrow niche contribute to
plasma cell survival, including eosinophils, monocytes/macrophages, dendritic cells and
Tregs. These immune cells are frequently dysregulated in myeloma, both numerically and
functionally, promoting a pro-tumour immunosuppresive environment.
Eosinophils
Eosinophils are known producers of crucial plasma cell growth factors such as IL-6, APRIL
and TNFα [127][128] and are found in close proximity to plasma cells [129][130]. The
number of eosinophils in direct contact with plasma cells substantially increases with dis-
ease progression, from approximately 20% in normal donors and MGUS, to 60-70% in
MM [129], suggesting that these cells are a key component of the bone marrow niche. In
concordance with this, eosinophils have been shown to support plasma cells ex vivo in a
contact-independent manner [127][129]. Although clear components of the plasma cell niche,
the essentiality of these cells has been challenging to determine.
An initial report by Chu et al suggested that eosinophils were a crucial component of
the bone marrow niche [127]. Using ∆dblGATA-1.BALC/c mice, which exhibit a complete
deficiency in eosinophils [131], Chu et al reported significantly lower bone marrow plasma
cell frequencies, both at steady state and following antigen challenge. Bone marrow PCs were
initially restored following the adoptive transfer of eosinophils from an immunocompetent
mouse. In immunocompetent mice, eosinophil ablation using anti-Siglec-F (a cell surface
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protein found predominantly on eosinophils) antibodies resulted in the rapid and substantial
loss of established bone marrow plasma cells, suggesting that eosinophils were vital in
maintaining bone marrow plasma cells. Wong et al [132] also reported that the growth of
MOPC315.BM, an aggressive murine myeloma cell line, was delayed in both ∆dblGATA-
1.BALB/c mice and in wild-type (WT) BALB/c mice following eosinophil depletion using
an anti-IL-5 antibody. Wong et al also noted that only the bone marrow niche was affected,
with no observable differences in MOPC315.BM frequencies in peripheral tissues between
WT and ∆dblGATA-1 mice. A third group also reported a reduction in bone marrow PC
frequencies following IL-5-antibody-mediated eosinophil depletion, that corresponded with
a decrease in total IL-6 and APRIL mRNA [133].
Meanwhile, several other groups have tried and failed to demonstrate the essentiality of
eosinophils in maintaining bone marrow PCs. Cravedi et al [134] reported no discernible
differences in the frequencies of bone marrow PCs in ∆dblGATA1.BALB/c mice compared
with WT mice at steady state, although there was a slight difference following alloantigen
stimulation that coincided with an increase in splenic PCs. In sharp contrast, on the C57BL/6
(B6) background, they observed a reduced frequency of both bone marrow and splenic
plasma cells in naïve ∆dblGATA1.B6 mice but any differences were lost following immuni-
sation. Two other groups have also reported no discernible differences in bone marrow PC
frequencies in either the ∆dblGATA1 mice or in immunocompetent mice following Siglec-F
antibody mediated depletion[135][136]. Interestingly, Haberland et al initially reported a
significant increase in the numbers of PCs within the bone marrow and spleen in the in
∆dblGATA-1 mice compared to WT controls. However, this was completely abrogated
following backcrossing of these mice to the WT mice, suggesting that the discrepancies
in these studies may have been caused by a difference in the microbiota as a result of the
different facilities used to source the mice [136].
It therefore appears unlikely that eosinophils are absolutely vital for plasma cell survival
in the bone marrow niche. There are many cellular sources of IL-6 and APRIL within the bone
marrow, and it is possible there is a certain level of redundancy/flexibility. In line with this,
∆dblGATA-1 mice have been reported to also exhibit numerical and functional aberrations in
basophils [137]. Basophils also express the IL-5 receptor [138] whilst a subset of monocytes
have been reported to express Siglec-F [139] and so the reported loss in bone marrow plasma
cells may have been a result of the disruption of several cellular components. Although not
essential, eosinophils may still contribute to malignant plasma cell survival and promote
an immunosuppressive environment through the production of anti-inflammatory cytokines
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such as IL-4, IL-10, IL-13 and TGF-β [128]. Eosinophils also contribute to immunological
tolerance by upregulating CD80 expression. CD80 binds cytotoxic T-lymphocyte–associated
antigen 4 (CTLA-4) and PD-L1, two checkpoint molecules that provide inhibitory signals to
immune effector cells [140]. In addition to immune evasion, eosinophils contribute to bone
destruction through the secretion of IL-3 and monocyte chemoattractant protein-1 (MCP-1)
[129].
Macrophages
Macrophages (Mφ ) have long been known to promote the survival and progression of a
number of solid and haematological malignancies. These tumour-associated macrophages
(TAM) closely resemble M2-macrophages (alternatively activated),which are involved in
regulating the immune response, secreting high levels of anti-inflammatory cytokines [141].
These macrophages are therefore pro-tumorigenic, promoting immune evasion and are con-
cordantly elevated in those patients with active MM (27%) compared to non-active myeloma,
MGUS and control patients (9.2, 7.4 and 1.5% respectively) [142].
Mφ infiltration is driven by a number of chemoattractants in the bone marrow, including
MCP-1, also known as CCL2), CXCL12, macrophage inflammatory protein 1-alpha (MIP-
1α , or CCL3), MIP-1β , CCL14 and CXCL10, that are upregulated in MM[143][141][144].
These chemoattractants stimulate macrophage proliferation, and in conjunction with other
factors such as IL-10, promote the polarisation towards a TAM phenotype [141]. As well
as promoting the infiltration and polarisation of Mφs, myeloma cells also upregulate cell
surface expression of CD47 [145]. CD47 is an integrin-associated receptor and acts as an
immune checkpoint, binding signal regulatory protein alpha (SIRPα) on macrophages to
inhibit phagocytosis of the tumour cell [145]. In a similar fashion, CD47 prevents cell killing
by CD8+ T cells and attenuates the cross-priming abilities of dendritic cells, encouraging
immunological tolerance [146].
In the bone marrow these polarised macrophages secrete high levels of IL-6 [147], IL-10
[141] and VEGF [145], promoting plasma cell survival, immune-suppression and neovas-
culogenesis respectively. TAMs also stimulate BMSCs, promoting an increased production
of IL-6, CXCL10 and Regulated on Activation, Normal T cell Expressed and Secreted
(RANTES, CCL5) [148]. It has been reported that patients with elevated levels of CXCL10
exhibit reduced CXCR3 expression on both peripheral blood and bone marrow natural killer
cells. Disruption of the CXCR3 axis is associated with an impaired recruitment of NK cells
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into the tumour and CXCL10 expression may therefore be another mechanism promoting
immune evasion in myeloma [149]. Mφ also protect myeloma cells from both spontaneous
and drug-induced apoptosis in a contact-dependent manner [150].
Megakaryocytes
Megakaryocytes are also producers of IL-6 and APRIL and, similar to eosinophils and
stromal cells, are in close contact with plasma cells within the bone marrow, constituting
part of the niche [151][132]. Megakaryocyte-deficient mice (c-Mpl-/-) exhibit significantly
reduced numbers of plasma cells within the bone marrow compared to WT mice, although
interestingly, there were no differences in the frequencies of splenic plasma cells. Following
immunisation, there were initially fewer numbers of antigen-specific bone marrow PCs in the
c-Mpl-/- mice compared to controls. At a later timepoint, however, the frequencies of antigen-
specific PCs between the two groups was comparable [151]. As previously mentioned, it
may be that there is a level of redundancy within the bone marrow. In concordance with this,
Wong et al [132] observed that megakaryocytes supported myeloma growth and survival
only under suboptimal conditions.
Dendritic cells
Dendritic cells are crucial in mediating the anti-tumour response of the immune system.
Tumour cells by themselves are poor antigen presenting cells and generally require assis-
tance for the efficient stimulation of immune effector cells, such as cytotoxic CD8+ T cells.
Dendritic cells, conversely, efficiently process and present captured tumour antigens on
both MHC-class II and on MHC-class I (cross-presentation) to stimulate helper (CD4+)
and cytotoxic T cells [152]. Because of their crucial role in priming the immune system,
these cells are frequently targeted by the tumour. These dysregulated cells promote both
the survival and immune-evasion of plasma cells and concordantly are identified in close
proximity to these cells in vivo and at increased frequencies in the bone marrow of patients
[153].
These dendritic cells predominantly protect malignant PCs from CD8+ T cell-mediated
lysis. This protection appears to be mediated in a contact dependent manner, and in vitro
is abrogated following the addition of a CD28-blocking antibody [154]. Plasma cell CD28
expression is upregulated in myeloma and the incidence of CD28+ cells increases with
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disease progression, from 19% at MGUS to 93% at extramedullary disease. Serial studies
in individual patients confirmed the emergence of CD28+ myeloma cells with tumoural
expansion and therapeutic failure [155]. The binding of malignant plasma cells to DCs
via CD28 stimulates dendritic cell IL-6 production as well as indoleamine 2,3 dioxygenase
(IDO) [156]. IDO is a key anti-inflammatory factor and induces both T cell anergy, inhibiting
cell activation and promoting apoptosis, and promotes the differentiation of naïve CD4+ T
cells to the immunoregulatory Tregs [156][157] Additionally, DCs fail to upregulate the co-
stimulatory molecule CD80 following activation, potentially as a result of the high levels of
TGF-β and IL-10 within the myeloma bone marrow [158]. In addition to protecting MM cells
from immune-mediated destruction, CD28-mediated interactions with DCs promote plasma
cell survival and proliferation as well as a reduced sensitivity to drug-induced apoptosis [153].
T cells
Cytotoxic T lymphocytes are one of the predominant immune effectors capable of specifically
recognising tumour-associated antigens to induce target cell lysis, either through the release
of cytotoxic granules or through Fas-mediated apoptosis. Full T cell activation requires
two independent signals. The first is the recognition of the MHC-bound antigen, shortly
followed by the binding of T cell CD28 receptor to either CD80 or CD86 ligands. CD28
also binds to inhibitory ligands, known as checkpoint molecules, that regulate the immune
homeostasis by dampening effector cell activation [159]. As with other immune effectors,
these cells are dysregulated in cancer and cytotoxic T cell anergy is a frequent observation
in MM patients. These cells exhibit a low proliferative response to stimuli and a reduced
cytotoxic response as a result of impaired degranulation and cytokine secretion [160]. These
anergic T cells upregulate the inhibitory checkpoint molecules, including PD-L1, CTLA-4,
CD244 and CD160 and concurrently downregulate CD28 [160]. This is in part mediated by
the upregulation of IDO within the tumour and impaired DC priming, but also through the
upregulation of CD86 and PD-1 on MM plasma cells [161][162].
Regulatory T cell populations are also skewed in myeloma. These CD25+FOXP3+ T
cells are crucial in maintaining homeostasis and self tolerance through the suppression of
immune responses. This suppression is mediated through the production of IL-10 and TGF-β ,
limiting the expansion and functions of effector cells, inhibiting pro-inflammatory cytokine
production and polarising DCs towards a tolerogenic phenotype [163]. The frequency of
these cells in the bone marrow increases with disease stage and infiltration correlates with
a lower OS [164]. Tregs may also directly promote myeloma cell survival and have been
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shown to contribute to normal BM PC homeostasis. The loss of these cells following sys-
temic infection correlated with a depletion in the frequencies of long lived plasma cells, that
was rescued following administration of an IL-2-anti-IL-2 antibody complex that restored
Treg frequencies [165]. The high levels of anti-inflammatory cytokines within the bone
marrow promote Treg differentiation and enhance their recruitment into and activity in the
tumour [163][120]. This includes the already mentioned IDO, IL-10 and TGF-β but also
includes APRIL. Compared with CD25- conventional T cells, Tregs express significantly
higher levels of the APRIL receptor, TACI. The APRIL/TACI axis inhibits caspase 3/7 and
capase 8-mediated apoptosis, enhances Treg IL-10 and TGF-β secretion and potentiates Treg
mediated suppresion of conventional T cells [120].
Other T lymphocyte subsets elevated in myeloma include Th22 and Th17 cells. The
differentiation of Th17 cells from naïve CD4+ T cells is promoted in myeloma by the high
tumour levels of TGF-β and IL-6. These cells are the predominant producers of IL-17
which exerts immuno-regulatory effects, triggering BMSC RANKL upregulation to stimulate
osteoclastogenesis and thereby promoting bone re-absorption, and enhances myeloma cell
proliferation and adhesion to BMSCs [166][167]. Th22 cells are also derived from CD4+
T helper cells, primarily involved in the secretion of IL-22. The frequency of these cells
increases with disease progression and IL-22 has been shown to enhance myeloma cell
growth and prevent drug-induced apoptosis [168].
Natural Killer cells
Natural killer cells are one of the most important regulators of cell-mediated cytotoxicity,
involved in the killing of both cancerous and infected cells. NK cells, similarly to CD8+ T
cells, exert their cytotoxic effects on target cells through the release of perforin/granzyme
and the direct ligation of Fas-receptors. However, in contrast to T cells, NK cells are not
regulated by antigen specificity. Instead they are capable of selectively targeting malignant
cells without prior priming, regulated by a careful balance of inhibitory and activating re-
ceptors. Reactivity against ’self’ is prevented by the inhibitory receptors which bind MHC
Class I molecules and prevent NK cells from targeting normal, healthy cells [169]. ’Loss of
self’, the downregulation of MHC-Class I through cellular stress such as viral infection or
malignancy, removes this inhibition and triggers cell lysis.
As myeloma progresses, NK cells generally exhibit a reduction in cytotoxic potential
[170] as a result of the immunosuppressive environment within the tumour. The anti-
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inflammatory cytokines already mentioned, including TGF-β and IL-10, trigger the downreg-
ulation of activating receptors on the NK cell surface, such as Natural Cytotoxicity Triggering
Receptor 3 (NCR3), Natural killer group 2 member D (NKG2D), CD224, DNAX Accessory
Molecule-1 (DNAM1) and CD335 [171][172]. Conversely, inhibitory receptors, such as
PD-1, are upregulated [173]. These cytokines also suppress the secretion and activity of
pro-inflammatory cytokines, such as IL-12 and IL-18, that activate NK cells [174], and
IL-6 has been implicated in downregulating NK cell expression of perforin and granzyme
B [175]. Myeloma cells are also capable of adapting their surface molecule expression to
evade immune detection. Typically tumours are considered to downregulate MHC Class
I molecules in order to prevent Cytotoxic T cell mediated killing, concurrently rendering
these more susceptible to NK cell attack. Conversely, myeloma cells upregulate MHC Class
I expression with disease progression that correlates with an increased resistance to NK
cell-mediated cytotoxicity [176], suggesting that escape from NK cells is important in the
pathogenesis of myeloma. Other mechanisms of immune escape involve the upregulation of
inhibitory ligands, such as PD-1 ligand (PD-L1) [162], and the increased shedding of MHC
Class I chain-related protein A (MICA) [177].
Regulatory B cells
A small subset of B cells, termed regulatory B cells (Bregs), also contribute to the im-
munosuppresive tumour microenvironment. The frequencies of these IL-10 secreting
CD19+CD24hiCD38hi cells are significantly higher in newly diagnosed MM compared
to patients on maintenance therapy [178] and have been implicated in attenuating NK cell
ADCC against myeloma cells using elotuzumab [179].
Osteoclasts
One of the common features of disease in myeloma are bone lesions, with more than 80% of
MM patients developing osteolytic bone disease [11]. Under normal physiologic states bone
marrow remodelling is controlled by three cell types: osteoblasts, osteocytes and osteoclasts.
Osteoclasts (OC) are involved in mediating bone resporption, whilst osteoblasts (OB) are
involved in bone production [180]. In MM the OC-OB balance is disrupted and osteoclas-
togenesis is promoted whilst osteoblastogenesis is inhibited. As already mentioned, the
VLA-4:VCAM-1 interaction between the stroma and myeloma cells promotes the secretion
of several cytokines and growth factors. This includes the pro-osteoclastogenic cytokine
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RANKL and IL-6. Simultaneously, these cells promote the downregulation of osteoprotegerin
(OPG), an inhibitor of OC activation and differentiation. Other pro-osteoclastogenic cy-
tokines and chemokines upregulated in MM include IL-1, IL-3, TNF-α , CCL3 and MIP-1α
[181][182]. Malignant plasma cells also upregulate Dickkopf-1 (DKK1) that further blocks
osteoblast differentiation [183], and CD47 expression. CD47 has already been described as
preventing immune-recognition of the tumour, but may also contribute to the observed oste-
olytic disease. CD47-mediated contact promoted the differentiation of immature dendritic
cells into multinucleated giant cells that bore functional and phenotypical similarity to OC.
Blockade of CD47 inhibited osteoclastogenesis and reduced bone marrow resorption [184].
1.6 The treatment of myeloma
The last two decades have seen a dramatic improvement in the estimated OS for myeloma
patients. This can almost certainly be attributed to the introduction of autologous stem cell
transplantation (ASCT) and novel agents such as the proteasome inhibitors (PIs) and im-
munomodulatory drugs (IMiDs). These have become the mainstay of treatment for myeloma,
typically used as multi-drug regimes in combination with chemotherapeutics and/or corticos-
teroids, although the specific combination depends on disease stage, health and fitness, prior
lines of therapy and country legislation.
1.6.1 Autologous stem cell transplantation
For eligible patients (<65-75 years of age and generally low-risk), high dose myeloablative
therapy followed by a stem cell transplant (HDT-ASCT) to repopulate the bone marrow is
typically the first line of therapy. Initial reports demonstrated that HDT-ASCT dramatically
improved both event-free and overall survival (OS) compared to conventional chemothera-
peutics and as a result has been the mainstay of therapy for over 20 years [185].
1.6.2 Proteasome inhibitors
The ubiquitin-proteasome system plays an essential role in cellular protein homeostasis.
Short-lived regulatory proteins such as those involved in cell cycle, DNA repair and apopto-
sis, as well as damaged and misfolded proteins, are targeted for degradation by ubiquitination.
Polyubiquitinylated proteins are then detected and cleaved by the proteasome, a multi-
catalytic enzyme complex [186]. Proteasome inhibitors disrupt this system and prevent the
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degradation of proteins, which accumulate within the cell and trigger endoplasmic reticulum
(ER) stress. The cells response to this proteotoxic stress is the unfolded protein response
(UPR) in an attempt to re-establish ER homeostasis. Failure of the UPR triggers cell cycle
arrest and apoptosis [187]. Cancer cells, and especially plasma cells which secrete high titres
of Ig, have an elevated proteasome activity and are considerably more sensitive to proteasome
inhibition than other cell types [188].
Bortezomib (Velcade) reversibly inhibits the chymotrypsin-like activity of the proteasome
[187] and was the first in class PI, receiving FDA accelerated approval in 2003 as a result of
the dramatic survival benefits observed. In a phase III clinical trial comparing bortezomib
and dexamethasone, survival at a median follow up of 22 months showed a 6-month survival
benefit. This benefit was so considerable, that the high-dose dexamethasone arm was halted
and all patients were offered bortezomib instead [189]. Although bortezomib has considered
to be one of the predominant therapeutics behind the dramatic improvements in myeloma
OS in the last two decades and despite initial encouraging results in individuals, resistance
does occur and patients eventually relapse. This resistance is mediated through several
mechanisms, including the upregulation of the proteasome subunits and mutations in the
bortezomib binding domain [190]. This has led to the advent of second generation PIs, such
as carfilzomib, ixazomib and oprozomib and encouragingly, thus far there appears to be no
cross-resistance between bortezomib and carfilzomib [191]. However, because the of the
ubiquitous expression of the proteasome, there is the likelihood of numerous off-tumour
effects. As a result, recent research has focussed on upstream targets, such as NEDD8.
NEDD8 is a ubiquitin like protein, regulating the activity of the cullin RING (really interest-
ing new gene) ubiquitin E3 ligase family. However, thus far, these avenues have been fairly
disappointing, and the leading therapeutic, MLN4924 (pevonedistat), has shown limited ef-
ficacy in RRMM patients in a phase I trial, achieving stable disease (SD) as a best result [192].
1.6.3 Immunomodulators
Despite its notoriety, thalidomide has emerged as an efficacious treatment for myeloma and
has become one of the mainstays of therapy. Thalidomide was initially trialled in cancer more
than 50 years ago in 1965 due to its anti-angiogenic properties [193]. Despite demonstrating
anti-myeloma activity, thalidomide did not receive any further interest until the late 90’s
when Singhal et al trialled the immunomodulator (IMiD) in five patients with end-stage
myeloma as a ‘compassionate-use protocol’. One patient with more than 95% plasma cell
infiltration in the bone marrow, who had been unresponsive to multiple salvage therapies,
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showed a dramatic improvement with nearly a complete remission within three months [194].
As a result thalidomide was introduced for the treatment of myeloma in combination with
dexamethasone in 2006. A close derivative, lenalidomide, was also approved in the same
year for RRMM and in 2015 for newly diagnosed patients. The exact mechanism of these
agents was largely unknown for several years and they were broadly classified as IMiDs
for their immunomodulatory actions, enhancing the activation and cytolytic activity of NK
cells [195] and inhibiting Tregs [196]. These anti-angiogenic agents potentiate the effect
of dexamethasone and PIs and have also been shown to induce apoptosis and G1 arrest in
myeloma cells, as well as downregulating IL-6 and TNFα production [197].
More recently, the primary target of thalidomide and its derivatives has been reported as
cereblon (CRBN) [198]. CRBN is a component of the cullin-4 RING E3 ubiquitin ligase,
part of the ubiquitin-proteasome pathway. Thalidomide/lenalidomide prevent the ubiquitina-
tion and degradation of CRBN, stabilising this ubiquitin ligase complex and promoting the
ubiquitination and degradation of target proteins, including IKAROS Family Zinc Finger 1
and 3 (IKZF1 and IKZF3) [198]. These two proteins are implicated in a number of cellular
processes, particularly in B and T cells, including IKZF3 in the repression of IL-2 expression
[199]. Similarly to PIs, patients eventually become resistant to IMiDs, although there appears
to be no cross-resistance between these two agents or a third IMiD (pomalidomide) [200].
Having recently identified the predominant target of IMiD activity, novel immunomodulators
are arising that specifically target CRBN. This includes CC-122 (avadomide), CC-220 and
CC-90009, all of which are in early-stage clinical trials for haematological malignancies.
Thus far, CC-122 has shown early promise as a single-agent, with an overall response rate
(ORR) of 18% in heavily pre-treated RRMM [201].
1.6.4 Chemotherapeutics
The alkylating agent, melphalan, has been used as a front-line therapy in combination with
steroids for myeloma for over 50 years [202]. Melphalan induces multiple DNA cross-
links, disrupting DNA replication and transcription and promoting cell death by apoptosis
[203]. Despite its efficacy, melphalan is associated with severe side effects including bone
marrow suppression and the long-term risk of leukaemia/myelodysplastic syndrome [204].
Cyclophosphamide is another routinely used alkylating agent that has demonstrated equiv-
alent efficacy to melphalan, but a much more favourable toxicity profile [205]. Despite
initial efficacy, patients inevitable acquire resistance to the agents through the upregulation
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of drug-efflux pumps and the overexpression of DNA repair proteins [206].
To combat resistance, more alkylators are being introduced for the treatment of myeloma,
including bendamustine which was recently licenced in Europe for MM. This is an old
alkylating agent that exerts its anti-cancer effect in a unique mechanism compared to other
alkylators [207]. Bendamustine has been shown to be both efficacious and well tolerated in
both RRMM and newly diagnosed MM in combination with bortezomib and prednisolone
or with thalidomide and dexamethasone [208][209]. Importantly, this chemotherapeutic has
demonstrated efficacy in disease that is refractory to other alkylating agents [207]. Other
agents include tinostamustine, a fusion molecule of bendamustine and the histone deacetylase
inhibitor vorinostat [210]; evofosfamide, a hypoxia-activated prodrug of the DNA alkylator
bromo-isophosphoramide mustard [211]; and melflufen, a melphalan pro-drug [212].
1.6.5 Corticosteroids
Alongside melphalan, corticosteroids such as dexamethasone have long been used in the
treatment of myeloma. These synthetic steroid hormones induce cell cycle arrest and apopto-
sis following binding to and activation of the glucocorticoid receptors [213]. In conjunction
with their cytotoxic effects, corticosteroids can also be used to decrease the severity of
chemotherapeutic side effects, acting as antiemetics and relieving high fever, weakness and
fatigue [214]. However, resistance does occur as cells both downregulate the number of
receptors and express alternative isoforms [215].
1.7 Novel therapeutic agents
Despite the recent improvements in myeloma OS, the disease is still considered incurable
and the majority of patients are expected to eventually relapse and become refractory to
all available lines of therapy. These patients have an incredibly poor outlook. In a study
undertaken by the International Myeloma Working Group (IMWG) to assess the outcome
of these patients, they reported that individuals who had become refractory to bortezomib
and at least one IMiD had a median event-free survival and overall survival of just five and
nine months respectively [216]. This study highlights the need for therapeutics with new
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mechanisms of action to treat these refractory populations.
1.7.1 Small molecule inhibitors
Numerous small molecule inhibitors have been trialled in myeloma in an attempt to increase
specificity of treatment and to reduce the side-effects commonly associated with traditional
chemotherapeutics. This includes histone deacetylase (HDAC) inhibitors, such as panobinos-
tat, the first and only HDAC inhibitor to receive FDA approval for the treatment of RRMM.
These inhibitors inhibit the formation of aggresomes (aggregation of misfolded proteins),
triggering the UPR, and increase the acetylation of proteins involved in numerous onco-
genic pathways [217]. Other small molecule inhibitors currently under investigation include
afuresertib, an inhibitor of the serine/threonine protein kinase Akt; ABT-199 (Venclexta),
a BCL-2 inhibitor; the BTK inhibitor ibrutinib; CDK inhibitor dinaciclib; kinesin spindle
protein inhibitor filanesib; as well as various other PI3K, MDM2 and kinase inhibitors [218].
1.7.2 Immumnotherapy
Recently, there has been a surge of interest in immunotherapy for the treatment of myeloma.
This covers a broad spectrum of approaches to stimulate or enhance the immune system to
attack the tumour and includes the adoptive transfer of T cells, monoclonal antibodies and
oncolytic viruses. Haematological malignancies are considered to be particularly amenable to
immunotherapy for several reasons. Firstly, as part of the haematopoietic system, these cells
are in constant contact with immune cells and are localised to where adoptively transferred
T cells will naturally home to. Additionally, these cells are routinely subject to immune
regulation and are therefore immunostimulatory by nature. In contrast to solid tumours, these
malignancies are much easier to penetrate, and sampling is relatively easier for assessing
therapeutic efficacy. Finally, the cell surface of many haematopoietic cells has been exten-
sively characterised and there are several well-established antigens to target [219].
CAR T cells
Chimeric antigen receptor (CAR) T cells are genetically engineered T cells. These cells
have been modified to express a tumour antigen-specific receptor that is comprised of a
single-chain variable fragment (similar to an immunoglobulin) linked to an intracellular T
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cell signalling domain. This redirects patient derived T cells against the tumour [220]. These
have shown promising success in a number of haematological malignancies, including acute
lymphoblastic leukaemia (ALL), chronic lymphocytic leukaemia (CLL), diffuse large B-cell
lymphoma (DLBCL) and Non-Hodgkin lymphoma (NHL) [220]; and are being investigated
in myeloma, with more than 35 active registered CAR T cell clinical trials [221]. The
most advanced CAR T cell therapy for myeloma is bb2121, targeting BCMA. bb2121 has
shown early promising activity, with an ORR of 89% in heavily pre-treated patients. These
patients had received a median of 7 prior lines of therapy including a proteasome inhibitor
and an IMiD, involving 29% who were refractory to bortezomib, lenalidomide, carfilzomib,
pomalidomide and daratumumab, demonstrating that these novel CAR T cells can be used to
circumvent current mechanisms of resistance [222].
Oncolytic viruses
Oncolytic viruses are another promising, novel approach for the treatment of myeloma.
These modified viruses specifically infect, replicate in and kill tumour cells. The release of
tumour antigens following target cell death triggers a second response against the tumour,
stimulating the immune system to target the remaining, antigen-expressing tumour cells.
Several clinical trials are currently ongoing, including a phase I/II trial using the Edmonston
strain of measles virus engineered to express the human sodium iodine symporter (MV-NIS).
This virus enters the cells through CD46, a cell surface protein upregulated in MM [223] and
concentrates radioactive iodine within the myeloma cells [224].
Monoclonal antibodies
Amongst the novel immunomodulatory agents, one of the most promising and advanced areas
of development has been in monoclonal antibodies (mAb), with two recent FDA approvals
for their use in myeloma. The use of monoclonal antibodies for the treatment of cancer
is not novel and it has now been more than 20 years since the FDA approval of the first
therapeutic antibody for cancer, rituximab (Rituxan) [225]. Since then, antibody therapy has
revolutionised the treatment for both solid and haematological malignancies, with more than
20 antibodies currently FDA approved [226]. These antibodies have become increasingly
popular as therapeutics for a number of reasons. Firstly, unlike small molecules, they are
highly specific for their target and as a consequence tend to exhibit much fewer side effects.
As a result of this specificity, side effects also tend to be much more predictable, and in
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combination with recombinant manufacturing technology, these antibodies tend to have a
much shorter development time compared to traditional small molecule drugs. Furthermore,
these antibodies are less likely to exhibit drug-drug interactions with other agents and be-
cause of their distinct mechanisms of action, can be used in multi-drug combinations. These
molecules also tend to have long half-lives and can be administered on a less frequent dosing
schedule (typically weekly to start and then fortnightly or even every three weeks) than
conventional chemotherapeutics [226][227][228].
These therapeutic antibodies mediate tumour cell elimination through a variety of mech-
anisms. As already mentioned (section 1.4.1), these antibodies can target a tumour cell
for immune-mediated killing via ADCC, ADCP or CDC. Alternatively, these antibodies
can directly ligate tumour cell surface receptors, triggering apoptosis or inhibiting essential
growth factor signalling cascades or can target immune cell surface receptors, enhancing
their activation or reversing immune-suppression. In addition, antibodies may also be directly
conjugated to cytotoxins as antibody drug conjugates (ADCs) [226].
Daratumumab
Daratumumab is a first in class, fully human IgG1 monoclonal antibody targeting CD38,
a type II membrane glycoprotein. CD38 is a nucleotide-metabolising ectoenzyme and re-
ceptor, involved in mediating migration, bone marrow stromal cell adhesion and signal
transduction; and is expressed on nearly all other lymphoid and myeloid cells, as well as
non-haematopoietic tissue [229]. The high expression of CD38 on myeloma cells, as well as
its receptor function, made CD38 an attractive target for a therapeutic monoclonal antibody
for myeloma.
Daratumumab was initially identified from a panel of 42 CD38-targeted human mAbs
as the only antibody that induced ADCC and CDC in myeloma cell lines, subsequently
demonstrating anti-tumour activity in an in vivo xenograft model [230]. Daratumumab
has since been shown to also mediate myeloma cell death through ADCP [231]. Dara-
tumumab demonstrated encouraging results in early clinical trials and was well-tolerated
with single-agent efficacy in heavily pre-treated RRMM with an ORR of 31% in a com-
bined analysis of the phase I/II GEN501 and phase II SIRIUS study [232]. The addition of
lenalidomide/bortezomib and dexamethasone further enhances daratumumab activity and
this multi-drug combination significantly prolonged progression-free survival (PFS) from
just 7.1 months for bortezomib and dexamethasone alone to 16.7 months (POLLUX trial,
median) [233]. The triplet combination of lenalidomide-dexamethasone and daratumumab
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Fig. 1.3 Mechanism of action for therapeutic monoclonal antibodies. Therapeutic antibodies
can be utilised in cancer in several ways. Antibodies can be targeted directly against the
tumour cell to induce apoptosis, prevent receptor-ligand interactions or deliver toxins directly
to the tumour. Alternatively, mAbs can be used to enhance immune responses against the
tumour cell. ADCC=Antibody dependent cell-mediated cytotoxicity. CDC=Complement
dependent cytotoxicity. ADCP=Antibody dependent cellular phagocytosis. MAC=Membrane
attack complex.
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was approved both by the FDA in 2016 and early this year as a monotherapy by The National
Institute for Health and Care Excellence (NICE), although only as a fourth-line agent for
RRMM patients in England and Wales [234].
Aside from mediating direct myeloma cell cytotoxicity through ADCC/CDC, daratu-
mumab also targets the immunoregulatory compartment within the tumour microenvironment
[178]. As aforementioned, CD38 is highly expressed on numerous leukocytes, including
NK cells, monocytes, B cells and T cells. Both Bregs and Tregs are sensitive to daratu-
mumab. Following treatment, there is a significant reduction in the frequencies of both of
these populations, reversing immune suppression and allowing the expansion and activity
of the pro-inflammatory, anti-tumour immune cell populations. Furthermore, CD38 has
been implicated in the formation of osteoclasts and treatment with daratumumab has been
observed to reduce both the number and activity of these immunosuppresive cells, which
may further contribute to promoting an anti-tumour immune response [235].
The promise of CD38 has led to the advent of other CD38 targeting antibodies: such as
isatuximab. This monoclonal antibody binds a distinct epitope, directly inducing apoptosis
and inhibiting enzyme activity, as well as triggering cell death through ADCC, CDC, and
ADCP [236]. Following on from a promising phase II trial, ORR of 50% as a single agent
[237], isatuximab is currently recruiting for phase III trials (IKEMA (NCT03275285) and
IMROZ (NCT03319667)).
Elotuzumab
Elotuzumab is another first in class, humanised IgG1 antibody that targets Signalling lympho-
cytic activation molecule F7 (SLAMF7, also known as CS1 and CD319), a type I membrane
protein. SLAMF7 was initially identified by an extensive bioinformatic analysis of genes
upregulated in plasma cells compared to normal B cells [238], although it has been subse-
quently shown to be expressed on numerous leukocyte subsets including NK cells, NK-like
T cells, CD8+ T cells, monocytes and dendritic cells [239]. Similar to daratumumab, elo-
tuzumab mediates myeloma cell killing through ADCC and CDC [238]. However, despite
demonstrating a favourable safety profile, elotuzumab does not demonstrate any single agent
activity, with no objective responses achieved in a phase I trial [240]. A follow up phase
I/II trial demonstrated that, despite this, elotuzumab acted synergistically with lenalidomide
and dexamethasone and a phase III trial reported a modest improvement in PFS and OS
(4.1 months for both) with an equivalent safety profile at a three year follow up compared
to lenalidomide-dexamethasone alone in RRMM [241]. Elotuzumab also indirectly medi-
1.7 Novel therapeutic agents 31
ates anti-tumour activity by targeting the SLAMF7-expressing NK cells. Antibody binding
provides a co-stimulatory priming signal, enhancing the activity of these anti-tumour cells
[239]. Currently elotuzumab is FDA approved, and although it is approved for use in Europe,
elotuzumab has not received NICE approval for use in the UK by the NHS [242].
Checkpoint inhibitors
As already eluded to in section 1.5, the immune system is constantly regulated by a carefully
controlled balance of positive and negative signals to maintain immunological homeostasis.
Tumours take advantage of these inhibitory signals to promote immunological tolerance,
upregulating negative co-stimulatory molecules such as PD-L1. These checkpoint molecules
are key inhibitors of immune activation, and therapeutic blockade may have the potential to
reverse the immunosuppressive tumour microenvironment and enhance the anti-tumorigenic
immune response. However, thus far checkpoint inhibitors have proven disappointing in
early clinical trials with limited efficacy as a single agent although they may act in synergy
with immunomodulators such as lenalidomide [243][244].
Antibody drug conjugates (ADCs)
Although naked antibodies that trigger immune-mediated killing have shown encouraging
results, these are heavily reliant on a fully functioning immune system. In myeloma, and
many other cancers, the immune system is frequently dysregulated and myeloma NK cells
have been shown to be much less effective than their normal counterparts at mediating ADCC
by elotuzumab, partly explaining its poor single agent efficacy [245]. As a result, these
antibodies are commonly used in combination with chemotherapeutics to achieve anti-tumour
efficacy, and as a result, systemic toxicities are still a concern [246]. In contrast to naked
antibodies, ADCs do not rely on a fully functioning immune system and instead combine the
specificity and stability of antibody therapeutics with the cytotoxicity of chemotherapeutics
or radioisotopes. These antibodies recognise specific tumour antigens and, following tumour
cell binding, are internalised. Once in the cytoplasm, the linker between the antibody and
toxin is cleaved by various methods, releasing the cytotoxic payload and inducing cell death
[247]. Although ADCs offer several advantages over naked antibodies, their challenging
development has hindered the availability of these antibodies in the clinic. One of the pre-
dominant difficulties faced by these first-generation ADCs included the highly heterogenous
conjugation methods resulting in variable drug:antibody ratios (DAR) [248], with one report
observing a DAR as variable as 0 to 6 in one batch. This DAR is highly critical, too low
and the drug is not potent enough, meanwhile, too high and the ADC may aggregate [249].
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Furthermore, the linkers of these early ADCs were highly unstable, deconjugating in the
plasma and releasing the payload before reaching the tumour [249]. The introduction of
site-specific conjugation techniques and improved linkers in the third- and fourth-generation
ADCs have overcome these hurdles, and the full potential of ADCs is now being realised with
more than 100 ADC clinical trials currently active [221], several of which are for myeloma.
The most advanced and promising ADCs currently under trial in myeloma are lorvo-
tuzumab mertansine, indatuximab ravtansine and GSK2857916. Lorvotuzumab mertansine
is a CD56 (NCAM-1) targeted antibody conjugated to the maytansinoid mertansine (DM1),
that was both well-tolerated and achieved an ORR of 18% as a single agent and 58% with
lenalidomide-dexamethasone in a phase I trial in RRMM [250][251]. Indatuximab ravtansine
is an anti-CD138 antibody conjugated to DM4 that shown encouraging activity, achieving an
ORR of 78% in combination with an immunomodulator and dexamethasone [252][253]. One
of the most promising ADCs thus far is GSK2857916, targeting BCMA. As a single agent,
GSK2857916 demonstrated an ORR of 60% in a phase II study and was recently granted
FDA breakthrough therapy designation for RRMM [254]. Other ADCs currently in or have
recently completed early phase trials includes the anti-CD74 hLL1-DOX (NCT01101594),
another BCMA-directed ADC MEDI2228 (NCT03489525), the anti-CD48 SGN-CD48A
(NCT03379584), a CD46-ADC FOR46 (NCT03379584) and SGN-CD352A (NCT02954796)
against CD352 (SLAMF6) [221], but the results from these trials have not yet been released.
These ADCs have demonstrated proof-of-concept clinical success in myeloma, with
encouraging safety profiles. However, several of these agents have failed to demonstrate
significant single-agent activity. Furthermore, resistance to some naked antibodies, such as
daratumumab, is beginning to emerge [255] and as such there is still an urgent requirement
for the discovery and characterisation of novel antibody targets.
1.8 Plasma membrane profiling
1.8.1 The plasma membrane as a drug target
Membrane proteins play an essential role in nearly all cellular processes, involved in the
transduction of growth, proliferation and survival signals; movement of substances across
the membrane; adhesion; migration; and regulation of the immune system. As such these
proteins are of significant interest as therapeutic targets. This is evidenced by the fact that
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although they only compromise 20-30% of the human proteome, they make up more than
half of all current drug targets [256].
In addition, these molecules are much more accessible for therapeutic modulation com-
pared to intracellular targets, particularly in the case of monoclonal antibodies. These
therapeutic agents are too large to pass through the cell membrane and the majority of them
rely on their effector functions to mediate cell killing, requiring extracellular accessibility to
recruit immune effector cells. As a result, nearly all antibody therapies target extracellular
antigens [257]. Although the cell surface proteome represents a highly attractive therapeutic
target, analysis of these proteins has been considerably difficult.
One common technique is to use gene expression profiling (GEP), relying on mRNA
abundance as a surrogate for protein expression, and has been used with some degree of
success [238]. However, gene expression is regulated by numerous factors, both pre and
post-transcriptionally and as a consequence, the overlap between gene and protein expression
is low [258]. Interestingly this may depend on the function of the gene. For instance, a few
studies have reported that some genes, such as structural genes, have a very high correla-
tion whilst those genes involved in signal transduction and the regulation and development
of biological processes tend to have a very poor correlation between mRNA and protein
abundance [259][260]. Recently, Dytfeld et al attempted to identify differentially-regulated
proteins indicative of a very good partial response or greater to bortezomib and observed
that nearly all of the 166 proteins identified by GEP were different to those identified as
differentially regulated by mass spectrometry [261]. Overall, RNA can be considered a poor
approach for the identification and characterisation of novel plasma membrane protein targets.
Proteomics on the other hand, allows the direct comparison of not only protein ex-
pression between groups but also provides information on protein-protein interactions and
post-translational modifications. As already discussed, several proteins have already been
identified as potential targets for myeloma. The majority of these, including CD38, CD46,
CD48 and CD352 [262][223][263][264], were identified by flow cytometry, either relying
on published literature that suggested a role in other neoplasms or PC differentiation or by
arbitrarily testing panels of newly described antibodies. Not only is this approach highly
restricted by the availability of reliable antibodies and/or prior knowledge but is also highly
limited by the number of proteins that can be analysed at once.
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1.8.2 Plasma membrane proteomics
Mass spectrometry (MS) is a powerful analytical technique capable of quantifying thousands
of proteins in a single run. Peptides are initially ionised and then separated according to
their mass-to-charge ratio (m/z). The resultant protein mass ’fingerprints’ are then used to
identify each protein and the relative abundance of each ion used for quantification [265].
This technique has provided invaluable insight into the myeloma cell proteome but has
traditionally been limited in its detection of membrane proteins due to their relatively low
abundance. As already mentioned, these proteins make up less than a third of the whole
cell proteome and are easily obscured by the vast array of highly expressed intracellular
proteins, resulting in their significant under-representation in whole cell proteome studies
[266]. Pre-fractionation enrichment is therefore vital to reduce the complexity of the sample
and to enable the identification of these low-abundance proteins. A number of methodologies
have been utilised, such as 2-DE (2-dimension electrophoresis) separation, isolation by
physiochemical properties or enrichment by affinity-based approaches.
2-dimension electrophoresis
2-DE has been the traditional approach for the analysis and separation of proteins in complex
samples. The first step in 2-DE is the separation of proteins by their isoelectric point, the pH
at which the molecule has neutral charge, across an immobilised pH gradient. Proteins are
then resolved according to their molecular weight as in polyacrylamide gel electrophoresis
(PAGE). Gels can then be stained using silver, coomassie or fluorescent dyes to compare
the relative protein expression between of samples between gels. Unknown proteins are
then excised, digested and identified by peptide mass fingerprinting of tandem MS [267].
Although 2-DE has been the staple of quantitative protein analysis for the last few decades,
this technique often struggles with reproducibility and is limited in its detection of membrane
proteins. These proteins are typically hydrophobic as a result of their transmembrane domain
and as a result require strong detergents to solubilise them, which may slow or skew protein
migration [268]. These highly hydrophobic proteins also tend to precipitate at their pI, pre-
venting them from entering the acrylamide gel [268]. Furthermore, membrane proteins are
also frequently quite large proteins, and may fall outside of the 2-DE range (10 to 150kDa)
[269].
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Density gradient centrifugation
An alternative, crude approach is density gradient centrifugation, using sucrose to separate
membrane fractions from other subcellular structures. However, because plasma membranes
exhibit similar physiochemical properties to other intracellular membranes, there is often a
high level of contamination from other subcellular membranes such as mitochondria, golgi
and rough ER and the overall enrichment is often low (less than 30%) [270]. Although
the reported enrichment has improved with the addition of a two-phase aqueous polymer
partition, the overall number of plasma membrane proteins identified has been low, ranging
from 105 to 580 proteins [270][271][272].
High pH and proteinase K
The high pH and proteinase K method offers a substantial improvement over this crude
technique. Agitation at a high pH favours the formation of membrane ‘sheets’ and protease
accessible peptides are then cleaved from the membrane using proteinase K (a serine protease
with a broad cleavage specificity) and separated by centrifugation. Using this technique,
Blackler et al reported a 72% enrichment for integral membrane proteins, although the total
number of plasma membrane proteins identified was still low [273]. It is also possible that,
using this technique, many proteins that don’t have a cleavage site or are inaccessible are
excluded from analysis.
Colloidal silica-beads
Colloidal silica-beads have also been used to varying success. A thin layer of cationic
colloidal silica-microbeads are applied to intact cells, forming an ionic interaction with the
anionic phospholipid head groups of the membrane. Microbeads are subsequently cross-
linked by an anionic polymer and cells are lysed. This results in the formation of a large,
open sheet with the associated plasma membrane which can be easily separated from cell
debris and lysate by centrifugation. Membranes are then washed and solubilised by sodium
dodecyl sulfate (SDS) [274]. The reported enrichment using this technique widely varies,
from 16 to 81% and often the total number of plasma membrane proteins identified ranges
from less than 100 to just under 400 proteins[275][276][277][278].
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Affinity purification
Alternatively, plasma membrane proteins can be extracted from whole cell lysates using
affinity purification. Many membrane proteins are glycosylated [279] and can be recognised
and captured by immobilised lectins [280]. Overall, the enrichment using this technique has
been high (41 to 88%) but similar to the aforementioned techniques, yields a low number of
proteins, commonly between 100 and 250 [281][282][283].
Similar to lectin-affinity purification, cell surface proteins can be biotinylated and captured
by immobilised streptavidin. Commonly used is the amine-reactive N-hydroxysulfosuccinimydyl-
S,S-biotin (NHS-SS-biotin). However, although reported to be membrane impermeable, a
few studies have observed the specific-labelling of intracellular proteins suggesting that it
at least partially membrane-permeable and as a result, the reported enrichments are highly
variable (16 to 67%) [284][285][286].
Cell surface proteins can also be biotinylated using aminooxy-biotin. Aldehydes are
introduced onto sialylated plasma membrane glycoproteins by periodate oxidation, subse-
quently followed by the oxime ligation of the aminooxy-biotin to these aldehydes [284].
Because these sialylated glycoproteins are restricted to the PM and subcellular organelles of
the secretory and endocytic pathways of cells and both the periodate and aminooxy-biotin
are cell impermeable at 4°C, this technique yields biotin-labelling that is cell surface only
[287]. This technique has been optimised by Weekes et al and has been coined as plasma
membrane profiling (PMP) [288]. This technique not only substantially enriches for plasma
membrane proteins (68%), but also identifies upwards of 700 proteins [288]. PMP has
already been successfully applied by the Lehner group to elucidate protein interactions [288]
and to identify proteins involved in mediating immune evasion [289][290].
1.8.3 Protein quantification
Although mass spectrometry is capable of identifying hundreds to thousands of proteins, it is
not inherently quantitative and several strategies can be employed to enable the relative and
absolute quantification of identified proteins. Labels can be either incorporated onto peptides
before analysis or can be directly quantified using label-free strategies.
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Label-free proteomics
Due to their associated low-costs label-free proteomics are becoming increasingly popular.
Protein abundance is estimated using either the number of spectra detected for each protein
or from the chromatographic peak intensity [291]. Despite recent improvements, these
techniques are still considered inaccurate and perform poorly with proteins with low-spectral
counts, greatly reducing the quantifiable number of proteins within a sample or resulting in an
underestimation of abundance [292][293]. Conversely, label-based techniques are considered
to be much more accurate, although potentially at the cost of the total number of proteins
identified [293].
Isotope labelling
Traditionally peptides have been labelled using stable isotope labelling by amino acids in
cell culture (SILAC). ’Heavy’ or ’light’ amino acids are introduced into the culture medium
and are metabolically incorporated into proteins as cells proliferate and grow [294]. ’Heavy’
and ’light’ samples are then combined before digestion and further downstream processing.
During LC (liquid chromatography)-MS/MS analysis, the labelled peptides elute simulta-
neously and the relative abundance ratio is used to infer protein abundance. This technique
has been utilised in myeloma to elucidate novel signalling proteins and pathways involved in
proteasome inhibition [295] and to explore protein-protein interactions [296]. However, it is
fairly limited in its use for primary samples that do not grow well ex vivo such as myeloma
cells and in both of these studies, the authors relied on the use of human myeloma cell lines
(HMCLs).
An alternative to metabolic labelling that is amenable to the low-proliferative nature of
plasma cells is the labelling of digested peptides using isotope tags, such as ICAT (isotope-
coded affinity tag). The ICAT reagent is comprised of three elements, a cysteine reactive
group to enable peptide binding, a biotin tag for affinity purification, and an isotopically
labelled linker. This linker may be either ’heavy’ or ’light’ depending on whether it contains
eight deuterium or hydrogen atoms. Enriched protein samples are digested, labelled and
then combined before MS analysis. Similar to SILAC, ’heavy’ and ’light’ peptides co-elute
following LC and the relative abundance of each sample is determined by the signal intensity
ratio of the peptide pair [297]. Although this technique can be used with primary samples
that grow poorly ex vivo, there are several disadvantages. One common problem with isotope
labels is that there is a slight separation of the heavy and light peptides and as a result they
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Fig. 1.4 Overview of the TMT label. The TMT label consists of a mass reporter, an amine-
reactive NHS-ester group and a linker (mass normalizer). All labels within a set share an
identical structure but different numbers and combinations of 13C or 15N. (Thermo Fisher
Scientific)
may elute as separate fractions compromising sensitivity and accuracy. This can also lead
to redundancy, resulting in an under-sampling of the proteome [298]. Additionally, as with
SILAC, this technique is limited to just two samples.
Isobaric tags
Unlike isotope tags, isobaric tags have identical mass, resulting in identical mobility and
subsequent co-elution during MS analysis. These isobaric tags are comprised of an amine
reactive moiety for peptide binding, a mass reporter tag with a unique number of 13C or
15N substitutions and a mass normaliser that balances the tag mass so that all tags within a
set have the same mass (fig 1.4). During tandem mass analysis, fragmentation of the label
releases the mass reporter tag to produce a unique reporter ion mass. The relative intensities
of these reporter ions can be used for relative quantification of the samples [298]. Two
commercial tags are available, the isobaric tag for relative and absolute quantitation (iTRAQ)
and the tandem mass tag (TMT). Both enable the simultaneously analysis of 4, 6, 8 or 10
biological samples, representing a significant improvement over isotope-labelling techniques.
By labelling the peptides directly and not relying on the incorporation of labelled amino
acids, freshly isolated myeloma cells can be quantitatively analysed [286][299][261].
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Fig. 1.5 Overview of the PMP and TMT labelling workflow. Cell surface proteins are biotiny-
lated and isolated from whole cell extracts using affinity purification before denaturation,
reduction, alkylation and digestion. Peptides are then labelled with isobaric mass tags (TMT
10plex) and analysed on a nanoLC-MS3 platform. Spectra are mapped against and annotated
using the Uniprot human database.
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1.9 Aims
As discussed in section 1.8.2, a number of mass-spectrometry-based approaches have been
undertaken to characterise the cell surface proteome. However, the number of proteins
identified using these techniques have generally been low, in the range of a few hundred,
or have not been quantitative. Furthermore, those few studies that have been undertaken in
myeloma have relied on using HMCLs or have not enriched for plasma membrane proteins
[261][286][295][299]. Although these studies represent significant improvements over other
techniques such as flow cytometry, Western Blot and GEP, the myeloma cell surface pro-
teome is still uncharacterised and there are likely to be many unidentified proteins. As these
proteins play an essential role in tumour survival, mediating immune evasion, promoting
drug resistance and transducing growth signals, they are of great interest as novel therapeutic
targets and prognostic biomarkers.
This thesis is split into three sections, with the overall aim of identifying and characteris-
ing a novel antibody drug conjugate target for the treatment of multiple myeloma.
In the first section of this thesis I aim to quantitatively characterise the myeloma cell
surface proteome using the relatively novel technique, plasma membrane profiling, in both
HMCLs and in primary disease. I then aim to demonstrate this technique provides an accurate
and quantitative representation of the plasma membrane by validating this dataset using flow
cytometric techniques. As HMCLs are genetically well-characterised, I also aim to compare
protein and RNA expression to determine any associations with the underlying genotype that
may help elucidate the molecular consequences of these genetic events. Finally, I aim to use
this dataset to identify a list of novel candidate ADC targets.
In the second section of this thesis I aim to establish a recombinant protein mammalian
expression system to facilitate antibody generation. It is expected that a number of the
identified targets will not have commercial or reliable antibodies available and it will be
necessary to generate tool antibodies for further characterisation of these top targets.
In the final section of this thesis my aim is to characterise those novel targets that already
have commercially available tool antibodies. I will use these antibodies to assess off-tumour
expression in healthy tissue and on-tumour expression in a larger sample population. For
any candidates that demonstrate an acceptable expression profile, I will assess whether these
proteins are internalised to deliver a cytotoxin and trigger myeloma cell death. Finally, I aim





Complete RPMI: Roswell Park Memorial Institute (RPMI) 1640 medium (Life Technologies)
supplemented with 10% heat-inactivated fetal bovine serum (FBS, S. American Origin, Life
Technologies) and 1% GlutaMax (Life Technologies).
Complete DMEM: Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies high
D-glucose (4.5g/L)) supplemented with 10% heat-inactivated FBS and 1% GlutaMax.
Complete IMDM: Iscove’s Modified Dulbecco’s media (IMDM) (Life technologies) supple-
mented with 10% heat-inactivated FBS and 1% GlutaMax.
Serum-free media (SFM): DMEM (high glucose) supplemented with 1% GlutaMax without
FBS.
All FBS was heat-inactivated by incubating at 56°C for 1h and was identified as tetracycline-
free by Life Technologies.
2.1.2 Cell lines
All cells were passaged twice weekly and were grown under normoxic conditions at 37°C,
5% CO2. Cell counts were performed by trypan-blue exclusion (Corning) using haemocy-
tometers (improved Neubauer).
Suspension cells: The HMCLs (INA-6, JIM3 (ECACC 10081204), KMS-12-BM (DMSZ
ACC 551), LP-1 (DMSZ ACC 41), MM.1S (ATCC CRL-2974), NCI-H929 (ATCC CRL-
9068), OCI-My5, OCI-My7, OPM-2 (DMSZ ACC 50) and SK-MM-1) and K562 (ery-
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throleukemic cell line, ATCC CCL-243) were grown in complete RPMI medium, with the
exception of OPM-2 which was maintained in complete RPMI supplemented with 5% instead
of 10% heat-inactivated FBS. INA-6 were supplemented with 3ng/ml recombinant human
interleukin-6 (Roche). Suspension cells were maintained between 3x105 and 1x106 cells/ml.
Adherent cells: HEK-293T (human embryonic kidney, ATCC CRL-11268), HEK-
293FT (derived from 293T, a kind gift from Dr A. Reyes1), hTERT RPE-1 (retina, pig-
mented epithelium, ATCC-CRL-4000), CD40L-expressing L cells (murine fibroblast, ATCC
CRL-2648) and M2-10B4 (murine stromal cell, ATCC CRL-1972) were maintained in com-
plete DMEM media and split when cells reached 80-90% confluency. Both the CD40L- L
cells and the M2-10B4 were a generous gift from Dr R. Tooze2. For passaging, adherent
cells were washed with phosphate buffered saline (PBS, pH 7.4) and detached using trypsin
(Thermo Fisher Scientific) at 37°C. Trypsin was neutralised with at least ten times volume of
complete DMEM, cells collected and centrifuged at 300g for 5min and seeded at the required
dilution (typically 1:25 for routine passaging).
HEK-293FT were maintained in blasticidin (15µg/ml, Invivogen) and zeocin (100µg/ml,
Invitrogen) prior to transfection.
2.1.3 Cryopreserving and thawing cells
All cell lines are cryopreserved in 90% FBS with 10% dimethyl sulfoxide (DMSO, Thermo
Fisher Scientific) (v/v) at a concentration of 10x106 cells/ml for suspension cells or 1/3 of a
confluent 100mm culture dish for adherent cells. Cells were initially stored at -80°C in a Mr
Frosty freezing container (Thermo Fisher Scientific) before being transferred to long term
storage at -150°C.
Cells are rapidly thawed by gently agitation in a 37°C water bath before transfer to 10ml
of pre-warmed complete media. Cells are then centrifuged at 300g for 5min and re-suspended
in complete media. Suspension cells are seeded at 5x105 cells/ml for 24 hours before a
viability check and re-seeding at 3x105 cells/ml in fresh complete media. All adherent cells
are seeded into 100mm culture dishes and left until confluency.
1M Zeviani group, Mitochondrial Biology Unit, University of Cambridge
2Faculty of Medicine and Health, University of Leeds
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2.1.4 Cell line verification
Cell line identities were verified by genomic DNA sequencing to confirm the presence of
mutations known to be unique to each cell line. These were identified from the Keats Lab
HMCL preliminary mutations list, which contains all the mutations currently identified to
date by exome sequencing (see section 2.16). Genomic DNA was extracted from 5x106 cells
from each cell line using the DNeasy blood and tissue kit (Qiagen). Forward and reverse
primers were designed to flank each unique mutation (table 2.1) and DNA amplified by
polymerase chain reaction (PCR) using BioTaq DNA polymerase (Bioline) following the
recommended 3-step PCR protocol (35 cycles). Amplified PCR product was resolved on
a 1.5% agarose gel in TAE buffer (40mM Tris, 20mM acetic acid, 1mM EDTA) using 4x
loading buffer (250mM Tris-HCl (pH 6.8), 0.0008% bromophenol blue (w/v), 40% glycerol
(v/v)) and visualised using GelGreen nucleic acid stain (Biotium). DNA bands were extracted
using the QIAquick gel extraction kit (Qiagen) following the manufacturer’s instructions.
Purified PCR products were then sequenced by Sanger sequencing (Source Bioscience) and
results analysed by FinchTV (PerkinElmer).




























Table 2.1 HMCL sequencing primers
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2.1.5 Mycoplasma Testing
All cell lines were tested and confirmed to be mycoplasma free before PMP. Cells were
cultured for four days in complete media and supernatant collected and stored at -20°C.
Mycoplasma testing was performed using a nested PCR (table 2.2). PCR products were
visualised on a 2% agarose TAE gel.





Table 2.2 Mycoplasma detection primers
2.2 Primary samples
Patient sample processing and the aminooxy-biotin labelling of MM plasma cells was
performed in collaboration with Dr S Surget and Dr J Ballester-Beltran3. Bone marrow
aspirates (BMA) were obtained from myeloma patients after informed consent (Causes of
clonal blood disorders (07/MRE05/44)). Red blood cells (RBC) were lysed using RBC
lysis buffer (155mM ammonium chloride, 12mM sodium bicarbonate and 0.1mM EDTA,
pH 7.2) and the remaining leukocytes washed and re-suspended in PBS/0.5% (w/v) bovine
serum albumin (BSA, Thermo Fisher Scientific). Plasma cell infiltration was determined by
flow cytometry (CD138-PE, see table 2.8). Samples with a high infiltration were processed
for PMP and remaining samples were either discarded, stored at -150°C or analysed by
flow cytometry for target expression using the appropriate antibody in combination with
CD138-PE. Additionally, SEMA4A was used in conjunction with CD14, CD19, CD3, CD34
and CD66b for profiling of heematopoietic cell subsets (see section 2.9).
For PMP, plasma cells were isolated using CD138 microbeads (Miltenyi Biotech) on an
autoMACS Pro Separator (Miltenyi Biotech) and CD138+ cell purity was confirmed by flow
cytometry before proceeding with biotinylation (see section 2.3).
3Mike Chapman group, Department of Haematology, University of Cambridge
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2.3 Plasma membrane profiling
2.3.1 Biotinylation
1x108 HMCLs or 1x107 primary myeloma cells were washed four times in ice-cold PBS pH
7.4 before resuspension in an aminooxy-biotin mix (1mM sodium (meta)periodate (Thermo
Fisher Scientific), 10mM aniline (Sigma), 100mM aminooxy-biotin (Biotium), PBS, pH
6.7). Samples were incubated with rotation at 4°C for 30min in the dark. Glycerol (Sigma)
was added to a final concentration of 1mM and cells were washed a further three times in
ice-cold PBS, pH 7.4. 5x105 cells were taken before and after biotinylation to check the
biotin labelling efficiency by flow cytometry using streptavidin-APC (table 2.8). Biotinylated
cells were pelleted and stored at -20°C until enough samples were collected to perform the
pulldown.
2.3.2 Pulldown
Sample were incubated for 30min in PMP lysis buffer (1% Triton X-100 (Thermo Fisher
Scientific), 1x protease inhibitor tablet (complete mini, without EDTA, Roche), 150mM
sodium chloride, 10 mM Tris-hydrochloride (TRIS-HCl)) at 4°C on rotation. Cell debris
was removed by centrifugation at 13,000g for 10min, repeated twice. The total protein
concentration was determined using the Pierce™ BCA Protein Assay Kit (Thermo Fisher
Scientific) following manufacturer’s instructions. Each lysate was adjusted to the same final
total protein amount per 10plex before incubation for three hours at 4°C with high affinity
streptavidin agarose beads (50µl bead slurry/sample). The beads were washed on SnapCap
filter columns on a vacuum manifold as follows (all washes and incubations in 400µl): 20
washes of lysis buffer, then 20 washes of PBS/0.5% (w/v) SDS followed by incubation with
PBS/0.5% (w/v) SDS/100mM dithiothreitol (Sigma) for 20min at room temperature (RT)
with continuous mixing. Beads were centrifuged at 1,000g for 1min and washed 10 times
in urea buffer (6M urea (PlusOne, VWR), 50mM Triethylammonium bicarbonate (TEAB)
(Sigma), pH 8.5). Beads were then incubated in urea buffer/50mM iodoacetamide (Sigma)
with continuous mixing in the dark for 20min at RT before pelleting by centrifugation (1,000g
for 1min). Beads were washed ten times in urea buffer, and five times in 50mM TEAB buffer
before resuspension in 50µl of 50mM TEAB/0.5µg trypsin (modified sequencing grade,
Promega) and digested overnight with continuous mixing at 37°C. Beads were pelleted by
centrifugation, and the supernatant containing the digested peptides collected. Beads were
washed in 200µl 50mM TEAB, centrifuged and the supernatant removed and pooled with the
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first supernatant.
For the initial PMP, TMTZero and patient sample test runs, samples were processed as
described above but were not subjected to a BCA assay and total protein amount adjustment.
2.3.3 Peptide labelling
All individual peptide samples were dried in a vacuum centrifuge, before resuspension in
25µl 50mM TEAB/16% (v/v) acetonitrile (ACN) (Thermo Fisher Scientific). Peptide samples
were then either left unlabelled (for initial test runs) or were labelled using TMTZero or
TMT10plex (Thermo Fisher Scientific) (annotated in the manuscript).
TMTZero: 5µl of the TMTzero label was resuspended with the LP1 peptide test sample,
incubated for 2 hours at RT and then quenched with 21µl 1% trifluoroacetic acid (TFA).
Samples were dried in a vacuum centrifuge and resuspended to a final concentration of 10%
DMSO/0.5% TFA.
TMT10plex: 5µl of each TMT label reagent from the TMT10plex label reagent set
(Thermo Fisher Scientific) was added to each individual peptide sample, incubated for 2
hours at RT and quenched with ammonium formate (final concentration 20mM). Peptide
samples were pooled, dried in a vacuum centrifuge and re-suspended in 5% DMSO/0.5%
TFA.
2.3.4 High pH Reverse Phase Fractionation
All fractionation, mass spectrometry based acquisition and data processing was performed
by Dr J. C. Williams4.
High pH Reverse Phase Fractionation was conducted on an Ultimate 3000 Ultra-high perfor-
mance liquid chromatography (UHPLC) system (Thermo Fisher Scientific) equipped with a
2.1mm × 15cm, 1.7µm Aqcuity BEH C18 column (Waters, UK). Solvent A was 3% ACN,
Solvent B was 100% ACN, solvent C was 200mM ammonium formate (pH 10). Throughout
the analysis solvent C was kept at a constant 10%. The flow rate was 400µL/min and UV
was monitored at 280nm. Samples were loaded in 90% A for 10min before a gradient elution
of 0–50% B over 36min followed by a 10min wash with 90% B. 100µL fractions were
collected throughout the run. Peptide containing fractions were orthogonally recombined into
4Paul Lehner group, Department of Medicine, University of Cambridge
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12 fractions and dried in a vacuum centrifuge. Fractions were stored at -80°C prior to analysis.
2.3.5 LC-MS Analysis
All samples were resuspended in 5% DMSO/0.5% TFA. Samples were analysed using a
nanoLC-MS platform consisting of an Ultimate 3000 RSLC nano UHPLC (Thermo Fisher
Scientific) coupled to an Orbitrap Fusion (Thermo Fisher Scientific) instrument. Solvent A
was 0.1% formic acid (FA) and solvent B was 80% ACN/0.1% FA. Samples were loaded at
10µL/min for 5min onto an Acclaim PepMap C18 cartridge trap column (300µm x 5mm, 5µm
particle size) in 0.1% TFA. After loading a linear gradient of 3-32% solvent B was used for
sample separation over a column of the same stationary phase (75µm x 75cm, 2µm particle
size) before washing at 95% B and equilibration. Electrospray ionisation was achieved by
applying 2.1kV directly to a stainless steel emitter tip.
Analysis was performed using tandem-mass spectrometry (Synchronous precursor se-
lection (SPS)-MS3), in which the parent ion in the MS scan is selected, isolated and further
fragmented. A select few of the detected MS2 ions are selected and fragmented again to
generate MS3 ions. The instrument settings were as follows: MS1: Quadrupole isolation,
120,000 Resolution, 500,000 automatic gate control (AGC) target, 50ms maximum injection
time, ions injected for all parallisable time. MS2: Quadrupole isolation at an isolation width
of m/z 1.6, precursors were fragmented by collision-induced dissociation (CID) (normalised
collision energy (NCE) of 30%) with ion trap scanning out in rapid mode from m/z 120, AGC
target of 5,000 and a 70ms maximum injection time. MS3: In SPS mode the top 10 MS2
ions were selected for Higher-energy collisional dissociation (HCD) fragmentation (65%
NCE) and scanned out in the orbitrap at 50,000 resolution with an AGC target of 20,000 and
a maximum accumulation time of 120ms, ions were not accumulated for all parallelisable
time. The entire MS/MS/MS cycle had a target time of 3s. Dynamic exclusion was set to +/-
10ppm for fragmentation was trigged on precursors 5,000 counts and above.
2.3.6 Data Processing
Spectra were searched by Mascot within Proteome Discoverer 2.1 in two rounds of searching.
First search was against the UniProt Human reference proteome and a compendium of
common contaminants (Global proteome machine). The second search took all unmatched
spectra from the first search and searched against the human trEMBL database (Uniprot).
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The following search parameters were applied: peptide and fragment mass tolerances were
set to 10ppm and 0.6Da respectively, fixed modifications of carbamidomethyl (C) and TMT
(N-term, K) and variable modifications of oxidation (M) and trypsin (/P). MS3 spectra were
used for reporter ion based quantitation with a most confident centroid tolerance of 20ppm.
Peptide-spectrum match (PSM) false discovery rate (FDR) was calculated using Mascot
percolator and was controlled at 0.01% for ‘high’ confidence PSMs and 0.05% for ‘medium’
confidence PSMs. For unlabelled samples, the Hi3 method was used for protein quantitation.
See section 2.16 for further details on protein annotation and analysis of the dataset.
2.4 Molecular Biology
2.4.1 Preparation of competent cells
A single-use aliquot of one shot Stbl3 chemically competent cells (Thermo Fisher Scientific)
were thawed on ice and streaked on a LB/Agar plate without antibiotic and grown overnight.
A single colony was picked and grown in 2.5ml of LB broth (typtone 10g/L, sodium chloride
5g/L, yeast extract 5g/L) without antibiotic overnight, shaking at 37°C. This starter culture
was then used to inoculate 250ml SOC medium (2% tryptone 0.5% yeast extract, 10mM
sodium chloride, 2.5mM potassium chloride, 10mM magnesium chloride, 10mM magne-
sium sulfate and 20mM glucose). Bacteria were grown at 37°C with shaking until reaching
an optical density (OD) of 0.3 to 0.5. Culture media was placed on ice for 10min before
centrifugation at 2,880g for 10min at 4°C and the supernatant discarded. Pelleted cells were
re-suspended in 100ml cold buffer 1 (30mM potassium acetate, 100mM rubidium chloride,
10mM calcium chloride dihydrate, 50mM manganese(II) chloride tetrahydrate, 15% (v/v)
glycerol, pH 5.8) and incubated on ice for 30min before centrifugation (2,880g for 15min at
4°C). Supernatant was removed and cells re-suspended in 10ml cold buffer 2 (10mM MOPS
buffer,10mM rubidium chloride, 75mM calcium chloride dihydrate, 15% glycerol, pH 6.5)
on ice for 30 minutes. Bacteria were then aliquoted and snap-frozen on dry ice for storage at
-80°C until use.
2.4.2 Transformation of competent cells
Aliquots of competent Stbl3 were thawed on ice for 10 minutes. Up to 1/5 of the total volume
was added of either ligation mix or plasmid DNA (10pg to 100ng) and cells incubated on ice
for 30min. Stbl3 were then heat-shocked at 42°C for 45 seconds before being placed back on
ice for 2 minutes. Pre-warmed SOC medium was added and bacteria incubated at 37°C and
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225rpm (Thermoshaker, Thermo Fisher Scientific) for 1h. Cells were spread on a LB/agar
plate with 100µg/ml ampicillin and cultured overnight at 37°C.
2.4.3 RNA extraction and cDNA synthesis
Cells were collected and RNA extracted using the QIAGEN RNeasy kit, as per the manu-
facturer’s guidelines. Genomic DNA was removed using the recommended gDNA removal
spin columns and total RNA was quantified using a NanoDrop Lite Spectrophotometer
(Thermo Fisher Scientific). cDNA synthesis was performed from 2µg of total RNA using the
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Sequence specific
primers (table 2.3) were used to generate cDNA for pcDNA5 constructs, whilst oligo-dT(18)
were used for the pcDNA3 and pLenti6.2 constructs. Random hexamers were used for cDNA
for qRT-PCR.








Table 2.3 Sequence specific primers for cDNA synthesis
2.4.4 DNA cloning
Specific cloning strategies are described in the relevant sections below. DNA fragments were
amplified from cDNA by PCR using Phusion Hot Start II High Fidelity DNA polymerase
following the manufacturer’s guidelines. Amplified PCR products were resolved on a 0.8%
agarose TAE gel and bands were extracted using QIAquick gel extraction kit. Purified PCR
products and plasmid backbones were digested for 1-3 hours at the appropriate temperature
and buffer for each enzyme (New England Biolabs). Digested plasmids were visualised and
extracted from agarose gels in TAE buffer, whilst digested PCR fragments were purified
using QIAquick PCR purification kit (Qiagen).
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Annealed oligos were prepared as follows: 2µM of oligonucleotides were diluted in
buffer 2.1 (New England Biolabs), heated to 98°C, 5min before allowing to gradually cool to
room temperature.
Annealed oligos or amplified PCR fragments were ligated into the appopriate digested
backbone using T4 DNA ligase (New England Biolabs) following manufacturer’s instructions.
Ligations were either performed at 16°C overnight or 1-2 hours at room temperature then
heat inactivated at 65°C for 10min and transformed in Stbl3 chemically competent cells.
Bacteria were plated onto LB/agar plates with ampicillin (100µg/ml) and cultured overnight
at 37°C. Several colonies were selected from each construct and grown in LB with ampicillin.
Plasmid DNA was extracted using Qiagen’s QIAprep spin miniprep kit and the presence of
the insert confirmed by Sanger sequencing. For larger amounts of plasmid DNA, Qiagen’s
plasmid Midi kit was used. DNA concentrations were determined by NanoDrop.
Generation of SEMA4A hairpin constructs
Short hairpins targeting luciferase (control) or SEMA4A were selected from The RNAi Con-
sortium (TRC) library database (Broad Institute) (available from www.portals.broadinstitute.org-
/gpp/public). Complementary oligonucleotides containing the hairpin and appropriate restric-
tion enzyme sites were ordered from Sigma (table 2.4) and annealed before insertion into the
pLKO.1_puro vector (Addgene 10878), pLKO.1_TET (Addgene 21915) or pLKO.1_GFP at
the EcoRI and AgeI restriction sites (see figures 2.1 and 2.2). pLKO.1_GFP was created by
Dr M Chapman, replacing the puromycin resistance cassette under the hGPK promoter in
the pLKO.1_puro vector with eGFP.
Generation of SEMA4A rescue constructs
Additional restriction enzyme sites (AscI, XmaI, SmaI, PmeI and SalI) were added to the
pLenti6.2/V5-DEST vector (Thermo Fisher Scientific) at the EcoRI/BstBI restriction sites
using the annealed oligos pLenti_MSC_F/R to generate pLenti6.2_modified_MCS (table
2.5). BFP was cloned from the pKLV_U6_sgRNA(BbsI)-PGKpuro2ABFP vector (a gift
from Dr P. Lehner5 by PCR using the primers pLenti_BFP_F1/R1, including the T2A se-
quence upstream of the BFP gene and an additional linker (Gly-Ser-Gly) at the N-terminal
(table 2.5). The amplified BFP fragment was inserted into pLenti6.2_modified_MCS at
5Department of Medicine, University of Cambridge
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Table 2.4 Small hairpin oligonucleotides used for generating pLKO.1 constructs
the PmeI/BstBI sites to generate pLenti.6.2_T2A_BFP. Using NCI-H929 cDNA (oligodT
primers), full-length (wild type, WT) or mutant (SEMA4A∆C) was PCR cloned and inserted
into pLenti.6.2_T2A_BFP at the AscI/PmeI sites, immediately upstream of the T2A linker
sequence (figure 2.3). The kozak sequence was included for both constructs and the stop
codon removed from the 3’ end of SEMA4A(WT).
















Table 2.5 Primers and oligonucleotides used for generating pLenti6.2 constructs
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Generation of pcDNA5 constructs
The extracellular domains of EPHB2, NEO1, PLXNA1, PLXNC1, ROBO1, SEMA4A and
SEMA4D were PCR cloned from HMCL cDNA, see table 2.3 for primers used. These
primers were designed to include the kozak sequence at the N-terminal and a TEV pro-
tease cleavage site and 6x his-tag followed by a stop codon at the C-terminal. Ampli-
fied PCR fragments were inserted at the appropriate restriction enzyme site (see table
2.6 and figure 2.4). The extracellular domain and the full-length SEMA4A were PCR
cloned from NCI-H929 cDNA (oligo dT primers) and inserted into pcDNA3.1 (Thermo
Fisher Scientific) using SEMA4A_pcDNA5_F1/R1 (1-683, extracellular domain only) and
SEMA4A_pcDNA5_F1/R2 (1-761, full-length) (fig 2.5).














































Table 2.6 Primers used for generating pcDNA5 and pcDNA3.1 constructs
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2.5 Transfection
Transient transfection: Per condition, 3.2x105 293T cells were seeded per well of a 6 well
plate in complete DMEM and left overnight to adhere. 1µg of plasmid (pLenti6.2/pcDNA3.1)
was combined with 3µl TransIT-LT1 (Mirus Bio) in 250µl of Opti-MEM (Life Technologies)
and left at room temperature for 20-30min. Transfection mixture was then added to the cells
drop-wise.
Stable transfection of 293FT: 7x104 293FT cells were seeded per well (6 well plate)
per condition in antibiotic-free complete DMEM and left to attach overnight. 150ng of
vector (pcDNA5) was combined with 1350ng of pOG44 (Thermo Fisher Scientific) and
6µl TransIT-LT1 in a total volume of 250µl Opti-MEM. DNA was incubated for 20-30min
at room temperature and added drop-wise to the cells. Media was changed 24 hours later
and replaced with complete DMEM supplemented with blasticidin (15µg/ml). At 48 hours,
media was replaced again with complete DMEM, plus blasticidin and hygromycin B Gold
(100µg/ml, Invivogen). Media was then changed every two days, maintaining antibiotic
selection and surviving colonies redistributed until cells were fully selected. Verification of
the tetracycline-inducible expression was confirmed by western-blot using an anti-His-tag
antibody (table 2.9)
2.6 Protein production and purification
pcDNA5 construct expressing 293FT cells were seeded at 20-30% confluency and left to ad-
here overnight. Cells were then switched to SFM with doxycycline (30ng/ml, Sigma). At 72
hours cells were supplemented with additional fresh SFM with doxycyline (1/3 of the initial
media volume). Cell culture media containing the secreted recombinant proteins was col-
lected on day 7, clarified by centrifugation at 300g for 5min, and filtered through a 22µm filter.
For protein purification, cell culture media and all buffers were cooled to 4°C and all
steps performed in a cold-room. Filtered media was loaded onto a HisTrap Excel column
(1ml, GE Healthcare) and washed using 96% buffer A (20mM sodium phosphate and 0.5M
sodium chloride, pH 7.4) and 4% buffer B (20mM sodium phosphate, 0.5M sodium chloride
and 1M imidazole, pH 7.4). Recombinant proteins were then eluted from the column over 4
to 100% buffer B gradient (final concentration of imidazole: 40mM to 1M) at a flow rate
of 1ml/min. 0.5 to 1ml fractions were collected throughout the run. Protein-containing
54 Materials and Methods
fractions (as determined by UV absorbance at 280nm) were pooled and buffer exchanged
using a Dialyzer Maxi (molecular weight cut-off 12-14kDa, Novagen) into TEV cleavage
buffer (50mM Tris-HCl, 0.5M sodium chloride, pH 8.0). The his-tag was cleaved by TEV
protease overnight at 4°C (1.25U/µg). The cleaved recombinant protein was loaded back
onto the HisTrap column and collected in the flow-through fraction. Bound cleaved his-tag
and other contaminants were eluted by a 1M imidazole wash to clean the column. Protein
concentration was determined using the NanoDrop. Collected fractions were visualised by
SDS-PAGE or western-blot (see section 2.10).
2.7 Lentiviral transduction of suspension cells
Lentivirus was used for stable transduction of suspension cell lines, using a 2nd generation
production system. 3.2x105 293T cells were seeded per condition per well in a 6 well plate in
complete DMEM and left to attach overnight. 1µg of either the pLenti6.2 or pLKO.1 vectors
of interest were mixed with 900ng of the packaging plasmid psPAX2 (Addgene 12260) and
100ng of the envelope plasmid pMD2.G (Addgene 12259) with 6µl of TransIT-LT1 in a
final volume of 126µl opti-MEM. The DNA mixture was left at room temperature for 30min
before adding drop-wise to the adhered 293T cells. Media was changed at 24 hours and the
virus-containing media harvest at 40-48 hours. Media was filtered using a 0.45µm filter and
either used straight away or stored at -80°C until use.
Cells were re-suspended in the harvested viral supernatant at 8x105cells/ml. Polybrene
(Sigma) was added to a final concentration of 6µg/ml and cells centrifuged at 750g for 30min
at room temperature before overnight culture at 37°C and 5% CO2. Media was changed and
replaced with complete RPMI, with or without antibiotics. Puromycin (Gibco) was added at
2 or 3µg/ml for NCI-H929 and MM.1S respectively and blasticidin at 10µg/ml for both.
2.8 Hairpin competition assay
K562, NCI-H929 and MM.1S were transduced with diluted lentiviral media containing
pLKO.1_shLUC_GFP, pLKO.1_shSEMA4A_636_GFP or pLKO.1_shSEMA4A_567_GFP
so that only ≈50% of the cell population expressed the hairpin of interest. Cells were main-
tained in complete RPMI and split to 3x105 cells/ml every 4 days. Hairpin expression was
confirmed by flow cytometry using GFP expression as a surrogate. SEMA4A knockdown
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was also confirmed using SEMA4A-eFlour710 (table 2.8). The proportion of GFP+ cells
was measured at day 4, 8, 12 and 16 by flow cytometry.
2.8.1 Knockdown and rescue
SEMA4A(wt) or SEMA4A∆C expressing NCI-H929 and MM.1S cells were generated by
lentiviral transduction using the pLenti6.2 constructs: pLenti6.2_hSEMA4A∆C_T2A_BFP
and pLenti6.2_hSEMA4A(wt)_T2A_BFP. As a control, cells were also transduced with the
empty parental vector pLenti6.2/V5. Following transduction, cells were maintained in blasti-
cidin selection and SEMA4A and BFP expression confirmed by flow cytometry (5E3, table
2.8) and western blot (GeneTex antibody, table 2.9). As described in section 2.8 endogenous
SEMA4A was then knocked down by lentiviral transduction of the pLKO.1_GFP constructs
and GFP expression monitored by flow cytometry at day 4, 8 and 12.
For the second experiment, pLKO.1_TET_shLUC or pLKO.1_TET_shSEMA4A-636 ex-
pressing MM.1S were generated by lentiviral transduction. Following transduction, cells were
maintained in puromycin selection before transduction with pLenti6.2_hSEMA4A∆C_T2A_BFP,
pLenti6.2_hSEMA4A(wt)_T2A_BFP or the empty parental vector pLenti6.2/V5. 24 hours
following transduction, endogenous SEMA4A was knocked down by the introduction of
doxycycline to the cell culture media (1µg/ml). SEMA4A expression was monitored by flow
cytometry and Flow-Count Fluorospheres (Beckman Coulter) used to determine total cell
counts at day 7 and 14.
2.9 Flow cytometry
All immunostainings were performed in PBS at 4°C for 20min for unconjugated antibodies
or at room temperature for 13min in the dark for conjugated antibodies. For unconju-
gated antibodies, unbound antibody was removed by PBS wash before incubation with a
fluorescently-labelled secondary antibody for 13min at RT. FC block (Miltenyi Biotech)
was included for all patient samples. Sample acquisition was performed on a Gallios Flow
Cytometer (Beckman Coulter) and analysed using the Kaluza analysis software (Beckman
Coulter, version 1.3). Viable cells were identified and selected for downstream analysis
by forward/side scatter profiles and/or, where noted, by the exclusion of a live/dead stain
(see table 2.9). Debris and doublets were also excluded from analysis. Compensation was
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determined using single stains, prepared from pooled samples, and isotype-matched control
antibodies used to determine background fluorescence. The median fluorescence intensity
(MFI) was determined as the ratio of median fluorescence of each antibody over its isotype
control. All flow cytometry antibodies used are listed in table 2.8.
2.10 Western blot
Collected cells were lysed in RIPA lysis buffer (50mM Tris-HCL (pH 7.4), 150mM sodium
chloride, 2mM EDTA, 1% (v/v) IGEPAL CA-630, 0.5% (w/v) sodium deoxycholate, 0.1%
(w/v) sodium dodecyl sulfate (SDS) and protease inhibitor (complete mini, without EDTA,
Roche)) on ice for 40min, vortexing for 20s every 10 minutes. Cellular debris was removed
by centrifugation at 16,000g for 20min at 4°C. The protein concentration of each lysate was
determined using the Pierce BCA protein assay kit (Thermo Fisher Scientific). Cell culture
media samples were collected at various time points and centrifuged at 400g for 5min to
remove cellular debris. Lysate (30µg) and supernatant samples were mixed with 4x NuPAGE
LDS Sample Buffer (Thermo Fisher Scientific) at a 3:1 ratio and denatured at 70°C for 10min.
Proteins were then resolved on tris-glycine mini gels (cast to a final acrylamide percentage
of between 6 and 12%) using a tris/glycine/SDS buffer system (Bio-Rad). Gels were then
either transferred to PVDF membrane (Millipore) using the Bio-Rad mini-PROTEAN tetra
cell (100v for 1h) or developed in Quick Coomassie (Generon) following manufacturer’s
guidelines. Membranes were blocked for 1h at room temperature in blocking buffer (0.5%
(v/v) gelatin from cold water fish skin (sigma), 0.1% (v/v) Triton x-100, 0.02% (w/v) sodium
azide, in PBS) and immunoblotted with primary antibody diluted in blocking buffer overnight
at 4°C. Membranes were washed in PBS-Tween-20 (0.1%, w/v) and incubated with the ap-
propriate fluorescently-labelled secondary antibody diluted in blocking buffer plus 0.1%
Tween-20 and 0.01% SDS (w/v) for 1h at room temperature. Membranes were washed again
and imaged using the Odyssey FC OFC-1095 (LI-COR) imaging system. Protein expression
was quantified using the Image Studio Lite software (version 4.0, LI-COR). All western-blot
antibodies used are listed in table 2.9.
2.11 Quantitative real time-PCR
Quantitative real time-PCR (qRT-PCR) was performed using BioTaq DNA polymerase in
the supplied buffer supplemented with EvaGreen Dye (20x in water, Biotium) in 96-well,
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low-profile, semi-skirted, white PCR plates (Starlab). Samples were plated in triplicate and a
no-template control well included. Primer efficiency was tested using cDNA serially diluted
1 in 4. Plates were run on a CFX96 machine (Bio-Rad) following a normal three-step PCR
protocol (40 cycles) followed by a melt curve from 65 to 95°C. Data was analysed using the
Bio-Rad CFX manager software (version 3.1). Relative gene expression was calulated as
E(Cqexp−Cqre f ) where E= (primer efficiency(%)100 )+1, Cqexp= average Cq for experimental sample
and Cqre f = average Cq for reference sample and using the housekeeping gene (RPL37a) for
normalisation.













Table 2.7 Primers used for real-time PCR
2.12 Antibody internalisation
2.12.1 Flow cytometry
HMCLs were incubated with either an unconjugated antibody directed against SEMA4A,
NEO1 or ROBO1 (table 2.8) or an isotype-matched control at 4°C for 30min. Unbound
antibody was removed following two PBS (ice-cold) washes and labelled cells split into three
groups. The first group were re-suspended in pre-warmed complete RPMI and cultured for
3 hours at 37°C, whilst the second group of cells were re-suspended in ice-cold complete
RPMI and kept on ice for 3 hours. The last group was taken as t0. Samples were taken at
hourly intervals and immediately incubated with a PE-conjugated secondary antibody (goat
anti-mouse IgG, table 2.9) at room temperature, 13min before fixation (1% formaldehyde
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in PBS) at 4°C for 30 minutes. Samples were washed and re-suspended in PBS before
analysis by flow cytometry. Internalisation was calculated as the ratio between the remaining
surface-bound antibody at tx compared to t0.
2.12.2 Microscopy
NCI-H929 were incubated with unconjugated SEMA4A antibody for 30min at 4°C. Unbound
antibody was removed by PBS washes and cells were then incubated at 37°C. Samples were
removed at t0 and t3 and immediately fixed on ice in 4% formaldehyde solution for 30min.
Cells were then incubated with an Alexa-Fluor 555 conjugated secondary antibody under
permeabilising conditions (2% FBS and 0.1% (w/v) saponin (Sigma) in PBS) for 1h at room
temperature. Samples were washed and resuspended in PBS/FBS/saponin with LAMP-1-
Alexa-Fluor 488 for 1h at room temperature in the dark. Cells were washed, nuclei stained
using DAPI, and attached to poly-L-lysine (Sigma) coated glass slides for 30min at 37°C.
Slides were then mounted using Prolong Diamond Antifade Mountant (Life Technologies)
and images captured using a Leica DFC7000T microscope and the Leica application suite
software (Leica Microsystems). Captured images were analysed by ImageJ (National Insti-
tutes of Health).
2.13 ADC cytoxicity assay
Suspension cells (5x103 per well) or RPE-1 cells (2.5x103) were seeded in a 96-well flat-
bottom plate in complete media. RPE-1 cells were left to adhere for 4-6 hours and treated
with 0 or 250µM hydrogen peroxide (Sigma) for 1h at 37°C, 5% CO2 before media was
replaced with fresh complete DMEM. Antibody-ZAP complexes or ADCs (see below) were
added to the cells and plates incubated for 72 hours at 37°C and 5% CO2. Cell viability was
determined by adding activated XTT reagent (Biotium) and incubating plates for 2-4 hours
at 37°C. Absorbance at 450nm was recorded hourly until the non-treated readings were >
0.3 and background absorbance subtracted from all wells (650nm). Cell viability (%) was
calculated as a percentage of the control (media only) wells. EC50 values were obtained from
sigmoidal dose-response curves using GraphPad Prism software.
Preparation of Fab-ZAP-antibody complexes: Various dilutions of SEMA4A (5E3),
ROBO1 (770502) or isotype control antibodies were prepared in complete RPMI containing
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2.5mM Fab-ZAP (Advanced Targeting Systems), incubated at room temperature for 20
minutes and subsequently added to the cells.
Preparation of Biotin-ZAP-antibody complexes: SEMA4A antibody was biotinylated
using either the Biotin (type A) or (type B) conjugation kit (Abcam) following manufac-
turer’s guidelines. Biotinylation of the antibodies was confirmed by flow cytometry using
streptavidin-APC. Biotin-conjugated antibody or un-conjugated antibody were mixed with
biotin-ZAP (Advanced Targeting Systems) at 1:4 ratio (antibody:ZAP) and incubated for
20 minutes at room temperature. The antibody:ZAP complex was then diluted in complete
RPMI to various dilutions and added to the cells.
SEMA4A direct conjugation: The SEMA4A antibody (5E3) was directly conjugated to
either monomethyl auristatin E (MMAE) using a mc-vcPAB linker (malemide-based linker,
cysteine linked) or with mertansine (DM1) using a SMCC linker (NHS-ester based, lysine
linked) by Abzena, Cambridge. An isotype-matched control directly conjugated to MMAE
(mc-vcPAB linker) was also provided by Abzena. Various dilutions of these direct conjugates
were diluted in complete RPMI and added directly to the cells.
2.14 In vivo xenograft model
All in vivo work was performed by Dr G. Giotopoulos6. Mice were housed in pathogen free
conditions at Central Biomedical Services (University of Cambridge, Cambridge, UK) and
were allowed unrestricted access to food and water. All protocols were performed under
the Project Licence P846C00DB in accordance with the Animals (scientific procedures)
Act 1986 Amendment regulations 2012 and following ethical review by the University of
Cambridge Animal Welfare and Ethical Review Body (AWERB).
Establishment of an in vivo xenograft model: Dual GFP/luciferase expressing cell lines
(NCI-H929-MAC25 and MM.1S-MAC25) were generated by lentiviral transduction of
BLIV301PA-1-MSCV-GFP-T2A-Luciferase (Bioscience). Recipient male SCID (Severe
Combined Immunodeficiency) mice were sub-lethally irradiated with a single-dose of 2.5Gy
and injected with 0.5, 1 or 2.5x106 NCI-H929-MAC25 or MM.1S-MAC25 cells in 200µl in
PBS via the tail vein. Tumour establishment and growth was monitored by bioluminescence
imaging. Briefly, D-luciferin (100µl of 15mg/ml) was injected i.p., followed by inhalation
6Brian Huntly group, Department of Haematology, University of Cambridge
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anaesthesia (isoflurane) and after 7.5min, mice were imaged using the IVIS in vivo imaging
system (PerkinElmer).
Testing 5E3-MMAE activity in vivo: Recipient male NOD SCID gamma (NSG) mice
were sub-lethally irradiated as described above and injected with 1x106 MM.1S-MAC25
cells via the tail vein. Tumour establishment and growth was monitored by bioluminescence
imaging. Each animal then received a total of four doses (at 4mg/kg for each dose) of either
5E3, 5E3-MMAE or Trastuzumab-MMAE (isotype control) by means of tail vein injection
(on day 13, 15, 19 and 22 post transplantation, termed ‘Study day’ 0, 2, 6 and 9 respectively).
Mice were placed on tumour watch and imaging sessions were repeated weekly and at
sacrifice.
2.15 B cell to plasma cell generation
Plasma cell generation was performed as described in [94]. CD40L-expressing L cells were
gamma-irradiated using the Gammacell1000 and seeded in complete IMDM at 4.2x104
cells/well in a 24 well plate and left to attach overnight. Leukocyte cones were obtained from
the NHS Blood and Transport service and diluted in PBS/BSA (0.5% w/v) (1:2). Mononu-
clear cells were isolated by density gradient centrifugation using lymphocyte separation
media (Lymphosep, MP Biomedicals). B cells were isolated using a Human Memory B cell
Isolation kit (Miltenyi Biotech) and the autoMACS cell separator following manufacturer’s
guidelines. For isolating both naïve and memory B cells, the second selection step using
CD27 microbeads was not included. Isolated B cells were cultured at 2.5x105 cells/ml
with the irradiated CD40L L cells in complete IMDM supplemented with IL-2 (20U/ml,
Roche), IL-21 (50ng/ml, Peprotech) and F(ab’)2 goat anti-human IgG+IgM (Jackson Labs,
10ug/ml) for 3 days. On day 3, activated B cells were collected from the co-culture and
reseeded alone in complete IMDM supplemented with IL-2 (20U/ml), IL-21 (50ng/ml), Lipid
mixture 1 (1 in 200 dilution, Sigma), MEM amino acid solution (1 in 50 dilution, Sigma)
and TX-HYB hybridoma growth supplement (1 in 91 dilution, Gentaur) at 1x105 cells/ml for
a further 3 days. At day 5, M2-10B4 were gamma-irradiated and seeded in complete IMDM
at 8.3x105 cells/well in a 12 well plate and left to attach over night. On day 6, plasmablasts
were collected and re-seeded with the irradiated M2-10B4 at 5x105 cells/ml in the upper
compartment of a transwell (0.4µM pore, Corning) supplemented with IL-21 (50ng/ml), IL-6
(10ng/ml, Peprotech), IFNalpha (100U/ml, Peprotech), MEM amino acid solution, Lipid
mixture 1, and TX-HYB in complete IMDM. Media was then refreshed every 3.5 days. From
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day 13 onwards, IL-21 was removed from the culture media.
A small sample of cells were taken at day 0 post selection and at day 3, 6, 9.5, 13, 16.5
and 20 to be further analysed for CD38, CD138, CD20 and CD19 (table 2.8) expression by
flow cytometry.
2.16 Data repositories and data analysis
Data was analysed using both R (R: A language and environment for statistical computing.
R Foundation for Statistical Computing, Vienna, Austria. (URL http://www.R-project.org)
(v.3.5.1)) and GraphPad Prism Software (version 5). All statistical tests used are described in
the manuscript and where appropriate, multiple testing was corrected for using the Benjamini-
Hochberg (BH) method. Statistical significance was determined as a p<0.05 and FDR cut-offs
are detailed either in the methods or manuscript. Unless otherwise specified, all data is
presented as the median ± standard deviation.
Annotation of plasma membrane proteins: Where detailed plasma membranes were anno-
tated using either Gene Ontology Cellular Component (GOCC) terms (http://www.geneontolo-
gy.org/) or using a combination of GOCC and UniProt topological domain annotations
(http://www.uniprot.org) (see section 3.3.5). For statistical analysis, data generated from the
two PMP experiments were processed as follows: any proteins identified by a single, unique
peptide or only identified in one dataset were removed before log transformation, column
centering and scaling by the median absolute deviation.
Data from public repositories: For normal tissue expression, whole cell proteomic data
was taken from the Human Proteome Map (www.humanproteomemap.org) [300]. Expression
values were averaged and standardised to a 0 to 1 scale. SEMA4A IHC images and expres-
sion values were obtained from The Human Protein Atlas database (www.proteinatlas.org,
version 18) [301]. HMCL quantitative transcriptomics data (mRNAseq) and preliminary
mutations list (generated using exome sequencing) were downloaded from the Keats Lab
data repository (www.keatslab.org/data-repository) and RNA abundance was expressed as
FPKM values. A gene-specific RNA-to-protein (RTP) conversion factor for each cell line
was determined by calculating the ratio between mRNA and protein abundance following
normalisation of the PMP datasets as described above and log10 transformation of the RNA
dataset [302]. The average RTP was calculated across 9 of the 10 HMCLs and used to predict
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the protein abundance of the tenth cell line from mRNA expression.
Graphical art was obtained from SMART’s graphical art (Servier Medical Art by Servier,
https://smart.servier.com), licensed under a Creative Commons Attribution 3.0 Unported
License and used in the introduction, figure 1.5.
Antibody Conjugate Clone Supplier Isotype Dilution
CD138
PE MI15 Biolegend Mouse IgG1 1:50
APC MI15 Biolegend Mouse IgG1 1:50
CD16 FITC 3G8 Biolegend Mouse IgG1 1:33
CD14 APC-eFlour 780 61D3 eBioscience Mouse IgG1 1:50
CD19 APC HIB19 Biolegend Mouse IgG1 1:50
CD20 PE/Cy7 2H7 Biolegend Mouse IgG2b 1:100
CD220 (INSR) PE B6.220 Biolegend Mouse IgG2b 1:200
CD3 PE/Cy7 OKT3 Biolegend Mouse IgG2a 1:50
CD333 (FGFR3) Unconjugated 136334 R&D systems Mouse IgG1 1:100
CD34 FITC 581 Biolegend Mouse IgG1 1:50
CD38
APC HB-7 Biolegend Mouse IgG1 1:100
FITC HB-7 Biolegend Mouse IgG1 1:50
CD56 (NCAM1) PE/Cy7 MEM-188 Biolegend Mouse IgG2a 1:100
CD51 (ITGAV) PE NKI-M9 Biolegend Mouse IgG2a 1:25
CD66b FITC G10F5 Biolegend Mouse IgM 1:50
CD97 PE VIM3b Biolegend Mouse IgG1 1:20
Goat anti-Mouse IgG
PE Poly4053 Biolegend Goat IgG polyclonal 1:50
APC Poly4053 Biolegend Goat IgG polyclonal 1:50
NEO1 unconjugated EPR14696 Abcam Rabbit monoclonal 1:100
PLXNA1 Alexa 647 708954 R&D systems Mouse IgG2b 1:200
PLXNC1
unconjugated 1A12 NovusBio Mouse IgG2b 1:40
Alexa 647 544232 BD pharmingen Mouse IgG2b 1:20
ROBO1 unconjugated 770502 R&D systems Mouse IgG1 1:50
SEMA4A
unconjugated 5E3 Biolegend Mouse IgG1 1:500
PE 5E3 Biolegend Mouse IgG1 1:200
PerCP-eFlour 710 5E3 Thermo Fisher Scientific Mouse IgG1 1:24
SEMA4D PE A8 Biolegend Mouse IgG1 1:200
Streptavidin APC n/a Affymetrix n/a 1:500
Table 2.8 Antibodies used for flow cytometry. All dilutions are for 100,000 cells in a 50µl
final volume.
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Antibody Conjugate Clone Supplier Isotype Dilution
Viability stains
7-AAD n/a n/a Biolegend n/a 1:100
AnnexinV APC n/a Biolegend n/a 1:100
DAPI n/a n/a Thermo Fisher Scientific n/a 1:30000
ZombieAqua n/a n/a Biolegend n/a 1:100
ZombieRed n/a n/a Biolegend n/a 1:100
ZombieYellow n/a n/a Biolegend n/a 1:100
Western-blot
His unconjugated HIS.H8 ThermoFisher Mouse IgG2b 1:1000
NEO1 unconjugated EPR14696 Abcam Rabbit monoclonal 1:1000
SEMA4A unconjugated n/a GeneTex Rabbit IgG polyclonal 1:700
Goat anti-Mouse IgG IRDye800CW n/a LI-COR Biosciences Goat IgG polyclonal 1:15000
Goat anti-Mouse IgG IRDye680RD n/a LI-COR Biosciences Goat IgG polyclonal 1:15000
Immunofluorescence
Goat anti-Mouse IgG Alexa 555 A28180 ThermoFisher Goat IgG polyclonal 1:2000
LAMP-1 Alexa 488 H4A3 Biolegend Mouse IgG1 1:50
Table 2.9 Other antibodies/viability dyes used. All flow cytometry dilutions are for 100,000
cells in a 50µl final volume. Immunofluorescence dilutions are for 200,000 cells in 50µl final
volume.
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Fig. 2.1 pLKO.1_puro map
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Fig. 2.2 pLKO.1_GFP map
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Fig. 2.3 pLenti6.2/SEMA4A_T2A_BFP map. This vector was used for the stable expression
of shRNA-resistant mutant SEMA4A (lacking the intracellular domain, SEMA4A∆C) or the
full-length SEMA4A (SEMA4A(wt))
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Fig. 2.4 pcDNA5/FRT/TO map. This vector was used to stably express the depicted seven
genes of interest (GOI) for recombinant protein production and purification.
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Fig. 2.5 pcDNA3.1_SEMA4A map. This vector was used for the transient expression





Plasma membrane proteins represent the ideal therapeutic target since they are both easily
accessible and involved in mediating numerous biological processes. However, the char-
acterisation of these proteins has been challenging due to their low-abundance and highly
hydrophobic nature, frequently leading to under-representation by mass spectrometry-based
analysis [266]. A comprehensive profiling of this cellular compartment would provide not
only potential therapeutic targets but would also provide valuable diagnostic and prognostic
biomarkers. Furthermore, it will increase our understanding of tumorigenesis and the mech-
anisms of immune evasion. A recent technique, developed by Weekes et al [284] (PMP),
overcomes the traditional challenges of membrane proteomics. This technique utilises the
cell membrane impermeable aminooxy-biotin to tag and specifically isolate these plasma
membrane proteins from the contaminating intracellular proteins using immobilised strep-
tavidin. By combining this technique with the isobaric TMT labels, the plasma membrane
proteome of up to ten samples can be quantitatively compared at once.
The aim of this chapter is to employ PMP to identify and quantify plasma membrane pro-
tein expression in both HMCLs and myeloma patient samples. As the cell surface proteome
of primary myeloma cells has not yet been quantitatively analysed, a comprehensive dataset
would provide an invaluable tool for the myeloma community. Primary myeloma cells
are difficult to maintain in culture and as such HMCLs are an important tool for myeloma
researchers. However, there are clear caveats when using these cell lines. For instance, these
cell lines are typically obtained from advanced, extramedullary disease and have adapted to
survive outside of the tumour microenvironment, which regulates the expression of a number
of cell surface proteins (section 1.5). Furthermore, the hyperdiploid subgroup is substantially
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under-represented amongst the HMCLs and the method of obtaining these cell lines can have
a significant impact on the molecular heterogeneity of these cells [303][304]. Therefore, it
is important to profile both HMCLs, which provide a tractable functional model for target
validation, and primary cells since it will be of interest to compare the proteomic profile of
both groups.
An additional advantage to the profiling of HMCLs is that these cells have been exten-
sively characterised at both the genomic and transcriptomic level. The ten HMCLs used
in this thesis were selected to provide the best coverage of all the major chromosomal
translocations, copy number variations and other mutational events that occur in MM. By
comparing cell surface protein expression with the underlying genotype, I aim to improve our
understanding of myeloma cell biology and the downstream sequelae of specific mutations.
The traditional dogma of proteomics is that RNA is a poor proxy for protein abundance [258].
Interestingly, it has been shown that this may be highly dependent on the gene function and
some groups of transcripts may demonstrate a high correlation between RNA and protein
abundance [259][260]. It is not yet known if plasma membrane protein expression and RNA
abundance follow this tight correlation, although it is expected that this is unlikely to be the
case. In addition, Wilhelm and Edfors [302][305] have recently proposed that although the
RNA translation and protein degradation rates may vary greatly between different transcripts,
these factors remain surprisingly constant for any given protein across multiple tissue types.
Therefore, the abundance of any protein could be predicted from transcript expression us-
ing a RNA-to-protein (RTP) conversion factor. These reports warrant investigation, and it
would be of interest to see if plasma membrane proteins exhibit any correlation with tran-
script abundance and to determine if a RTP factor can be applied to predict protein abundance.
As well as profiling HMCLs and primary myeloma samples, it is also of interest to profile
normal plasma cells. Although not necessary for target identification, this would aid the
discovery of proteins involved in promoting tumorigenesis and are essential for myeloma
cell survival and growth. However, similarly to malignant plasma cells, it is difficult to
obtain sufficient numbers of these cells and there are the ethical considerations in obtaining
healthy, age-matched controls. Our initial proposal was to isolate plasma cells from the
discarded tops of femurs from total hip arthroplasty procedures. However, following personal
communication with CBSB (Cambridge Blood and Stem Cell Biobank), it was advised that
this approach would be limited in the isolation of intact and sufficient plasma cell numbers.
An alternative solution would be to generate these cells in vitro from peripheral blood B
cells [94]. Using a combination of cellular and non-cellular components, Cocco et al were
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able to recapitulate the BM niche and promote the differentiation of long-lived plasma cells.
Although these cells clearly exhibit some genetic differences from their BM counterpart, they
share a clear common gene expression profile [94] and could be considered representative.
3.1.1 Chapter overview
In this chapter I have addressed the initial concerns in the suitability of using this mass
spectrometry technique for the proteomic profiling of primary myeloma cells, confirming
biotinylation efficiency and TMT labelling, as well as the demonstrating the consistent en-
richment of plasma membrane proteins in both HMCLs and primary samples. Also described
is the in vitro generation of plasma cells from peripheral blood B cells following the method
described by Cocco et al [94]. Although I was able to generate cells that phenotypically
resembled plasma cells, I was unable to profile these by PMP because of cell-number con-
straints. However, I report the PMP of ten HMCLs and eight primary patient samples and
demonstrate that this dataset provides an accurate and quantitative representation of the
myeloma cell surface proteome, using a combination of flow cytometry and repeat profiling
to validate this dataset. By comparing RNA and protein abundance, I show that RNA expres-
sion alone is insufficient to determine plasma membrane protein expression, but that a RTP
factor can be applied, which provides a much more accurate estimation. Finally, applying
a bioinformatic approach, I have identified 16 novel potential targets for the treatment of
myeloma.
3.2 Results
3.2.1 Authentication of cell lines
To ensure that our results would be reproducible, it was first essential to authenticate the cell
lines used in this study and to ensure they were not misidentified. 32 human myeloma cell
lines have been extensively characterised at the genomic level by exome sequencing and
RNAseq by the Keats Lab1. From these publicly available datasets, missense mutations that
were unique to each cell line were identified, see table 3.1. The genomic DNA of each cell
line was analysed for the absence or presence of these identifying mutations. All cell lines
contained only the expected unique mutation, verifying that these cell lines were correctly
1Part of the Integrated Cancer Genomics Division at the Translational Genomics Research Institute, Phoenix,
AZ. See Materials and methods, section 2.16
72 Plasma Membrane Profiling
identified. The 10 identifying sequencing traces are shown in figure 3.1.
For MM.1S the sequencing trace suggested an issue with cross-contamination due to the
difference in intensity for adenine and guanine at the expected mutation site (fig 3.1). These
would have been expected to be equal for a heterozygous mutation. However, morphological
assessment and all flow cytometry analysis suggests that this is truly a single cell population.
This difference may be explained due to the DNAH14 locus, which is mapped to chromosome








OCI-My7 APC2 p.P406L cCc/cTc Heterozygous
INA-6 ELF1 p.I293L Att/Ctt Heterozygous
KMS-12-BM DOCK8 p.P1019L cCa/cTa Heterozygous
MM.1S DNAH14 p.K3359R aAa/aGa Heterozygous
OCI-My5 EYS p.E1412Q Gag/Cag Heterozygous
SK-MM-1 IRAK3 p.L399R cTa/cGa Heterozygous
NCI-H929 BRCA2 p.R2668G Aga/Gga Homozygous
JIM3 LRP10 p.P614A Ccc/Gcc Heterozygous
OPM-2 APOB p.F1480C tTt/tGt Heterozygous
LP-1 LRP10 p.R554Q cGa/cAa Homozygous
Table 3.1 HMCL identifying missense mutations. The amino acid and corresponding DNA
substitutions for the unique missense mutations used to identify the 10 HMCLs.
Fig. 3.1 HMCL sequencing traces. The genomic DNA sequencing traces for all 10 HMCLs
confirm the presence of the expected identifying missense mutation (highlighted in blue).
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3.2.2 Isolation of primary myeloma samples
PMP enriches for plasma membrane proteins, a relatively low abundant protein population.
Because of this a much larger starting amount of material is required compared to whole cell
proteomic techniques. Whilst HMCLs can be grown up accordingly and represent a pure
cell population, primary samples are much more complex, comprising a mix of different cell
types. The total number of cells obtained in a BMA and the percentage of plasma cells can
also be highly variable. The next consideration in this study, therefore, was to ensure that a)
enough plasma cells could be extracted from individual samples and that b) they were of a
sufficiently high purity for mass spectrometry.
Plasma cells were isolated from bone marrow aspirates using microbeads targeting CD138
(syndecan-1), a plasma cell marker. Samples were analysed by flow cytometry before and
after selection to determine sample purity. As shown in figure 3.2 depicting a representative
sample, there was a high level of purity for CD138 positive cells following selection. Greater
than 98% purity was achieved across all samples analysed which was sufficient for mass
spectrometry analysis. Morpholigical assessment by May-Grünwald-Giesma staining was
also used to further verify the purity following plasma cell isolation (data not shown). All
primary sample processing and biotinylation was performed in collaboration with Dr S Surget
and Dr J Ballester Beltran2.
Fig. 3.2 CD138+ cell purity before and after plasma cell separation. CD138+ cell purity was
assessed by flow cytometry before and after magnetic microbead selection. A representative
histogram is shown (BM014) with IgG1 isotype control in white (no fill) and anti-CD138-PE
in grey (filled).
2Mike Chapman Group, Department of Haematology, University of Cambridge
74 Plasma Membrane Profiling
Fig. 3.3 Total CD138+ cell counts from all samples processed. The total number of CD138+
cells was determined for each sample based on either cell counts following CD138 selection
or estimated by the percentage infiltration determined by flow cytometry. Samples which
were biotinylated for PMP are shown in blue.
Following discussions with Dr James Williamson, it was determined that a starting
number of 1x107 plasma cells would provide a sufficient quantity of protein following
biotinylation. This took into consideration the potential loss of cells during the multiple wash-
ing steps whilst remaining within an achievable range. Out of the 117 BMA processed to data,
only 17 samples provided ≥ 10x106 CD138+ cells. A total of 17 BMAs were biotinylated,
including some samples with less than the required starting number of cells. Figure 3.3 sum-
marises the total number of CD138+ cells per sample and the number of samples biotinylated.
3.2.3 Establishment of PMP
At the start of this project, plasma membrane profiling was a relatively new technique and
had not been applied previously to myeloma. In adopting PMP, several pilot experiments
were performed to confirm that each step of the protocol was working sufficiently.
One of first potential challenges that could be encountered in applying this technique is
the failure of the aminooxy-biotinylation reaction to sufficiently label the cell surface proteins.
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In conjunction with this, the acidic conditions required for labelling may be poorly tolerated
by the primary samples, which are fragile and can be difficult to handle ex vivo. The first
initial experiment was therefore to test the efficiency of this reaction in all ten HMCLs and a
selected few initial primary samples. Samples were incubated with aminooxy-biotin, sodium
periodate and aniline in PBS pH 6.7. The reaction was quenched following the addition of
glycerol and the incorporation of the biotin tag into plasma membrane proteins assessed by
flow cytometry using a streptavidin-APC conjugate. There was a clear separation between
samples before and after biotinylation, with a strong shift in signal intensity (average MFI
ratio of 720 ±261 (mean ±SD, n=10), figure 3.4. Primary samples also exhibited a high
incorporation of biotin, although there was a greater variability between samples (MFI ratio
of 1862 ±672 (mean ±SD, n=4)).
The biotinylation reaction itself was well tolerated, with a mean 12.9% reduction in
viability in the HMCLs following aminooxy-biotin labelling. As anticipated, primary cell
viability was more affected by the reaction but was still considered to be within an acceptable
range (27.6% average loss of viability between before and after biotinylation). Ensuring
that all centrifugation steps during the plasma cell isolation were kept at 4°C was found to
improve primary cell viability (personal observation).
Having confirmed that there would be no challenges presented by the initial biotinylation
step, I next proceeded to confirm that there would also be no technical challenges during
the second step (pulldown and labelling) of the PMP workflow and that I would be able to
achieve a high level of plasma membrane protein enrichment. This was a particular concern
for the primary samples in which I had observed a higher percentage of cell death, which may
compromise the cell membrane integrity and impact the amount of intracellular contaminants.
To assess the pulldown and labelling, a total of three pilot mass spectrometry runs were
performed.
From our preliminary biotinylation experiments, three samples were selected for these
pilot runs: two HMCLs and one primary sample. Biotinylated proteins were enriched by
affinity-purification before dentaturation, alkylation, reduction and finally digestion with
trypsin. Samples were then analysed using a nano LC-MS platform and the subcellular
localisation of identified proteins inferred from GOCC terms. The total number of proteins,
their relative abundance and subcellular localisation from these pilot studies are summarised
in fig 3.5. Protein enrichment was calculated as the percentage abundance.
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Fig. 3.4 Labelling of HMCLs and primary MM samples by aminooxy-biotin. Cells were
incubated with 1mM sodium periodate, 10mM aniline and 100mM aminooxy-biotin in PBS
pH 6.7 for 30 minutes at 4°C in the dark. A sample population was taken before biotinylation
(no fill) and after (fill) and incubated with streptavidin-APC before flow cytometric analysis.
A representative patient sample (BM001) is shown in pink.
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The first two MS pilot experiments assessed the level of plasma membrane protein en-
richment in the HMCL samples. In run one, a total of 413 out of 696 unique proteins were
identified as ’plasma membrane’ with an enrichment of 87.9%. For run two, sample peptides
were labelled using the isobaric TMTZero tag before MS analysis. 114 unique proteins
were identified, with 92 annotated as ’plasma membrane’ with a respective enrichment of
80.3%. The TMT tag was well incorporated, with 706 out of 718 (98%) peptide-spectrum
matches (PSMs) identified as containing a TMT modification. The acquisition method for
the TMT label (MS3) in conjunction with the short gradient used meant the total number
of proteins identified was much lower than the first run. As this list was smaller, the ’other’
proteins were manually annotated and a further seven determined to be plasma membrane
proteins due to their possession of an intracellular and extracellular domain as well as a
N-Acetylglucosamine modification in the later domain. Nine of the remaining ’other’ pro-
teins were identified as either naturally biotinylated, such as ACACA, or were environmental
contaminants (for example, K1C9 (keratin)). Overall, the plasma membrane protein en-
richment may therefore be potentially much greater than what is predicted using GOCC terms.
The final test run was to ensure that I was also able to achieve a high level of enrichment
in the primary samples. A total of 988 unique proteins were identified. 438 were classed as
’plasma membrane’. Although the ratio of ’non-PM’ to ’PM’ was higher compared with the
first two runs, the actual enrichment was still relatively high (77.5%). A further assessment of
these ’non-PM’ proteins revealed 252 were annotated as ’GO_extracellular_vesicular_exosome’
or ’GO_extracellular_region’, suggesting that these may be potential plasma membrane-
associated proteins. Overall, the level of PM protein enrichment across these preliminary
studies was consistently high, ranging between 77.5% and 87.9%, consistent with other
studies run by the Lehner group (personal communication).
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Fig. 3.5 Total number and enrichment of plasma membrane proteins identified in PMP
pilot studies. Biotinylated proteins from three separate pilot runs (OCI-My5, LP-1 and
BM002) were affinity-enriched before denatured, reduced, alkylated and digested with
trypsin. Peptides from run two (LP-1) were labelled using the isobaric tag TMTZero. All
samples were then analysed using a nanoLC-MS platform. A The total number of proteins
identified in all three runs. B Subcellular localisation enrichment as determined by protein
abundance. The number/percentage enrichment for ’plasma membrane proteins’ is shown in
blue.
3.2.4 In vitro generation of healthy plasma cell controls from B cells
Our initial aim was to employ PMP to characterise the cell surface proteome of both ma-
lignant and healthy plasma cells. Any proteins that were identified as aberrantly expressed
in the myeloma samples would be taken forward as potential monoclonal antibody target
candidates. However, there were several challenges associated with obtaining healthy, age-
matched samples, including the ethics of obaining BMAs from healthy donors and the rarity
of this cell population. A proposed alternative was to use an in vitro model of differentiation
to generate plasma cells from B cells isolated from the peripheral blood of healthy individuals.
Isolated B cells from healthy donors were stimulated using a combination of CD40L-
expressing cells, IL-2, IL-21 and F(ab’)2 anti-IgG/IgM over six days to drive differentiation
into plasmablasts. These plasmablasts were then further differentiated into a mature plasma
cell phenotype over the next seven days using a co-culture system with the stromal cell line
M2-10B4 and the addition of IL-21, IL-6 and IFNα . Between day 0 and day 6 I observed
a decrease in the expression of the pan B-cell marker CD20, with a concomitant increase
in CD38 expression. From day 6 onwards, I observed a further decrease in CD20, and an




Sample ID D0 D3 D6 D10 D13
LC002(i) 1 0.49 5.9 - 0.24
Starting from naive/memory B cells
Contamination of CD16+ cells (27%)
between D10 and 13
LC002(ii) 1 0.78 6.06 0.39 0.1 Starting from naive/memory B cells
LC003 1 0.79 5.3 2.1 0.95 Starting from naive/memory B cells
LC004(i) 1 2.6 66 18 2 Starting from memory B cells
LC004(ii) 1 2.8 38 15.4 4.4 Starting from memory B cells
Table 3.2 Cell amplification (fold increase relative to the day 0 B cell input) across the
timecourse of the differentiation protocol for each sample.
mature plasma cell phenotype, figure 3.6. CD16 expression was monitored to ensure that the
culture was not overtaken by any NK cells that may have been retained following selection,
as occurred in our initial test (LC002(i)). By day 13, 70% ±9% (mean ±SD, n=4) of the
population were CD38hiCD138pos.
Mirroring plasma cell differentiation in vivo, there was an initial expansion of the B cell
population between day 0 and day 6, closely followed by a population contraction. The
magnitude of this amplification greatly varied between samples, table 3.2, and our initial
experiments provided a low yield of plasma cells (0.1 and 0.95 total cells at day 13 for every
1 B cell seeded on day 0 for LC002(ii) and LC003 respectively). This was much lower
than expected based on personal communication with Sophie Stephenson3 and the available
published literature. By selecting only for mature B cells instead of starting with an unsorted
mixture of naive and memory B cells, I observed an improvement in the plasma cell yield (2
to 4.4 fold amplification in LC004(i) and (ii) respectively).
Although I was able to successfully generate plasma cells from healthy-donor derived
B cells and the cell yield was improving as I gained experience with the technique, the
associated costs, culture space and time that would be required to generate 1x107 plasma
cells resulted in the discontinuation of this approach. It was then determined to proceed and
profile eight primary samples without the normal BM plasma cell controls.
3Reuben Tooze’s Group, Faculty of Medicine and Health, University of Leeds
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Fig. 3.6 In vitro generation of healthy plasma cells. Healthy, peripheral blood B cells
were differentiated into plasma cells using a combination of CD40L, IL-2, IL-21, F(ab’)2
anti-IgG/IgM Il-6 and IFNalpha over 13 days. The example (LC003) depicted shows the
phenotypic changes as cells matured from CD20hiCD38lowCD138neg B cells at day 0 to
CD20l0wCD38hiCD138neg plasmablasts by day 6 to CD20negCD38hiCD138pos plasma cells
at day 13 and onwards. CD16 was used to monitor NK cell contamination. The forward/side
scatter plot exemplifies the extensive cell death I observed during this differentiation.
3.2 Results 81
3.2.5 Plasma membrane profiling of HMCLs and primary myeloma
samples
To characterise the cell surface proteome in myeloma, I chose to use two 10-plex experiments
to quantitatively compare both HMCL and primary samples. This would enable us to identify
proteins that are present in primary disease but also in cell lines, which provide a more
tractable model for target validation. Aminooxy-biotinylated proteins were prepared from
samples as previously described and captured using streptavidin-agarose beads. Proteins
were then denatured, reduced, alkylated and digested with trypsin on-bead. Digested peptides
were labelled using tandem mass tags (TMT10plex) to enable the relative quantitation of
up to ten samples at once. Following labelling, 3% of each sample per 10-plex was pooled
and 50% injected over a 90 minute gradient without fractionation as a test pool to determine
if any adjustments in sample quantity would be necessary prior to the final pooling. The
final pooled samples were subject to fractionation before MS analysis performed by Dr J
Williamson. A total of ten HMCLs and eight primary samples were profiled.
The initial PMP experiment was to characterise the HMCLs. These ten cell lines were
chosen to provide the best cover of all the major chromosomal translocations, copy number
variations and other mutational events that occur in myeloma (table 3.3). Across the ten
samples, 3,131 unique proteins were quantitatively analysed. Using Gene Ontology Cellular
Compartment (GOCC) classifications as an estimate of enrichment, 1,159 of these were
determined to be ’plasma membrane’ proteins with a mean enrichment of 66.9% ±6.6%
(SD) across all samples.
The second PMP experiment consisted of eight primary samples and a re-run of two
cell lines from the first PMP: KMS-12-BM and JIM3. These two lines were included to
provide reference samples for comparisons between the two experiments. KMS-12-BM
and JIM3 were chosen as these samples were considered to provide the largest coverage
of all proteins identified in the first run. The patient characteristics of the eight samples
profiled are detailed in table 3.4. These samples provided a good mix of patient charac-
teristics, with samples taken at both diagnosis (n=5) and at progression/relapse (n=3). A
greater total number of proteins were quantitatively analysed in this second run (4,962
unique proteins). The enrichment for plasma membrane proteins was lower compared with
the first run (51.8% ±4.2%(mean ±SD)), but still a substantial number of ’plasma mem-
brane proteins’ were identified (1,644 proteins). A further 874 proteins were annotated
as ’GO_extracellular_region/space/exosome’. The primary samples appeared to be much
more sensitive to the biotinylation protocol and so it is unsurprising that there was a higher




Subgroup RAS status p53 status
OCI-My7 t(11;14) CCND1 NRAS (G61K het) WT
INA-6 t(11;14) CCND1 NRAS (G12D het) Q331X het + K132M het
KMS-12-BM t(11;14) CCND1 WT R337L homo
MM.1S t(14;16) c-MAF KRAS (G12A het) WT
SK-MM-1 t(14;20) MAFB NRAS (G12D het) R175G het
OCI-My5 t(14;16) c-MAF WT Frameshift homo
NCI-H929 t(4:14) MMSET/FGFR3 NRAS (G13D het) WT
JIM3 t(4:14) MMSET/FGFR3 KRAS (G12D het) R273C homo
OPM-2 t(4:14) MMSET/FGFR3 WT R175H homo
LP-1 t(4:14) MMSET/FGFR3 WT E286K homo
Table 3.3 Known major genetic events of the HMCLs profiled. Het=heterozygous.
Homo=homozygous. WT=wild-type.






BM004 70 M D 22% 1q amplification and chr.13 deletion
BM014 68 M D 15% No IgH rearrangment
BM035 72 F D ND ND
BM040 59 M P/R 65% No abnormalities found
BM044(d) 76 M D 20% t(14;16), 1q amplification and chr.13 deletion
BM049(d) 62 M P/R 94% ND
BM066(d) 88 F D 27% 1q amplification and chr.13 deletion
BM068 65 F P/R 65% 1q amplifcation
Table 3.4 Patient sample characteristics. CD138 infiltration was determined by flow cyto-
metric analysis of the percentage of CD138+ cells present in each BMA post RBC lysis.
M=Male; F=Female; D=diagnostic sample; P/R= progression/relapse sample; ND=not done.
(d)=deceased.
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number of contaminating intracellular proteins. Protein enrichment by both total unique pro-
teins identified and by the relative abundance in both PMP experiments is shown in figure 3.7.
Fig. 3.7 Total number and enrichment of plasma membrane proteins identified by PMP.
Biotinylated proteins from HMCLs and primary samples were affinity-enriched before
denatured, reduced, alkylated and digested on-bead. Peptides were labelled using TMT10-
plex before pooling and MS3 analysis on a nanoLC-MS platform. A The total number of
unique proteins identified in HMCLs (PMP run one) and in primary samples (PMP run two).
B The relative enrichment of plasma membrane proteins as determined by protein abundance.
Proteins were annotated as ’plasma membrane’ or ’other’ using GOCC annotations.
Data was then processed as follows. Firstly, any proteins identified by only a single,
unique peptide were excluded on the basis that these had a high probability of being false
positives. These proteins tended to be of very low abundance. Next, as I was only interested
in proteins that had been identified in both HMCLs and primary samples, I excluded proteins
that were identified by only one PMP 10-plex. These were also proteins of low abundance
and were likely to have either been below the threshold of detection for the first run, or
were too variable to be detected consistently. Figure 3.8 shows the overlap between the two
datasets. Nearly all (2,077 out of 2,356) proteins from the HMCL PMP were identified in the
primary cells. Data was then log transformed before column-centering and scaling by the
median absolute deviation for all statistical analysis. Except where noted, all data is plotted
using the raw values.
Finally, protein subcellular localisation was re-annotated. Although GOCC terms alone
can give us a rough prediction as to whether a protein is localised to the ’plasma membrane’
or not, these GO terms are highly subject to inaccuracies and the completeness of the lit-
erature. Also, the plasma membrane is highly dynamic and proteins can associate with
the membrane in various ways. Thus, a more comprehensive annotation was required to
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Fig. 3.8 A venn diagram depicting the overlap of the proteins identified in both runs. Overall,
the majority of proteins identified in PMP run one (2077 out of 2356) were also identified in
PMP run two.
discriminate between proteins expressed on the cell surface and therefore ’targetable’ by a
therapeutic antibody, and those intracellular peripheral proteins which are less so. For this
annotation, extracellular and transmembrane domains were identified by Uniprot and used in
conjunction with GOCC terms. These domains are either curated by experimental evidence
or using topology prediction software. All proteins identified were then grouped into the
following five main categories4:
• Extracellular plasma membrane: Any protein that contained an extracellular and
transmembrane domain as curated by Uniprot.
• Other plasma membrane: Proteins that were annotated as ’plasma membrane’ by GO
terms but did not contain either an extracellular or transmembrane domain. This group
likely contains proteins that are peripheral or lipid-anchored membrane proteins.
• Secreted: Any proteins with either an Uniprot or GO annotation for ’secreted’, includ-
ing those annotated as ’extracellular exosome/region’ that did not fall into the above
two categories.
• Other membrane: Proteins that contained only a transmembrane domain with no other
annotations either by Uniprot or GO to infer plasma membrane localisation.
4Protein subcellular localisation strategy designed by Dr M Chapman
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• Non-membrane or unknown localisation: Any remaining proteins that did not fall
into the above categories. This included proteins with no evidence for membrane
localisation or those that were unannotated by both databases.
From this classification, a total of 1,319 proteins were classified as plasma membrane or
associated proteins with a mean enrichment of 79.5% ±5.59% (±SD, n=20). The summary
of the number of proteins identified for each category and their relative abundance is shown
in figure 3.9.
Fig. 3.9 The subcellular localisation of all proteins commonly identified by PMP. Using
a combination of Uniprot and GO annotations, the 2,077 proteins identified in both PMP
experiments were assigned to one of five groups. The total number of proteins A and their
relative enrichment (determined by protein abundance) B for each group is depicted.
To assess the reproducibility of PMP and to confirm it was appropriate to make compar-
isons between the two datasets, I compared protein expression in both cell lines between the
two experiments. There was a high inter-run consistency, with a strong positive correlation for
both KMS-12-BM (r(2,077)=0.755, p<0.0001) and JIM3 (r(2,077)=0.692, p<0.0001), figure
3.10. There was a slightly stronger correlation between ’extracellular’ and ’other’ plasma
membrane proteins, r(851)=0.784, p<0.0001 and r(851)=0.727, p<0.0001, for KMS-12-BM
and JIM3 respectively. This strong correlation gave us confidence in the dataset generated by
PMP.
To further validate our results, I compared the expression of six plasma membrane pro-
teins by flow cytometry (FCM) and PMP. These six antigens were selected as proteins which
were well described in the literature for myeloma and were known to have good working
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Fig. 3.10 A comparison between the two HMCLs reveals a high inter-run consistency. For
all proteins identified in both datasets, the relative expression was compared between PMP
run one and run two for both KMS-12-BM and JIM3. Correlation is reported as Pearson’s
correlation coefficient. *=p<0.05, **=p<0.01, ***=p<0.001.
flow cytometry antibodies available. The expression of each protein was measured by FCM
across all ten HMCLs and the MFI ratio compared against PMP expression. As seen in figure
3.11, there was a strong positive correlation between PMP and flow cytometry across all six
antigens ranging from the lowest correlation with CD38 (r(10)=0.657, p<0.05) to the highest
with FGFR3 (r(10)=0.993, p<0.001).
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Fig. 3.11 Protein expression by PMP is correlated with expression by flow cytomery. Protein
expression for the six selected antigens was measured across all ten HMCLs profiled and
the MFI ratio compared against the relative expression by PMP. There was a strong positive
correlation as determined by Pearson’s correlation for all six antigens across the HMCLs.
*=p<0.05, **=p<0.01, ***=p<0.001.
Lastly, as a commonly used method of target identification relies on using gene expression
profiling, I wanted to assess how well the results of PMP correlated with RNAseq data across
the HMCLs. Using the publicly available RNAseq dataset from the Keats Lab, I observed
that there was a poor correlation between transcript levels and protein abundance resulting
in correlation coefficents ranging from 0.13 to 0.21 (figure 3.12). I next investigated if a
conversion factor (RNA-to-protein (RTP)) could be applied to the RNA levels to predict
protein abundance. For each gene, a specific RTP factor was calculated using nine of the ten
HMCLs as a training set. The RTPs across these nine cell lines were averaged and used to
predict protein abundance in the tenth cell line. This was repeated for all the HMCLs profiled.
As shown in figure 3.12, by applying a RTP conversion factor, the correlation between RNA
and protein expression levels was significantly improved, with correlation coefficients of
0.78 to 0.89.
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Fig. 3.12 Protein abundance is poorly correlated with RNA expression but can be predicted
by applying a RTP conversion factor. The total relative protein expression determined by
PMP was compared against RNA expression in all ten HMCLs. In grey (’uncorrected’) is
the direct gene-specific correlation between RNA and protein for each cell line. In blue
(’corrected’) is the correlation between the predicted protein abundance (determined by
applying an averaged RTP conversion factor to RNA levels) and the actual relative protein
expression by PMP. Each plotted cell line was excluded from the calculation of the average
RTP. Pearson’s correlation coefficient are reported.
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3.2.6 Identification of proteins associated with underlying genetic aber-
rations
As these HMCLs profiled are genetically well characterised, our next aim was to identify
any plasma membrane proteins whose protein expression is linked to specific mutational
events. This may improve our understanding of myeloma cell biology and would enable the
identification of markers associated with ’high-risk’ cytogenetics.
A student’s t-test was carried out to test the difference between protein expression for
each subgroup compared with the other HMCLs (see table 3.3). The greatest number of
significantly differentially expressed proteins were identified within the t(11;14) subgroup
with a total of 11 proteins (SLC22A23, ENTPD1, RELL1, CXADR, HSDB17B11, ABCC4,
ST3GAL1, ADCY9, ALG1, SLC25A20 and NDRG3) reported as significant (p<0.01 with
a BH-adjusted p value (q value) of less than 0.25). Only one protein associated with the
t(MAF) subgroup was reported as significant (STIM1, p<0.001, q=0.226) and none with
a q<0.25 were reported for t(4;14). The top 5 differentially expressed proteins for each
subgroup (both signficant and non-significant) are shown in figure 3.13.
For the secondary mutations, 11 proteins associated with the TP53 subgroup were re-
ported as significant: C16orf54, VAV1, CCT7, SLC33A1, EVI2B, REEP5, FDFT1, GNPTAB,
ALG2, ERGIC1 and CD58. p<0.01, q<0.25). Only one protein was reported as significant for
the RAS mutated cell lines (MAP2K3. p<0.001, q=0.242). For both RAS and TP53, HMCLs
were broadly grouped into either WT or mutant. As a result some proteins may have been
missed that are associated with specific mutations, such as KRAS versus NRAS, figure 3.14.
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Although there appeared to be very few proteins that were significantly associated with
specific mutations, unsupervised clustering of the top 100 most variable proteins revealed
that there were distinct subgroups within the HMCLs profiled. Consensus clustering of
the plasma membrane proteins suggested a stable three-cluster solution (figure 3.15). This
three-cluster solution is shown in figure 3.16 as a heatmap of the relative protein expression
of the top 100 proteins across the 10 HMCLs (hierarchical clustering (Euclidean distance,
average linkage)). Within cluster one was OCI-My5, KMS-12-BM and MM.1S, cluster two
contained INA-6, OCI-My7 and SK-MM-1, and cluster three was JIM3, LP-1, NCI-H929
and OPM-2. Cluster three contained solely the t(4;14) cell lines which appeared distinct
from the other two subgroups, suggesting that there was a t(4;14) signature at the plasma
membrane. Importantly, this cluster was preserved despite the clustering method used, whilst
the other two groups appeared to be less stable. For instance, using Ward’s hierarchical
clustering (Pearson distance) KMS-12-BM was linked with the second cluster containing the
other two t(11;14) cell lines and SK-MM-1.
Fig. 3.15 Consensus clustering reveals three stable clusters within the ten HMCLs profiled.
Colour-coded heatmaps of consensus clustering (Euclidean distance; average linkage) for
K=3, 4 or 5 confirms that K=3 as the most stable number of clusters.
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Fig. 3.16 Unsupervised clustering analysis reveals a t(4;14) signature at the plasma mem-
brane. A heatmap comparing the relative expression of the top 100 most variable genes.
Hierarchical clustering (Euclidean distance, average linkage) of these proteins reveals three
subgroups, with one cluster containing solely the t(4;14) cell lines. This suggests that
the t(4;14) translocation may dysregulate the expression of a large number of cell surface
proteins.
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3.2.7 Comparison of protein expression between HMCLs and primary
samples
HMCLs are routinely used as functional models in myeloma as an alternative to primary
samples. These established cell lines provide a continuous source of cells that are both
easier to handle and manipulate. HMCLs have also been shown to recapitulate the molecular
heterogeneity of primary disease and can considered to be representative models [303].
Despite this, it is axiomatic that these cells will differ both genetically and phenotypically
from primary disease. Having profiled both sample types, I was interested in identifying any
proteomic differences between the two.
Fig. 3.17 More than 530 proteins are significantly differentially expressed between HMCLs
and primary samples at the cell surface. A volcano plot representation of the results of a
student’s t-test caried out, comparing protein expression by PMP between primary samples
and HMCLs. A fold change cut off was set at ± 1.5 and a significance cut-off of of <0.05
using BH-adjusted p values (q values). Significant proteins with a fold change >± 1.5 are
shown in pink, significant proteins with a fold change of less than ±1.5 shown in purple, non-
significant proteins with a fold change greater than ±1.5 are shown in green and the remaining
non-significant proteins in orange. Those with a positive fold change are over-expressed in
HMCLs compared with primary cells.
3.2 Results 95
A student’s t-test was carried out for all 2,077 proteins comparing protein expression
between primary cells and myeloma cell lines. 530 proteins were identified as being sig-
nificantly differentially expressed with a p<0.001 (q<0.001). There was an even divide
between up- and down-regulated proteins, with 276 proteins downregulated and 254 up-
regulated in HMCLs compared with primary disease. These results are summarised in the
volcano plot in figure 3.17. The top five proteins upregulated as ranked by fold change were
CTAG1A, EFNB2, ICAM5, RANBP2 and LRFN4. The top five downregulated proteins
were LRRC16A, SBF1, OSBP, GRK6, ITGB3. The top 100 most significant proteins and
their relative expression across all 20 samples are depicted in the heatmap in figure 3.18.
The heatmap reveals clear differences in protein expression between the two sample types.
Gene enrichment analysis was performed on these top 100 proteins. The most significantly
enriched gene sets are also shown in figure 3.18 alongside the raw and adjusted p values.
This analysis revealed an enrichment in cell signalling in primary cells, in particular proteins
involved in the negative regulation of the ERBB signalling pathway (q=2.5x10−5) and in the
non-canonical Wnt signalling pathway (q=3.5x10−5). In the HMCLs, there was an enrich-
ment for proteins involved in cell replication, such as the cell cycle process (q= 2.6x10−12)
and mitotic nuclear division (q=1.7x10−6).
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Fig. 3.18 The most significant differentially expressed proteins between HMCLs and primary
samples. The relative expression for the top 100 most significant proteins across all 20
samples profiled by PMP is shown as a heatmap, revealing clear differences between primary
samples and HMCLs at the cell surface. The results of the Gene enrichment analysis for
proteins upregulated in primary MM and those upregulated in HMCLs is also depicted,
alongside the raw and BH adjusted p values (q values)
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3.2.8 Identification of novel monoclonal antibody targets
To identify novel monoclonal antibody targets, proteins were prioritised by a number of
criteria. The first criteria was exposure at the cell surface and therefore proteins without
an annotated extracellular domain were excluded from the starting list of 2,077 proteins.
Proteins were then ranked according to a combination of a) high and ubiquitous on-tumour
expression, b) low off-tumour expression and c) the size of the extracellular domain. Having
observed clear differences between primary cells and cell lines, on-target expression was
calculated as the median expression in the primary samples only. Healthy tissue expression
was predicted using the publicly available whole-cell proteomics database (The Human
Proteome Map [300]). CD38 and SLAMF7 expression (the targets of daratumumab and
elotuzumab respectively) were used as a guide for a threshold for tolerable off-tumour expres-
sion. Figure 3.19 compares the median expression of each ’extracellular plasma membrane’
protein against the normalised length of the extracellular domain, which was used as an
approximation of antigenicity. Proteins are also colour-coded by their maximal expression in
the lung, liver, heart or kidney. This bioinformatic approach revealed 20 potential monoclonal
antibody targets, summarised in table 3.5. Two additional targets, ROBO1 and EPHB2, were
initially identified from the first PMP experiment and are discussed in the following chapters.
A final extensive literature review revealed that six proteins had already been identified as
therapeutic targets for MM and therefore were excluded from our list of top candidates
(CD38, SLAMF7, LY75, ITGA4, MERTK and IFNAR1).
The expression of these targets across all healthy tissue is summarised in figure 3.20.
Although none of the targets identified exhibited a ’clean’ off-tumour expression profile,
the majority of these proteins were expressed at low to medium levels in normal tissue.
Comparing with CD38, which is well described to be expressed on a multitude of cell types,
off-tumour expression at these levels did not appear to be a critical reason for exclusion
at this early stage. Importantly, there was no high expression in the heart, kidney, liver or lung.
Using this analytical pipeline, I identified 16 high-ranking candidates to take forward as
potential monoclonal antibody targets.
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Fig. 3.19 High ranking monoclonal antibody targets identified by high on-tumour and low
off-tumour expression. A scatterplot comparing the expression of all ’extracellular plasma
membrane’ proteins by the log median expression in primary cells against the length of
their extracellular domain (standardised). Each point (representing an individual protein) is
colour-coded according to their maximal expression in high-risk tissue (heart, liver, lungs and
kidney). Points in black did not have normal tissue expression data available (The Human
Proteome Map) [300]. Protein names highlighted in black are the novel targets identified
by the analytical pipeline to be taken further forward. Highlighted in blue are those that
were already described in the literature as potential therapeutic candidates. Proteins in red
are monoclonal antibody targets that are already FDA approved or are currently in clinical
trials for MM. ROBO1 and EPHB2 (*) are two proteins that were identified initially by high
expression in HMCLs whilst I was waiting for the primary PMP results and as such are













































































































































































































































































































































































































































































































































































































































































































































































































































































































































100 Plasma Membrane Profiling
Fig. 3.20 Expression of the highest ranking candidates in normal tissue. A whole cell mass
spectrometry dataset (The Human proteome Map [300]) was used to determine protein
expression of the top 20 hits in healthy, normal tissue. A maximum threshold of expression in
the high-risk organs (heart, kidney, liver and lung) was determined by the expression of CD38.
Proteins highlighted in green are those novel targets taken forward, whilst those highlighted
in blue are proteins that were identified by our analytical pipeline but were already described
as therapeutic targets for MM.
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3.3 Chapter conclusions
The overall aim of the work presented in this chapter was to establish the PMP technique
developed by Professor P Lehner and Dr M Weekes and to use PMP to quantitatively
characterise the myeloma cell surface proteome. To this extent, I profiled a total of ten
HMCLs and eight primary samples. A total of 2,077 proteins common to both experiments
were quantified, of which 1,319 were curated as ’plasma membrane’ or ’plasma membrane
associated’. From these proteins, I identified 16 monoclonal antibody target candidates to
take forward.
3.3.1 In vitro generation of plasma cells from B cells
Our initial proposal was to use PMP to quantitatively compare the cell surface proteome
between normal plasma cells and malignant cells. Due to the ethical challenges and the
potential difficulties in sourcing a sufficient number of cells from healthy donors, especially
considering the challenges with isolating enough cells in primary MM (fig 3.3), I considered
using an in vitro approach to generate plasma cells. Initial attempts at replicating this tech-
nique resulted in very low yields of cells, with less than one cell harvested at day 13 for every
B cell seeded at day 0. Despite this, there was a clear transition from a B cell to a plasma
cell phenotype with a decrease in CD20 and an upregulation in CD38/CD138, two essential
markers of plasma cells (fig 3.6). By selecting only for memory B cells, I observed a clear im-
provement in the number of viable cells at day 13 generated for every B cell seeded (2 to 4.4
cells, table 3.2). After day 13 there was a continued reduction in the number of viable cells,
but even at day 20 there was still a small viable population of CD20negCD138posCD38hi
plasma cells (data not shown). This improvement in cell viability would corroborate with
published literature that memory B cells enter the differentiation pathway much more readily
than their naïve counterparts [306]. However, this would not have been expected to impact
plasmablast numbers at days 3 to 6 [94] and it may be simply due to donor variation as these
two experiments were repeats of the same cone. An improvement in cell viability may have
also been due to the increased confidence in using this technique.
Despite this, I decided to not include these in vitro differentiated plasma cells for PMP for
several reasons. Firstly, the number of plasmablasts that would need to be cultured to generate
1x107 plasma cells and the associated costs was considered prohibitive. Especially consider-
ing that our amplification counts did not take into account that the final cell population at day
13 is not a CD138+ pure population. In the interests of time, I decided to proceed with the
profiling of malignant plasma cells only. Although I would be unable to make comparisons
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between healthy and malignant tissue, I would be able to profile a larger number of primary
samples and concluded that this would not impact target discovery, although this approach
may miss proteins involved in malignant transformation. Many proposed therapeutic targets
have not been identified through cross-comparisons and several, including CD38 and CD138
are expressed at comparable levels on normal and malignant plasma cells. Furthermore, it
has recently been shown that SLAMF7 (the target of elotuzumab) expression levels may be
lower in myeloma compared with normal bone marrow plasma cells and as such would been
missed by a straight comparison between normal and malignant cells [307][308][309].
3.3.2 Plasma membrane profiling of MM
Using PMP, 3,131 and 4,962 unique proteins were identified in HMCLs and primary samples
respectively, of which 2,714 were common to both datasets (fig 3.8). Although thresholds
setting the FDR are applied to peptide identification in mass spectrometry, the sheer number
of peptides identified means several false positives may be retained leading to false protein
identifications. To reduce the number of false identifications, I excluded proteins identified
by only one unique peptide, removing a total of 637 common proteins. This was a highly
conservative method and several proteins that have few tryptic peptides may have been lost.
However, typically these proteins were of low abundance and the majority were curated as
’non-plasma membrane’ and so were unlikely to be of interest for target discovery. They may
still represent potential biomarkers of interest though which are typically of low abundance,
and this is an important point to note when analysing this dataset. Less stringent methods
may be potentially applied to distinguish true and false identifications amongst single-hit
proteins [310].
As I was primarily interested in proteins highly expressed in primary MM but also re-
tained in HMCLs to enable later validation work, I focussed only on proteins common to
both datasets. As a result, a large number were excluded that were only identified in PMP run
one or two, primarily from the primary samples (figure 3.8). It could be considered that these
are proteins unique to primary MM but this is unlikely as two HMCLs were included in this
second run. Analysis of the GO term enrichment of these excluded proteins indicates these
were more commonly low-abundant, non-plasma membrane proteins and it could be possible
that these are proteins that were simply missed in the first run due to a higher threshold of
detection. Despite the exclusion of these proteins, there was still a large list of potential
targets left.
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The plasma membrane is highly dynamic, with the continuous recycling, secretion and
internalisation of proteins and can be subjective to external factors such as cell density. As
such, PMP is only capturing a particular ’snapshot’ of the cell surface proteome. Comparing
the expression of the commonly-identified proteins between both PMP experiments revealed
a strong positive correlation (figure 3.10, correlation coefficient of 0.69 to 0.76). Considering
that these HMCLs were profiled almost a year apart, at different passages and from different
stocks, our results by PMP appear to be highly representative of the HMCL cell surface
proteome. This, in conjunction with the positive correlation between PMP and FC (figure
3.11, correlation coefficients ranging from 0.66 to 0.99), gave us confidence in using this
dataset for target discovery.
One of the main arguments for proteomic profiling over the use of gene expression profil-
ing is the highly variable (and often low) correlation between RNA and protein expression at
the cell surface. Interested in how the RNA and protein levels compared for the ten HMCLs
profiled, I found very poor correlation (coefficients from 0.13 to 0.21) between the two at
a global level. Although on a case-by-case basis, I did identify some proteins that were
well-correlated with RNA. It could be argued that as the RNAseq was not performed directly
on the cells profiled that this may account for the poor correlation, but considering that at
least one line (NCI-H929) was derived from stocks from the Keats lab this is unlikely to
be the full explanation. This demonstrates that RNA expression alone is a poor proxy for
protein abundance and GEP should be used with caution for target discovery. However, simi-
larly to Wilhelm and Edfors [302][305], I demonstrated that by applying a RTP conversion
factor, protein abundance could be much more accurately predicted from RNA expression
data (figure 3.12). Thus far, I have determined a RTP factor for over 2,000 proteins which
may enable the future use of RNAseq data as a less costly approach to plasma membrane
proteomics, although it will be important to further validate the preliminary data shown here.
3.3.3 Association of cell surface protein expression with underlying ge-
netic aberrations
As the HMCLs are genetically well profiled, it was of interest to use these lines to determine
if there were any associations between the expression of cell surface proteins and major
MM mutational events. This was for several reasons. Firstly, an association with high-risk
cytogenetics, such as dup(1q) and TP53 mutations, could help prioritise potential targets.
Secondly, this would aid our understanding of myeloma cell biology and help elucidate the
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cell-surface consequences of those mutations involved in a) malignant transformation (pri-
mary translocations) and b) driving disease progression (secondary mutations). Comparisons
may also help identify biomarkers that could be identified by flow cytometry instead of FISH
analysis, which is generally more labour-intensive and challenging to perform in very small
samples, to help predict a patient’s prognosis. Finally, myeloma is know to be genetically
diverse and tumours highly heterogenous. If targets are associated with particular mutations,
this may help determine if a target is ubiquitously expressed or restricted to a subclone.
Although the ten HMCLs were chosen to represent the major mutational events, the
number of cells within each group was small (ranging from n=3 to 4). As a consequence
there was limited statistical power in comparing genotype and protein expression and it is
unsurprising that I found very few proteins associated with genetic events after correction for
multiple testing. Despite this, I did identify several proteins that were reported as significant
for the t(11;14) (n=11) and the TP53 (n=11) subgroups (figure 3.13 and 3.14). For a select
few of these proteins, there was a good correlation with RNA and it was possible to look
for associations in a larger cohort using the available RNAseq data. An example of this is
ENTPD1 which was also found to be significantly upregulated in t(11;14) cell lines at the
RNA level, with a mean of 6575.4±2603.3 (n=13) compared against t(MAF) and t(4;14)
(mean= 2603.3±3351.4, n=31) (t-test, p<0.01). Although not all mutations reported a signif-
icant result, these may reveal trends that can be validated in a larger cohort. Interestingly,
unsupervised clustering of the HMCLs revealed that there was a distinct t(4;14) signature,
with these cell lines strongly clustering together, separate from the other subgroups (figure
3.16). The remaining two clusters were harder to define and appeared to be less stable, with
slight modifications to the predicted subgroups depending on the clustering method used.
These clusters did not appear to be linked to secondary mutations and may represent the
t(11;14) and t(MAF) subgroups.
Between primary cells and HMCLs, a large number of proteins were reported as statis-
tically significant after correcting for multiple testing (n=530, t-test q<0.001, figure 3.17).
Some of these reported proteins may be a result of two separate PMP experiments. Despite
normalisation, there were some noticeable differences in the tightness of the spread of the
data (data not shown). Comparing expression across the 20 samples profiled of the most
significant proteins revealed the majority of these are likely to be genuine differences be-
tween the two sample types rather than between PMP runs (figure 3.18). GO enrichment
analysis revealed that the proteins upregulated in the primary samples were involved in cell
signalling pathways, whilst those down-regulated were implicated in cell cycle progression.
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The down regulation in cell cycle was unsurprising as human myeloma cell lines are much
more proliferative than their primary counterparts. The Wnt signalling pathway has long
been recognised as being dysregulated in both HMCLs and primary samples compared with
normal BMPCs so it was interesting that it appeared to be upregulated amongst the primary
samples. Wnt signalling is known to play a pivotal role within the bone microenvironment in
MM and this may in part explain the differences.
3.3.4 Identification of novel targets
One of the biggest challenges faced in this project was determining how to narrow down a
list of >2,000 potential targets to a much more manageable list. Having considered several
methods, I settled on the following criteria to rank proteins: high on-tumour expression, low
off-tumour expression and the length of the extracellular domain.
For on-tumour expression I used the median relative expression in primary cells only. As
seen in figure 3.17 there were clear differences between the relative expression of targets in
primary samples and HMCLs. Two of the targets (ROBO1 and EPHB2) that are described in
the next chapter were in fact initially identified using only the HMCL PMP dataset whilst
waiting for the final results of the primary PMP. As clearly seen in figure 3.19, these two
proteins were expressed highly in the HMCLs but exhibited much lower expression in the
primary samples. Although this didn’t discount them as targets, it did reduce their priority.
By comparing the median expression rather than the maximum or mean expression in MM,
it was hoped that more ubiquitous proteins would be ranked over targets that were highly
expressed in only a few samples.
High expression alone does not necessarily translate to a good target. A number of high-
ranked proteins were observed to be also highly expressed in normal tissues. To avoid targets
that would exhibit unacceptable off-tumour toxicity, proteins were also ranked according
to their off-tumour expression as determined by whole-cell proteomics. In addition, these
target-expressing cells may act as ’sinks’, binding the antibody and reducing the number
of therapeutic antibodies that reach the tumour [311]. To compensate, an increased dose is
required which may then be associated with an increase in adverse events. As a threshold for
off-tumour expression, I examined the normal tissue distribution of several MM therapeutic
antibody targets that have either been FDA-approved or are currently in clinical trials. None
of our novel targets exhibited ’clean’ off-tumour expression profiles but did appear to be
within a similar range of known therapeutic targets (figure 3.20).
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The last criteria was the length of the extracellular domain. Whilst a protein may be
highly expressed in primary MM, it may be completely inaccessible to an antibody if the
extracellular domain is too short or steric hindrance prevents binding. As an initial step,
all proteins without an extracellular domain were excluded. Using 2D antigen prediction
methods to rank proteins was initially proposed. But these sequence-based methods which
rely on a combination of residue scoring, hydrophobicity, flexibility as well as other sequence-
determined information, are poor at predicting discontinuous epitopes. Considering that
>90% of antibody-binding epitopes are estimated to be discontinuous, these sequence-based
methods would likely have been uninformative. Structure based methods may be much
more informative but are still limited by the number of resolved antigen-antibody structures
available [312]. As an alternative, the length of the extracellular domain was used to rank
proteins as a surrogate for ’targetability’. Although the length of the domain doesn’t directly
translate into antigenicity, it could be considered that the longer the extracellular domain is,
the greater the chance of containing an antigenic region. Comparing the ranking based on
2D-antigen prediction and the length of the extracellular domain found very little differences
between the two methods.
Overall, there were multiple approaches that could have been used to identify novel
target candidates, but using this approach resulted in the inclusion of the two FDA-approved
antibody targets amongst the top hits.
Chapter 4
Establishment of a recombinant protein
production system
4.1 Introduction
In the last chapter I demonstrated that PMP provides an accurate and comprehensive analysis
of the cell surface proteome and applied a bioinformatical approach to identify novel thera-
peutic targets. To identify the best candidate to proceed with, it will be important to verify
expression in a large number of patient samples and to determine off-tumour expression. It
is expected, however, that the validation of many of these candidates will be hampered by
the lack of reliable, commercially available antibodies that recognise the protein’s native
conformation. As such, it will be necessary to generate tool antibodies for the further charac-
terisation of these targets. Furthermore, it will be imperative to develop a proprietary antibody
targeting any lead ADC candidate. To this extent, we have established a few commercial
collaborations and will require recombinant protein for antibody generation.
There are numerous expression systems available for recombinant protein production,
such as bacterial, insect, yeast and mammalian. There are several advantages and dis-
advantages to each system. Although bacteria are frequently used as a low-cost system
that can generate large amounts of protein in a short period of time, these cells lack the
mammalian chaperones and post-translational machinery. Membrane proteins are typically
heavily glycosylated and as a result, mammalian proteins produced using these systems may
be misfolded or inactive [313][314]. Mammalian systems, on the other hand, provide the
required post-translational modifications although at the cost of a lower yield [314]. Other
considerations in the establishment of a recombinant protein production system include
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transient versus stable transfection and the type of promoter used. Whilst transient systems
are initially quicker to establish, the efficiency of transfection is dependent on the cell line
used and can be highly variable [314]. Meanwhile, stable over-expression of the recombinant
protein under a constitutive promoter may trigger cell stress as a result of the high metabolic
burden, affecting protein yield [313]. The use of an inducible promoter can inhibit protein
production until an appropriate time. Taking into consideration the advantages of all these
respective methodologies, I chose to use the pcDNA5 FRT/TO tetracycline-inducible plasmid
(Invitrogen) in a stable mammalian expression system. This vector is stably integrated
into the mammalian host genome at a FRT site in a Flp recombinase-dependent manner
[315]. The use of this system ensures that the integration site is not random and as such is
transcriptionally active and prevents the disruption of other transcripts.
To simplify protein purification, I considered expressing only the extracellular domain of
each protein of interest since it represents the region of interest for the targeting antibody. By
removing the transmembrane domain and retaining the native signal peptide, the recombinant
protein is secreted directly into the cell culture supernatant. This not only reduces the num-
ber of purification steps but also segregates these proteins from the cytoplasmic proteases,
enhancing stability, and prevents the accumulation of proteins that may trigger cytotoxic
stress [316]. The addition of a cleavable His-tag further simplifies purification, enabling
the affinity-mediated isolation of these proteins from other cell culture media contaminants
[317]. Cleavage of the His-tag enables further purification, separating the cleaved protein
from other His-containing proteins. These tags may also provide compositional stability,
improving recombinant protein yields [318].
4.1.1 Chapter Overview
In this chapter I describe the establishment of a mammalian recombinant protein production
system. I demonstrate that these over-expressed proteins are successfully accumulated within
the cell culture media and describe the optimisation of protein yield using valproic acid
(VPA). I describe the successful cloning of five of our candidate proteins and the purification
of three to homogeneity. Finally, I demonstrate that the difficulties in producing recombinant
SEMA4A is likely due to the compositional instability of the truncated protein.
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4.2 Results
4.2.1 Establishment of an expression system
To produce protein for antibody generation and subsequent target validation, I have developed
an inducible mammalian protein expression system. The extracellular domain of each target
was amplified from HMCL cDNA by PCR and fused with a C-terminal 6x His-tag and TEV
protease cleavage site before ligation into the pcDNA5/FRT/TO expression vector. Target
DNA was then transfected into 293FT and selected using antibiotic resistance to generate
stable target-expressing cell lines. The 293FT cell line is derived from the 293T cell line and
contains a single integrated flippase recognition target (FRT) site enabling the recombination-
mediated integration of the pcDNA5 vector into the genome (generated by Dr A Reyes1). To
induce protein expression, 293FT were switched to FBS-free media containing doxycycline
at 30ng/ml. For the remainder of this section, 293FT cells transfected with the parental,
empty vector will be referred to as pcDNA5 and 293FT cells transfected with target DNA
will be referred to as pcGOI (gene of interest), e.g. 293FT expressing pcDNA5_EPHB2_HIS
are simplified to pcEPHB2.
The inclusion of the native signal peptide and removal of both the intracellular and
transmembrane domains ensures that the protein is secreted into the media, simplifying
purification and minimising proteolytic degradation. I confirmed that this system was working
for all cloned targets by Western Blot. Target-expressing 293FT cells were switched to serum-
free media and recombinant protein production induced by the addition of doxycyline (Dox,
30ng/ml). Cell culture media and whole-cell lysates were collected at various time points
and analysed by western blot using a poly-His antibody to detect the His-tagged recombinant
protein. As shown in figure 4.1 depicting a representative experiment using pcEPHB2, there
was an accumulation over time in the cell culture media (lower panel) compared to the
whole-cell lysates (upper panel). For all recombinant proteins, the band detected by the
poly-His antibody was at the correct predicted molecular weight.
One disadvantage to using a mammalian expression system compared with bacterial
and yeast systems, is the limited cell density under standard culture conditions and as a
consequence, a reduction in the total amount of recombinant protein produced. The next
aim therefore was to optimise the expression system in order to ensure maximal protein
production efficiency. Initial experiments were focussed on determining the optimal time
for supernatant collection. pcDNA5, pcEPHB2 and pcPLXNC1 were cultured in FBS-free
1M Zeviani group, Mitochondrial Biology Unit, University of Cambridge
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Fig. 4.1 Recombinant protein is secreted into and accumulates in the cell culture media over
time. pcDNA5 and pcEPHB2 cells were switched to FBS-free media with or without Dox
(30ng/ml). Cell lysates and culture media samples were collected at various time points and
analysed by Western Blot. Recombinant protein was detected using a poly-His antibody.
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media with Dox for three, seven or ten days. At each timepoint, cell viability was assessed
by trypan-blue exclusion and a cell culture media sample collected. Recombinant protein
was detected by Western Blot using a poly-His antibody and total protein quantified by
densitometry and calculated as the fold increase from day 3. As expected, there was an
accumulation of protein within the supernatant over time, with a 2.7 and 4.5 fold increase
for pcEPHB2 at day 7 and 10 respectively and 3.5 and 4.8 fold increase for pcPLXNC1
(fig 4.2A). For all three transfected cell lines (pcDNA5, pcEPHB2 and pcPLXNC1), there
was a clear loss of viability over time from 100% at day 0 to 68% (± 2.6% (SD)) at day
3 to 36% (± 5.3%) and 12.8% (10.1%) at days 7 and 10 (fig 4.2B). Although the greatest
amount of protein was collected at day 10, the accumulation of cell debris, specifically the
highly viscous DNA, made the separation of the cell culture from the cell pellet much more
difficult. To minimise the contamination of these products and intracellular proteins, day 7
was selected as the optimal day for collection. Analysis of mRNA by qRT-PCR showed that
transcript levels began to decrease at 96 hours (data not shown), and so a 72 hour Dox dosing
schedule was chosen.
I also analysed the effect of adding a recombinant protein production enhancer to the
cell culture media. Valproic acid (VPA) is a histone deacetylase inhibitor that is commonly
used in mammalian expression systems to improve the quantity of recombinant protein
produced. pcDNA5, pcEPHB2 and pcPLXNC1 were switched to FBS-free media with Dox
and with or without VPA (0, 3, 4 and 5mM). At day seven, cell viability was assessed by
trypan-blue exclusion and a sample of cell culture supernatant collected and analysed by
western blot using an anti-Poly-His antibody. Comparing with and without VPA, there was a
clear increase in the quantity of recombinant protein produced, with a 1.6 to 2.1 fold increase
in pcEPHB2 compared to without VPA and 2.7 to 3.1 fold increase in pcPLXNC1 (fig 4.2C).
This increase in protein production was associated with improved cell viability from 19%
(± 3% (SD)) with 0mM VPA to 31% (± 2%) to 43% (± 7%) at 2-5mM VPA (fig 4.2D).
From these results, 3mM VPA was selected as the optimal concentration tested. Combining
the addition of VPA (3mM) with cell media collection at day 7 resulted in a 5.9 fold in-
crease in the amount of recombinant protein collected compared with 0mM at day 3 (fig 4.2E).
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Fig. 4.2 Optimisation of recombinant protein production using the mammalian expression sys-
tem. pcDNA5, pcEPHB2 and pDNA5 were cultured in FBS-free media with Dox (30ng/ml).
Cell culture media samples were collected at day 3, 7 and 10 and resolved by Western Blot
using a poly-His antibody. A Recombinant protein production was quantified by densitome-
try and calculated as the fold change from day 3. B Cell viability was assessed by trypan
blue exclusion. pcDNA5, pcEPHB2 and pDNA5 were cultured in FBS-free media with
Dox (30ng/ml), without or with VPA (0, 3, 4, and 5mM). Cell culture media samples were
collected at day 7 and resolved by Western Blot using a poly-His antibody. C Recombinant
protein production was quantified by densitometry and calculated as the fold change from
day 3. D Cell viability was assessed by trypan blue exclusion. Mean ± SD is plotted, n=3.E
Fold change of recombinant protein production at day 7 with the addition of VPA (3mM)
compared to day 3 (0mM VPA).
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4.2.2 Protein purification
Whilst establishing optimisation of the protein production, I proceeded with determining the
protein purification protocol. 293FT construct-expressing cells were switched to FBS-free
media for seven days with 30ng/ml Dox, without the addition of VPA. Cell culture media
was collected and clarified by centrifugation and then filtration. The His-tagged extracellular
domains were purified by immobilised metal affinity chromatography (IMAC) on a HisTrap
excel column using the ÄKTA purification system. These pre-packed columns are specialised
for the purification of recombinant His-tagged proteins from cell culture media. To maximise
the purity and quantity of protein recovered, I optimised the imidazole concentration used at
various stages during the protocol, settling on a 40mM wash and gradient (40mM to 1M)
elution. Protein containing eluate fractions (as determined by absorbance at 280nm) were
pooled and dialysed overnight to remove imidazole before cleavage of the His-tag by TEV
protease. The cleaved recombinant protein was further purified by re-running the sample
through the HisTrap excel column to remove contaminants and the cleaved His-tag. Using
this protein production and purification protocol, I have established a protocol for and purified
to homogeneity three of our top 16 targets: EPHB2, NEO1 and PLXNC1 (figures 4.3 to
4.5). For pcEPHB2, a total of 195µg His-tagged protein was collected from 64ml of culture
media. Following tag cleavage and further purification, 76% of the protein was recovered, as
determined by SDS-PAGE (fig 4.3A-D). 96µg of pcPLXNC1 was collected from 50ml of
cell culture media with a recovery efficiency of 88.6% (fig 4.5A-D) and 116µg of NEO1 was
collected from 64ml of media, of which 60.9% was recovered following tag cleavage and
further purification (fig 4.4A-D). Western blot analysis demonstrated that the purified protein
was detectable by a NEO1-targeted antibody and also revealed that some of protein was not
binding to the column and was being lost in the flow-through (fig 4.4E). The large single
peak obtained for all of the purified recombinant proteins in conjunction with the clean bands
resolved by SDS-PAGE demonstrates the high-level of purity I achieved using this technique.
I was also able to successfully clone and produce sufficient quantities of protein for both
PLXNA1 and ROBO1. PLXNA1 has been IMAC purified (164µg of His-tagged protein from
48ml of culture media) but at the time of writing has not been further purified following tag
cleavage (fig 4.6A-B). Due to the decision to not further proceed with ROBO1 as a target
(see the next chapter, section 5.2.2), the recombinant protein was not taken forward to protein
purification.
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Fig. 4.3 Purification of EPHB2 by immobilised metal affinity chromatography. A Chro-
matogram of initial purification of EPHB2 by IMAC from cell culture media using pcEPHB2.
The eluate fractions highlighted by the black dotted line were resolved by SDS-PAGE B. The
eluate fractions highlighted by the red dotted lines were dialysed and the His-tag cleaved by
TEV protease digest before further purification. C Chromatogram of the second purification
step. The flowthrough was collected and the fractions highlighted by black dotted lines
resolved by SDS-PAGE (D).
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Fig. 4.4 Purification of NEO1 by immobilised metal affinity chromatography.A Chro-
matogram of initial purification of NEO1 by IMAC from cell culture media using pcNEO1.
The eluate fractions highlighted by the black dotted line were resolved by SDS-PAGE B. The
eluate fractions highlighted by the red dotted lines were dialysed and the His-tag cleaved by
TEV protease digest before further purification. C Chromatogram of the second purification
step. The flowthrough was collected and the fractions highlighted by black dotted lines
resolved by SDS-PAGE (D). Fractions from the initial column exchange were analysed by
Western Blot using an anti-poly-His antibody (green) and an anti-NEO1 antibody (red).
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Fig. 4.5 Purification of PLXNC1 by immobilised metal affinity chromatography.A Chro-
matogram of initial purification of PLXNC1 by IMAC from cell culture media using pc-
PLXNC1. The eluate fractions highlighted by the black dotted line were resolved by
SDS-PAGE B. The eluate fractions highlighted by the red dotted lines were dialysed and the
His-tag cleaved by TEV protease digest before further purification. C Chromatogram of the
second purification step. The flowthrough was collected and the fractions highlighted by
black dotted lines resolved by SDS-PAGE (D).
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Fig. 4.6 Purification of PLXNA1 by immobilised metal affinity chromatography.A Chro-
matogram of initial purification of PLXNA1 by IMAC from cell culture media using
pcPLXNA1. The eluate fractions highlighted by the black dotted line were resolved by
SDS-PAGE (B)
Although I was able to successfully clone SEMA4A into the expression vector, the protein
production efficiency was very low (fig 4.7A). Western Blot analysis using a SEMA4A-
targeted antibody confirmed that this was the correct protein and was the same size as the
predicted molecular weight. Transcript expression was assessed by qRT-PCR and revealed
that there was a similar fold induction in mRNA with the addition of Dox compared to the
other constructs (50.9 ±10.5 fold change with the addition of Dox, n=2. Data not shown).
To exclude degradation as a possible mechanism, I analysed SEMA4A protein levels in the
supernatant by Western Blot at earlier time points. As seen in figure 4.7B, there was an
accumulation in the supernatant over the first 72 hours. There was also no discernible smear
or multiple bands in the supernatant. These results suggested that the protein was not being
degraded in the media. I hypothesised that this truncated construct was less stable than the
wild-type protein and that this was negatively affecting the efficiency of expression. To test
this hypothesis, I generated a full-length (wild type) construct of SEMA4A (SEMA4A(1-
761)). Both this construct and the extracellular-domain only construct (SEMA4A(1-683))
were fused to a C-terminal His-tag and Tev protease cleavage site, cloned into pcDNA3.1
and transiently transfected into 293T cells. Cells were switched to FBS-free media and cell
lysates and cell culture media collected at 72 hours. SEMA4A expression was analysed
by Western Blot. As seen in figure 4.7C, the efficiency of expression for the full length
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protein was much greater than the truncated recombinant protein although the inclusion of
the transmembrane domain inhibited secretion into the cell culture media.
Despite the low yield, I investigated if IMAC purification could be used to purify and
concentrate the recombinant protein. As seen in figure 4.8B there was a visible band that
matched the expected size of our recombinant protein, but this was not easily discernable
from the other contaminating proteins. As a result, I concluded it would be necessary to
investigate other SEMA4A constructs to identify more efficiently produced recombinant
proteins before proceeding further with protein purification.
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Fig. 4.7 Expression of recombinant SEMA4A. A pcDNA5, pcPLXNA1, pcSEMA4A were
cultured with and without Dox (30ng/ml) for 7 days in FBS-free media. Cell culture media
and cell lysates were collected and analysed by Western Blot. B pcDNA5 and pcSEMA4A
were cultured for 72 hours in FBS-free media with or without Dox. Cell culture media
samples were taken at 24, 48 and 72 hours and analysed by Western Blot. C Full-length
(SEMA4A(1-761)) or the truncated extracellular domain only (SEMA4A(1-683)) SEMA4A
was fused with a C-terminal His-tag and Tev protease cleavage site and cloned into pcDNA3.1.
293T were transiently transfected with either construct or the empty parental vector. Cell
culture media and cell lysates were collected at 72 hours and analysed by Western Blot.
Recombinant proteins were detected using a poly-His antibody (HIS) or an anti-SEMA4A
antibody (SEMA4A).
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Fig. 4.8 A Chromatogram of initial purification of SEMA4A by IMAC from cell culture
media using pcSEMA4A. The eluate fractions highlighted by the black dotted line were
resolved by SDS-PAGE (B). Arrow indicates predicted SEMA4A band as determined by the
calculated molecular weight.
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4.3 Chapter conclusions
As not all of our candidate proteins will have commercial antibodies available for target
validation, it will be necessary to generate proprietary tool antibodies. To produce the protein
required for antibody generation, I have established a mammalian expression system in
which only the extracellular portion of the protein is secreted into the media for convenient
harvesting.
At the time of writing, I have successfully produced four of our top targets (EPHB2,
NEO1 PLXNA1, PLXNC1) and purified three to a suitable level of homogeneity (as deter-
mined by SDS-PAGE). It was observed for at least one of the targets that there was substantial
protein loss in the flow-through (fig 4.4E). Although I observed a good recovery following
both purification steps, it may be necessary to adjust the protein purification protocol, either
through the addition of a second affinity column or an adjustment to the pH of the cell culture
media before purification.
Although I was able to produce SEMA4A, the production efficiency was very low and
it was difficult to discern the protein product from contaminating proteins even following
purification. As both wild-type and an intracellular-domain lacking mutant had been success-
fully expressed in three separate cell lines (see Chapter 5), I hypothesised that this was due to
a compositional instability of the truncated protein. A direct comparison of the wild-type and
truncated protein confirmed that this was the most likely explanation (fig 4.7C) and further
investigations will be necessary to assess the efficiency of different SEMA4A constructs.




SEMA4A as a Antibody Drug Conjugate
5.1 Introduction
Whilst establishing a recombinant protein expression system, I next sought to validate those
targets for which there were commercially available antibodies, comparing target expression
in a larger cohort of patients. This would provide us with a more detailed analysis of tar-
get expression within myeloma, comparing expression in newly diagnosed versus relapsed
refractory, and to identify any associations with subtype or subclones. Although the use
of the publicly available mass spectrometry dataset (The Human Proteome Map) [300] has
provided an initial assessment of off-tumour expression, it is possible that the low-abundant
plasma membrane proteins were under-sampled because this dataset was generated without
subcellular enrichment. Analysis of primary samples will therefore also enable us to deter-
mine off-tumour expression within the haematopoietic cell compartment.
Monoclonal antibodies have shown encouraging results thus far in the treatment of both
solid and haematological malignancies. However, their low single-agent efficacy often re-
quires the use of combination regimes with chemotherapeutics and as such, there are still
some concerns of systemic toxicity. Antibody drug conjugates on the other hand, combine
the specificity of antibodies with the cytotoxicity of chemotherapeutics to reduce off-tumour
effects [246]. Aside from high on-tumour and low-off tumour expression, an ideal ADC
candidate should also be internalised following antibody binding. To induce cell death, the
toxin must be released from the targeting-antibody. Non-cleavable linkers rely on complete
degradation of the antibody, whilst cleavable linkers rely on either the low pH of the late
endosome/lysosome or on lysosomal-specific proteases for cleavage [247]. Regardless of
the strategy used for release, nearly all ADCs rely on the intracellular compartment. In-
ternalisation alone, however, is not sufficient and it will be imperative to also assess any
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potential candidate antibodies in their ability to specifically deliver a toxin to induce cell-
death. The generation of an ADC is a costly and time-consuming process. An alternative
approach is to use a secondary antibody already directly conjugated to a toxin that can be
used to rapidly screen multiple antibodies (’piggyback’ system). These antibodies recognise
the Fc domain of the primary targeting antibody and are internalised alongside as part of
the immunoglobulin-membrane protein complex. Following internalisation, the secondary
antibody is released in the cytosol and triggers cell death [319]. Although this system may
not accurately reflect the properties of a lead ADC, they do provide a proof-of-principle that
will enable the identification of a lead candidate.
In this chapter I identify SEMA4A as a promising therapeutic target. SEMA4A is a
class IV transmembrane Semaphorin, a family of glycoproteins characterised by a conserved
Sema domain. With a very short intracellular domain (57 amino acids), SEMA4A primarily
functions as a ligand and mediates its signalling through its binding partners, the Plexin
and Neuropilin family of receptors [320][321]. Although the Semaphorin family have been
classically described as neuronal axon guidance molecules [322], SEMA4A appears to play
an important role within the immune system. Initially identified on dendritic cells, SEMA4A
functions as a co-stimulator, enhancing the proliferation and differentiation of T helper cells
and augmenting IL-2 production in vitro [320]. Meanwhile, SEMA4A -/- dendritic cells
are markedly impaired in their priming ability [323] and SEMA4A blockade impairs the
generation and response of antigen-specific T cells in vivo [320]. SEMA4A has also been
implicated in immune regulation. Blockade of the SEMA4A-Neuropilin-1 signalling axis
attenuated the differentiation, proliferation and suppressive activity of Tregs in vitro and
significantly reduced tumour growth in WT C57BL/6 mice in vivo, suggesting that SEMA4A
blockade may reverse immune tolerance [321].
In addition to its role in the immune system, SEMA4A may also play a crucial role
in photoreceptor survival. Although SEMA4A -/- mice overall appear to be healthy and
phenotypically normal, with no observable defects in the brain, lung, kidney, testis or heart,
they do exhibit signs of severe retinal dysfunction [323][324]. At birth these mice have
normal retinal development but over time there is a gradual disruption in the outer segment of
photoreceptors with a complete loss within 3 to 4 weeks as a result of light-induced apoptosis
[324][325]. This anti-apoptotic role for SEMA4A in the retina appears to be mediated by its
involvement in endosomal-sorting pathways. Under oxidative stress, one of the major forms
of damage from light exposure, SEMA4A in retinal pigment epithelial (RPE) cells prevents
the sorting of prosaposin to the lysosomal pathway and instead promotes its exosomal release,
5.1 Introduction 125
promoting photoreceptor survival [324]. In concordance with these findings, SEMA4A
mutations have been subsequently identified in patients with retinal degeneration [326].
Classically considered a ligand, a recent report suggests that SEMA4A may additionally
function as a receptor and transduces a ’reverse signal’. Sun et al reported that SEMA4A
regulates the migration of cancer cells and dendritic cells following the interaction with its
ligand PlexinB1. The pro-invasive and migratory behaviour of these cells appeared to be
dependent on Scrib, a scaffold protein, which interacts with and regulates the activity of the
small GTPases Cdc42 and Rac1 [327].
The role of SEMA4A in myeloma cell biology, and if it possesses reverse signalling
capabilities, is currently unknown. One of the reported mechanisms of resistance to antibody
therapeutics is target downregulation [328]. Following daratumumab infusion, there is a
significant reduction in CD38 cell surface expression on myeloma cells [329]. Whilst this
may be a mechanism of tumour escape, it may in fact also promote tumour cell death through
the loss of contact with the cellular compartment of the bone marrow niche [329]. It would
therefore be of considerable interest to determine if SEMA4A play an essential role in tumour
cell biology and if target downregulation is a viable mechanism of resistance.
5.1.1 Chapter Overview
In this chapter I describe the identification of commercial antibodies suitable for target
characterisation and the subsequent profiling of these proteins in a larger sample of patients
by flow cytometry. From these results, I identify three therapeutic target candidates: ROBO1,
NEO1 and SEMA4A, all of which demonstrated rapid receptor internalisation following
antibody binding. However, I show that in an in vitro ADC cytotoxicity assay, only the
SEMA4A antibody demonstrated selective cell killing activity. The SEMA4A-ADC also
significantly delayed myeloma growth in an orthometastatic xenograft model. Finally, I
show that loss of SEMA4A using RNAi-knockdown conveys a competitive disadvantage,
although I am unable to conclude that this is target specific following the failure to reverse
the phenotype using shRNA-resistant rescue constructs.
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5.2 Results
5.2.1 Characterisation of novel target candidates in primary myeloma
samples
In chapter 3 I identified 16 potential monoclonal antibody target candidates: ADAM17,
CD97, BTN2A1, EPHB2, EVI2B, LRRC8C, LRRC8D, NEO1, PLXNA1, PLXNC1, PT-
PRG, ROBO1, ROR2, SEMA4A and SEMA4D (table 3.5). As the number of samples
profiled by mass spectrometry was small, the next aim in this project was to characterise
tumour expression in a larger cohort of patients as well to compare expression between
malignant plasma cells and other leukocyte populations. This would also enable us to analyse
the ubiquity of expression within plasma cells to determine if any of these potential target
antigens were restricted to particular subclones. In order to do so, it was first necessary to
identify commercially available antibodies against our potential targets that were suitable for
flow cytometry as well as functional assays for target validation.
Out of 16 targets, 10 had commercially available antibodies that were recommended for
flow cytometry (ADAM17, CD97, EVI2B, NEO1, PLXNA1, PLXNC1, ROBO1, ROR2,
SEMA4A and SEMA4D). Seven of these were tested by comparing protein expression by
flow cytometry against PMP expression across a selection of the HMCLs profiled (figure
5.1A). Five of the antibodies were considered to be target-specific and suitable for further use
based on a strong positive correlation between PMP and flow cytometry protein expression,
with correlation coefficients ranging from r(10)=0.849, p<0.001 (NEO1) to r(10)=0.957,
p<0.001 (ROBO1). This included CD97, SEMA4A and SEMA4D. The PLXNA1 antibody
exhibited very low MFI ratios across the cell lines tested (1.06 to 1.54, n=5) and a strong
negative correlation r(5)=-0.847, p>0.05 and so was considered unsuitable. Two different
antibody clones were tested for PLXNC1 (544232 and 1A12), neither of which exhibited
strong, target-specific binding. Despite high PMP expression, the fold change compared
with the isotype control was very low and across the HMCLs there was a poor correlation
with PMP, r=0.359 and 0.292 for clone 544232 and 1A12 respectively, p>0.05 for both.
As PLXNC1 expression by PMP correlated well with RNA expression by RNAseq (Keats
Lab), I confirmed target expression by qRT-PCR. As seen in figure 5.1B comparing PLXNC1
expression by qRT-PCR and PMP, cell line expression of the target had not changed since
profiling. Although the antibody targeting ROBO1 exhibited weak signal, it did appear to be
highly target specific as determined by correlation with PMP and so was considered suitable
for primary sample screening.
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Fig. 5.1 Five out of 16 novel targets have working, commercially available antibodies suitable
for flow cytometry. To identify working antibodies for the novel targets, target expression
across a selection of HMCLs was analysed by flow cytometry (MFI ratio) and compared
against protein expression by PMP A. For five of the seven targets analysed there was a
strong positive correlation with PMP, as determined by Pearson’s correlation, validating
these antibodies as suitable for primary sample screening. B PLXNC1 expression by RNA
was quantified in all 10 HMCLs profiled by qPCR and compared with protein expression by
PMP to confirm that cell line expression had not changed since profiling, n=1. *=p<0.05,
**=p<0.01, ***=p<0.001. † NEO1 staining performed by Dr S. Surget.
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These five antibodies were then used to assess target expression in primary myeloma
samples by FC. BMA from patients at all stages of disease were processed as described in
materials and methods (section 2.2) and target expression by flow cytometry was compared
as the fold change between CD138pos and CD138neg leukocytes, figures 5.2 to 5.5. For
CD97 and SEMA4A, in which a proportion of CD138neg leukocytes also expressed the target
of interest, the mean fold change was calculated between CD138pos and CD138neg/Targetpos
cells. For all samples, a single-sample t-test was performed on log-transformed data.
CD97 was expressed in all HMCLs and primary samples profiled by PMP. In HMCLs,
there was a similar median expression (974.15) compared with CD38 (1643.45) and SLAMF7
(612), the targets of daratumumab and elotuzumab respectively. By PMP, CD97 expression
was greater in the primary samples compared with HMCLs (fig 5.2A). By flow cytometry,
CD97 was highly and uniformly expressed in CD138+ cells across all samples analysed.
However, there was also high CD97 expression on CD138neg leukocytes and the mean fold
change of CD97 expression in CD138+ cells over other leukocytes was not significant (1.79
±2.42 (mean fold change ±SD), t(6)=0.4462, p>0.05) by a one-sample t-test (fig 5.2C). As
CD97 was predicted to have a similar level of expression to haematopoeitic cell subsets in a
number of other tissues (figure 5.2D), this target was not taken further forward.
By PMP, NEO1 had a similar expression to SLAMF7 in both HMCLs and primary
samples but was expressed at a much lower level than CD38 in patient samples (fig 5.3A).
Flow cytometric analysis of primary samples revealed that NEO1 expression was largely
restricted to CD138+ plasma cells, with little to no expression in CD138neg leukocytes. This
difference was statistically significant by a one-sample t-test (mean fold change of 4.58 ±3.26
(SD), t(14)=7.323, p<0.0001 (fig 5.3C)). Although NEO1 expression was uniform within
each sample across plasma cells, there was clear variability between samples. This variability
in expression was independent of disease stage with a mean fold change of 4.996 ±2.34(SD)
at diagnosis and 5.09 ±4.272 (SD) at progression/relapse. Analysing the whole-cell mass
spectrometry dataset, NEO1 showed low to medium expression in a few tissues (including the
frontal cortex, ovary and testis) but importantly was not expressed in tissues associated with
severe or lethal toxicities, including the heart, kidney, liver nor lungs (fig 5.3D). Although
there was predicted expression in the frontal cortex and spinal cord, it is anticipated that a
therapeutic antibody would be unable to cross the blood brain barrier [330].
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Fig. 5.2 CD97 is highly expressed in both plasma cells and other CD138neg leukocytes. A
CD97 expression in HMCLs and primary samples by PMP. B Flow cytometry gating strategy
for comparing CD97 expression in primary samples. C The fold change of CD97 expression
in CD138pos plasma cells over CD138neg/CD97pos leukocytes. CD97 was not signficiantly
differentially expressed in plasma cells compared with other CD97pos leukocytes, n=7. D
Predicted normal tissue expression from The Human Proteome Map [300].
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Fig. 5.3 NEO1 is highly expressed in plasma cells and with little to no expression in CD138neg
leukocytes. A NEO1 expression in HMCLs and primary samples by PMP. B Flow cytometry
gating strategy for comparing NEO1 expression in primary samples. C The fold change
of NEO1 expression in CD138pos plasma cells over CD138neg leukocytes. NEO1 was
expressed at a significantly higher level in in plasma cells compared with other leukocytes,
n=15. D Predicted normal tissue expression from The Human Proteome Map [300].
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As previously discussed, ROBO1 was initially selected as a potential target due to high
expression in HMCLs by PMP (fig 5.4A). Despite a similar expression profile to CD38
and SLAMF7 in HMCLs, ROBO1 expression was much lower in primary samples (median
expression of 1089.95). Despite the low expression, ROBO1 appeared to be plasma cell
restricted amongst all leukocyte subsets by flow cytometry (fig 5.4B and C), with a statisti-
cally significant fold change of 1.8 (±0.689 (SD)), t(14)=5.709, p<0.0001 over CD138neg
populations. There were two distinct populations of ROBO1hi and ROBO1low, but similarly
to NEO1, these two populations were independent of disease stage with a mean fold change
of 1.773(±0.49 (SD)) at diagnosis and 1.879 (±0.85 (SD)) at progression/relapse.
Compared to ROBO1, SEMA4D was uniformly expressed at a high level across all
HMCLs by PMP, with a similar expression to SLAMF7 in primary samples (fig 5.5). By
flow cytometry, SEMA4D was consistently expressed by all CD138pos cells, but was also
expressed by all other leukocytes, with a mean fold change of 0.873 ±0.912 (SD), t(2)=0.853,
p>0.05 (fig5.5C). Even though this was a small sample size, the high leukocyte expression
was consistent with the whole cell mass spectrometry dataset (fig 5.5D) and this target was
not taken further forward.
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Fig. 5.4 ROBO1 is more highly expressed in CD138pos plasma cells than other leukocytes
A ROBO1 expression in HMCLs and primary samples by PMP. B Flow cytometry gating
strategy for comparing ROBO1 expression in primary samples. C The fold change of ROBO1
expression in CD138pos plasma cells over CD138neg leukocytes. ROBO1 was expressed at a
significantly higher level in plasma cells compared with other leukocytes, n=15. D Predicted
normal tissue expression from The Human Proteome Map [300].
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Fig. 5.5 SEMA4D is more highly expressed in CD138neg leukocytes than plasma cells. A
SEMA4D expression in HMCLs and primary samples by PMP. B Flow cytometry gating
strategy for comparing SEMA4D expression in primary samples. C The fold change of
SEMA4D expression in CD138pos plasma cells over CD138neg leukocytes, n=3. D Predicted
normal tissue expression from The Human Proteome Map [300].
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SEMA4A was more highly expressed than SLAMF7 in both HMCLs and in primary
samples by PMP but was expressed at a lower level than CD38 (fig 5.6A). By flow cytometry,
SEMA4A was highly expressed in the majority of primary samples analysed. Although there
was a subset of leukocytes that also expressed SEMA4A, SEMA4A expression was greatest
in CD138pos plasma cells with a mean fold change of 3.232 ±3.38 (SD) that was statistically
significant by a single-sample t-test (t(21)=3.026, p<0.01) (fig 5.6C). SEMA4A expression
was independent of disease stage, with a mean fold change at diagnosis of 2.92 ±2.31 (SD)
compared to 4.04 ±4.36 (SD) at progression/relapse. Consistent with this, BM068, which
exhibited similar SEMA4A expression to KMS-12-BM when profiled by PMP, showed
comparable levels by flow cytometry two years later (SEMA4A MFI of 60.2 in plasma cells
versus 41.5 ±8.4 (SD) in KMS-12-BM. Overall, SEMA4A was highly expressed in CD138+
plasma cells compared with other leukocytes and importantly, had low off-tumour expression
outside of haematopoeitc lineages by whole-cell mass spectrometry (fig 5.6D).
To further differentiate SEMA4A expression on normal haematopoeitic cell populations, I
utilised a more comprehensive flow cytometry panel to compare levels of SEMA4A between
the major subtypes. Samples were processed as previously described for flow cytometry. The
following markers were used to identify leukocyte populations: CD66b as a pan-granulocyte
marker, CD14 for monocytes and macrophages, CD3 as a T-cell marker, CD19 for B cells
and CD34 as a stem-cell marker. SEMA4A expression on CD235a+ red blood cells (RBC)
was also analysed for one patient sample that was processed without RBC lysis. To enable
comparisons between samples, SEMA4A expression on each subtype was calculated as the
fold change over CD66b+ granulocytes, which appeared to exhibit the most consistent ex-
pression. B cells and T cells exhibited minimal expression (mean fold change of 0.13 ±0.07
(SD) and 0.097 ±0.04 (SD) for B and T cells respectively). There was notable relatively
higher expression on monocytes (mean fold change 1.15 ±0.38 (SD)) and granulocytes.
Importantly, CD34+ stem cells exhibited very low SEMA4A expression with a mean fold
change of 0.31 ± 0.26 (SD) and there was also minimal expression on RBC (0.20 fold
change, n=1). Overall, SEMA4A expression was still greatest on CD138pos plasma cells in
the majority of samples, with a mean fold change of 2.37 ± 1.82 (SD) (figure 5.7).
5.2 Results 135
Fig. 5.6 SEMA4A is more highly expressed in CD138pos plasma cells than other leukocytes
A SEMA4A expression in HMCLs and primary samples by PMP. B Flow cytometry gating
strategy for comparing SEMA4A expression in primary samples. C The fold change of
SEMA4A expression in CD138pos plasma cells over CD138neg/SEMA4Apos leukocytes.
SEMA4A was significantly more highly expressed in plasma cells than other leukocytes,
n=22. D Predicted normal tissue expression from The Human Proteome Map [300].
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Fig. 5.7 SEMA4A expression is greatest in CD138pos plasma cells compared with other
leukocyte populations A Flow cytometry gating strategy for differentiating SEMA4A ex-
pression in normal haematopoietic cell populations. B Flow cytometry gating strategy for
analysing SEMA4A expresssion on CD34+ stem cells. C Summary of SEMA4A expression
in all patient samples analysed by comparing the mean fold change in each population against
CD66b+ granulocyte SEMA4A expression, n=13.
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5.2.2 Internalisation of targets
As ADC toxicity is directly related to surface expression, I decided to discontinue with both
CD97 and SEMA4D as potential targets. Both of these proteins exhibited high off-tumour
expression amongst haematopoietic cell subsets and were predicted to be expressed at a
substantial level in a number of other, normal tissues.
The cellular internalisation of an ADC is essential for efficacy. Therefore, the next
aim of this project was to determine if any of the remaining targets (ROBO1, SEMA4A
and NEO1) were suitable as ADCs by assessing internalisation following antibody-binding.
Internalisation of the antibody-antigen complex was tracked using a flow-cytometry assay
that also enabled analysis of the kinetics of the response.
Surface antigens on live cells were labelled using an unconjugated primary antibody
at 4°C before unbound antibody was washed away and cells incubated at either 4 or 37°C
for three hours. Samples were taken at various timepoints and any remaining surface-
bound primary antibody labelled using a fluorescent-labelled secondary antibody under
non-permeabilising conditions before fixation and analysis by flow cytometry. The MFI ratio
was used to calculate the proportion of the remaining surface-bound antibody compared with
t0. As membrane trafficking is limited at lower temperatures, internalisation at 4°C was used
as a control to prevent receptor endocytosis.
By flow cytometry, both ROBO1 and SEMA4A appeared to be internalised following
antibody binding. Incubation of SK-MM-1 with mAb-770502 (targeting ROBO1) at 37 °C
was associated with a decrease in surface-bound antibody over time, with a maximal loss
of 53.9% by one hour compared with the 4 °C control (fig 5.8). This loss was uniform
across all cells. Similarly, there was a loss in surface-bound mAb-5E3 (targeting SEMA4A)
in NCI-H929 cells following incubation at 37 °C with max internalisation at two hours
(51.4%) (fig 5.9). Again, this was uniform across all cells as shown in the flow cytometry
histogram. For both targets there was negligible recycling of antigen-antibody complexes
back to the cell surface. NEO1 also appeared to be internalised by flow cytometry with
a loss of 44% of surface-bound antibody by two hours (Dr S Surget, personal communication).
Following internalisation, it is also considered essential for ADCs to be trafficked to the
late endosome or lysosome for cleavage of the cytotoxic payload from the antibody. Im-
munofluorescence was used to follow antibody trafficking as well as to confirm that antibody
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Fig. 5.8 Cell surface ROBO1 expression is lost following mAb-770502 binding. SK-MM-1
cells were incubated for 20 minutes at 4°C with mAb-770502 before unbound antibody was
washed and cells incubated at 4 or 37°C for three hours. Remaining surface-bound antibody
was analysed by flow cytometry (left panel) and the proportion of remaining antibody was
calculated by the MFI as a proportion of the MFI at t0. n=1 (right panel).
Fig. 5.9 Cell surface SEMA4A expression is lost following mAb-5E3 binding. NCI-H929
cells were incubated for 20 minutes at 4°C with mAb-5E3 before unbound antibody was
washed and cells incubated at 4 or 37°C for three hours. Remaining surface-bound antibody
was analysed by flow cytometry (left panel) and the proportion of remaining antibody was
calculated by the MFI as a proportion of the MFI at t0. n=1 (right panel).
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loss at the cell-surface was endocytosis-mediated.
Similarly to the flow-cytometry assay, NCI-H929 cells were incubated with the un-
conjugated primary antibody at 4°C, washed to remove unbound antibody and shifted to
37°C for three hours. Samples were taken before and after incubation at 37°C and cells
were fixed on ice. Both internalised and surface-bound antibody were then labelled using a
fluorescent-labelled secondary antibody under permeabilising conditions. As seen in figure
5.10, there was clear cell surface localisation of mAb-5E3 at t0. By three hours, there was
a reduction in the remaining surface-bound antibody with a corresponding appearance of
antibody-containing vesicles. These vesicles appeared to be localised with LAMP-1 positive
lysosomes, as shown by the signal intensity profile overlay (fig 5.10B), suggesting that the
antibody-antigen complex is trafficked to the lysosome, the ideal subcellular localisation for
ADC delivery.
Although the ROBO1 antibody (mAb-770502) worked well for flow cytometry, the signal
couldn’t be detected by immunoflourescence (data not shown).
Fig. 5.10 mAb-5E3 (anti-SEMA4A) is internalised and co-localises with LAMP-1-positive
lyosomes. A NCI-H929 cells were incubated for 20 minutes at 4°C with mAb-5E3 before
unbound antibody was washed and cells incubated at 37°C for three hours. All primary
antibody was labelled using a fluorescent-labelled secondary antibody (red) under permeabil-
ising conditions. LAMP-1 positive lysosomes are green. B The image intensity profiles for
the dotted line shown in A. C Enhanced image of the boxed area in A. Representative figures
are shown for n=3.
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5.2.3 mAb-5E3 is effective as an ADC against SEMA4A-expressing
cancer cells
Having established that both mAb-770502 (ROBO1) and mAb-5E3 (SEMA4A) were in-
ternalised, and in the case of mAb-5E3, trafficked to the lysosome, I next investigated if
this internalisation was sufficient to deliver a cytotoxic payload to induce cell death. As the
creation of an ADC is both expensive and time-consuming, I used a ’piggyback’ system to
provide an initial assessment of potential ADC activity. This system utilises a secondary
antibody conjugated to a toxin that binds to and is internalised alongside the unconjugated
targeting primary antibody. For these experiments, I used an anti-mouse goat antibody
chemically linked to saporin, a ribosome inactivating protein that inhibits protein synthesis
resulting in cell death. Saporin is cell-membrane impermeable and is therefore only able
to induce cell death in cells that successfully internalise the antibody-complex. For both
mAb-770502 and mAb-5E3, two target-positive and one target-negative cell lines were tested.
Cells were incubated for 72 hours with increasing concentrations of the primary, targeting
antibody or an isotype-matched control antibody (mouse IgG1). The secondary antibody
concentration remained constant (2.5nM). Cell viability at 72 hours was assessed using a
XTT assay, a colourimetric assay in which the tetrazolium derivative (XTT) is reduced by
metabolically active cells [331].
Incubation with mAb-770-502 and the secondary antibody did not appear to induce cell
death across the three cell lines tested (fig 5.11B). Although there was a reported significant
difference in cell viability between mAb-770502 and the isotype control at 1nM for the cell
line SK-MM-1 (87.5% ±15.5% (SD) versus 120% ±4.14% (SD), p<0.01 using a student’s
t-test corrected for multiple testing by BH)), cell viability was not significantly different
compared with the secondary antibody alone (77.2% ±0.82% (SD), p<0.05) and it was
concluded there was no effect of mAb-770502 (fig 5.11).
In contrast, the co-incubation of mAb-5E3 and the secondary antibody showed strong
inhibition of cell viability with an EC50 in the picomolar range and no effect with the isotype-
matched control or secondary antibody alone (fig 5.12B, (n=3)). This loss of cell viability
was observed in the target-expressing cell lines only, with an EC50 of 6.02pM in NCI-H929
and 6.75pM in MM.1S. Maximal cell death was observed at the highest concentration tested,
0.1nM, with a mean difference in viability between the isotype control and mAb-5E3 of
56.4% and 47.2% for NCI-H929 and MM.1S respectively. For K562, a SEMA4Aneg ery-
throleukemic cell line, there was no difference in cell viability between the isotype control
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Fig. 5.12 mAb-5E3 (anti-SEMA4A) linked to a cytotoxic payload induces significant cell
killing activity A mAb-5E3 binding and SEMA4A expression by flow cytometry in all three
cell lines tested. B Dose response for mAb-5E3 inhibition of cell viability. NCI-H929,
MM.1S and K562 were incubated with increasing concentrations of either mAb-5E3 or an
isotype-matched control and a saporin-linked secondary antibody (Fab-ZAP, 2.5nM). Cell
viability at 72 hours was measured using an XTT assay and calculated as a percentage of a
media-only control. n=3, each performed in triplicate.
Biotinylated-EPR14696 (NEO1) in combination with a streptavidin-Zap secondary con-
jugate also failed to demonstrate cell-killing activity across a panel of NEO1-expressing cell
lines (personal communication with Dr S Surget).
5.2.4 SEMA4A expression is restricted to immune system organs
Having established that the mAb-5E3 targeting SEMA4A was both rapidly internalised
and capable of delivering a toxic payload to target-expressing cells, I decided to further
pursue SEMA4A as an ADC target. Aside from high expression and internalisation, another
necessary ADC target attribute is low off-tumour expression. Although the whole-cell mass
spectrometry dataset used for initial target selection suggested that SEMA4A expression
was highly restricted (fig 5.6D), I next sought to obtain additional evidence for off-tumour
expression using a second publicly available dataset: The Human Protein Atlas (Tissue
Atlas). The Tissue Atlas contains both mRNA and protein expression derived from antibody-
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based profiling using immunohistochemistry (IHC) across 44 normal human tissue types
(www.proteinatlas.org) [301].
Across the 44 tissues profiled by IHC, SEMA4A expression was only detectable in the
lymph nodes and tonsils (fig 5.13). Analysis of the cell types within these tissues revealed
medium expression in non-germinal centre and low expression in GC cells. Although
SEMA4A was predicted to be expressed at a low level in adrenal gland and prostate by the
whole-cell mass spectrometry dataset, there was no detectable expression in these two tissues
by IHC.
One tissue that was not curated in either of the two dataset was the retina. SEMA4A
mutations in RPE cells have been reported to cause retinitis pigmentosa and cone rode
dystrophy through defective endosomal sorting [332]. To investigate SEMA4A expression on
RPE cells, I analysed cell surface expression on RPE-1 cells, an immortalised RPE cell line,
by flow cytometry. As seen in figure 5.14A, there was no detectable SEMA4A expression on
RPE-1 cells (MFI ratio of 0.96). The addition of hydrogen peroxide, which is reported to
affect SEMA4A peripheral distribution [333], increased slightly the MFI ratio to 1.01 with
125µM H2O2 and 1.09 at 250µM H2O2 but was still considered to be negligible expression.
I next confirmed that RPE-1 cells would be unaffected by a SEMA4A ADC. RPE-1
cells were cultured with increasing concentrations of mAb-5E3 and the saporin-linked sec-
ondary antibody and cell viability assessed at 72h by XTT. mAb-5E3 did not exhibit cell
killing activity in RPE-1 cells, with no difference in viability between mAb-5E3 and the
isotype-matched control (99.0% ± 8.55% (SD) and 101.0% ± 10.55% (SD) respectively at
0.1nM). The addition of hydrogen peroxide (250µM) also did not affect cell viability, 94.5%
± 3.28% (SD) for mAb-5E3 and 86.7% ± 2.28% (SD) for the isotype-matched control at
0.1nM (figure 5.14B). NCI-H929 was included as a positive control, with 10.6% ± 3.07%
for mAb-5E3 at 0.1nM compared to 98.52% ± 10.77% (SD) for the isotype-matched control
(fig 5.14C). Overall, this confirmed that SEMA4A expression in RPE cells would not be a
concern in developing SEMA4A as as ADC target.
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Fig. 5.13 SEMA4A expression is restricted to immune system organs by IHC To investigate
SEMA4A off-tumour expression, immunohistochemistry data from The Human Protein Atlas
[301] was analysed. A Representative IHC samples from several normal human tissues B
Summary of SEMA4A expression across the 44 normal human tissues analysed based on
expert-curated annotations of the IHC samples.
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Fig. 5.14 SEMA4A expression on RPE-1 cells is negligble and insufficient to deliver a
cytotoxic payload A SEMA4A expression on RPE-1 in the presence and absence of hydrogen
peroxide was analysed by flow cytometry. B Dose response for mAb-5E3 inhibition of
cell viability. RPE-1 cells were cultured for 72 hours with increasing concentrations of
the primary targeting antibody mAb-5E3 or an isotype-matched control and a secondary
antibody conjugated to saporin (Fab-ZAP, 2.5nM). C As a positive control, NCI-H929 was
also cultured for 72 hours with 0.1nM mAb-5E3 or isotype-matched control and 2.5nM
Fab-ZAP. Viability was measured by XTT and calculated as a percentage of a media-only
control. n=1, performed in triplicate.
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5.2.5 Establishment of an ADC mouse model
Our next aim was to investigate the ability of mAb-5E3 to deliver the cytotoxic payload
and to eliminate HMCLs in vivo in a murine model of myeloma. As the kit used for the
initial testing of mAb-5E3 as an ADC (Fab-ZAP) was unsuitable for in vivo, I first needed
to assess the ability of an alternative kit (Strep-ZAP) to deliver the payload. Instead of a
secondary antibody, this kit utilises streptavidin chemically conjugated to saporin which
binds to a biotinylated antibody. To biotinylate mAb-5E3 I used two different kits (Abcam),
generating (B)-5E3-A and (B)-5E3-B. To confirm biotinylation and to compare binding
with the non-biotinylated antibody, MM.1S (SEMA4Ahi) and OPM-2 (SEMA4Alow) were
labelled using all three antibodies and either a fluorescent-labelled secondary antibody or
streptavidin-APC. By flow cytometry, both (B)-5E3-A and (B)-5E3-B showed comparable
levels of biotinylation (MFI ratio of 23.2 and 17.1 for A and B respectively). Neither of the
two biotinylated antibodies exhibited non-specific binding, with no detectable binding to
OPM-2 (MFI ratio of 0.95 and 1.03 for A and B). Although they cant be directly compared
because of the two different secondaries used for analysis, both biotinylated antibodies did
appear to exhibit less binding compared with the non-biotinylated mAb-5E3 (fig 5.15A).
To assess cell killing activity, MM.1S and OPM-2 were cultured with increasing concen-
trations of (B)-5E3-A/B or the unconjugated mAb-5E3 (negative control) and the streptavidin-
ZAP at a 1:4 ratio. Cell viability was measured by XTT at 72 hours. Compared to the non-
biotinylated antibody, both (B)-5E3-A and B exhibited cell killing activity with an EC50 of
36.6pM and 22.5pM for A and B respectively (fig 5.15B). Maximal cell death was observed
at 1nM, with a mean difference in viability between non-biotinylated and biotinylated of 55%
and 42.7% for A and B. There appeared to be no significant cell death observed in OPM-2
even at the highest concentration (93.5% (±19.56%), 98.4% (±10.38%) and 106.5% (±
8.41%) cell viability for A, B and non-biotinylated respectively).
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Fig. 5.15 Biotinylated mAb-5E3 is able to specifically deliver a cytotoxic payload to a
target-expressing HMCL. A Flow cytometric analysis of mAb-5E3 binding following biotiny-
lation with fluorescent-labelled streptavidin compared with non-biotinylated mAb-5E3 and a
fluorescent-labelled secondary antibody (GαM) B Dose response for mAb-5E3 inhibition of
cell viability. MM.1S and OPM-2 were incubated for 72 hours with increasing concentrations
of the two biotinylated mAb-5E3 ((B)-5E3-A or (B)-5E3-A) or the non-biotinylated mAb.
Streptavidin-ZAP was added at all concentrations at a ratio of 1:4 (primary antibody:Strep-
ZAP). Cell viability was measured at 72 hours by XTT and calculated as a percentage of a
media-only control. n=1, performed in triplicate.
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Co-incubation with either mab-5E3 with Fab-ZAP or (B)-5E3-A/B with Strep-ZAP
elicited similar maximal killing activity (≈ 45-55% loss of viability). However, using the
in vivo kit (Strep-ZAP) resulted in a five-fold higher EC50 compared with the Fab-ZAP kit.
After taking this into consideration and in conjunction with the fact that I was unable to
achieve > 56% killing activity using either kit, I decided to proceed with a direct conjugation
between two different toxins and mAb-5E3. Two custom ADCs were produced by Abzena
Ltd1. The first custom conjugate utilised a malemide-based linker (cysteine linked) to conju-
gate mAb-5E3 to the auristatin MMAE (monomethyl auristatin E, 5E3-MMAE). The second
used an NHS-ester based linker (lysine linked) to conjugate mAb-5E3 to the maytansinoid
DM1 (mertansine, 5E3-DM1). Unlike saporin, both DM1 and MMAE are routinely used
clinically and as such, these direct conjugates are more likely to provide us with a more
accurate representation of a lead ADC candidate. The following work is current, on-going
work at the time of writing and performed in collaboration with Dr J Ballester Beltran and
Dr G Giotopoulos2.
To establish the xenograft model, male SCID mice were sub-lethally irradiated and
injected (i.v.) with two human myeloma cell lines, NCI-H929 and MM.1S. These two cell
lines were lentivirally transduced to stably express luciferase using the dual luciferase/GFP
vector (BLIV301PA-1-MSCV-GFP-T2A-Luciferase (MAC25)). As these two cell lines have
both been used in the literature, our aim was to establish which cell line provided the most
representative model and to investigate the disease latency to establish a suitable imaging and
dosing schedule. 0.5x106 NCI-H929-MAC25 and MM.1S-MAC25 cells were injected i.v. in
male SCID mice and disease monitored using bioluminescence imaging. At day 10 there was
no detectable luciferase activity for either cell line (fig 5.16A, no image taken for NCI-H929-
MAC25). By day 25, mice injected with MM.1S-MAC25 showed clear engraftment that was
localised to the bone. NCI-H929-MAC25 did not engraft and even by day 42, there was no
discernable bioluminescence activity. A second experiment investigated a larger starting dose
of both MM.1S-MAC25 and NCI-H929-MAC25 (1 and 2.5x106 starting cells), fig 5.16B.
Even at the higher concentrations there was minimal engraftment for NCI-H929-MAC25 and
only one mouse (2.5x106 cells) exhibited discernable signal localised to the bone at day 21.
By day 12 there was detectable signal for both doses for MM.1S-MAC25. Although there
was a strong bioluminescent signal for the higher starting number of cells, both doses showed
similar disease latency. As a result, it was concluded to proceed with only MM.1S-MAC25
at 1x106 cells.
1Babraham Research Campus, Cambidge, UK
2Brian Huntly group, Department of Haematology, University of Cambridge
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Fig. 5.16 Establishment of an orthometastatic xenograft model. A 0.5x106 or B 1 and 2.5x106
MM.1S-MAC25 or NCI-H929-MAC25 were injected i.v. into male SCID mice and disease
establishment monitored by bioluminescence imaging.
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Having established MM.1S as the cell line that will be used for the xenograft model, I
next investigated the cell killing activity of the two direct conjugates on it. Both conjugates
exhibited similar binding profiles to the unconjugated mAb-5E3 by flow cytometry (fig
5.17A), confirming that the addition of the toxin did not impair antigen-antibody binding.
Next MM.1S-MAC25 cells were incubated with increasing concentrations of either 5E3-
DM1 or 5E3-MMAE and cell viability measured by XTT at 72 hours. Both 5E3-DM1 and
5E3-MMAE induced extensive cell death, with a loss in cell viability from 0.01pM to 10nM
of 86.63% and 96.6% for DM1 and MMAE respectively. 5E3-MMAE (EC50 of 44.7pM)
appeared to be more potent compared to DM1 (100pM EC50) (fig 5.17B).
Fig. 5.17 5E3-MMAE ADC is more potent than 5E3-DM1. A Flow cytometric analysis of
antibody binding of 5E3-DM1 and 5E3-MMAE compared with the unconjugated mAb-5E3
using a fluorescent-labelled secondary antibody. B Dose response for 5E3-ADC inhibition of
cell viability. MM.1S-MAC25 were incubated with increasing concentrations of two ADCs
(5E3-DM1 and 5E3-MMAE) to compare the two different conjugates. Cell viability was
measured at 72 hours by XTT and calculated as a percentage of a media-only control. n=1,
performed in triplicate.
I next tested these two ADCs on a panel of human myeloma cell lines, as well as on
the SEMA4Aneg cell lines, K562 and RPE-1 cells (fig 5.18). Across the highest SEMA4A-
expressing cell lines, 5E3-MMAE demonstrated substantial cell killing activity with an EC50
range of 53.7pM to 1.5nM. 5E3-DM1 appeared to be less potent, with an EC50 range of
129.9pM to 17.8µM. Unexpectedly, OCI-My7 appeared to be unaffected by the MMAE-
conjugate, despite a higher SEMA4A expression compared with KMS-12-BM. As this cell
line was still sensitive to the DM1 conjugate, this cell line is possibly less sensitive to the
MMAE toxin. Amongst the lower SEMA4A-expressing cell lines and the two SEMA4A
negative cell lines I did not observe any effect of 5E3-MMAE or 5E3-DM1. Although more
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Fig. 5.18 Comparison of 5E3-MMAE and 5E3-DM1 potency across a panel of cell lines.
A SEMA4A expression by mass spectrometry for those HMCLs profiled by PMP. B Dose
response for 5E3-MMAE in HMCLs, K562 and RPE-1 (with and without H2O2) after a 72
hour incubation. C Dose response for 5E3-DM1. Cell viability was measured by XTT and
calculated as a percentage of a media-only control. n=1, performed in triplicate. NR=EC50
not reached. FCM=Flow cytometry.
cell lines appeared to be sensitive to the DM1 toxin, the MMAE conjugate appeared to
demonstrate an enhanced potency in the SEMA4Ahi cell lines and so I decided to proceed
with this conjugate.
5.2.6 5E3-MMAE significantly delays myeloma growth in an orthometastatic
xenograft model
I next sought to establish the efficacy of 5E3-MMAE in vivo. Male NSG mice were sub-
lethally irradiated and injected (i.v) with MM.1S-MAC25 and disease establishment con-
firmed by bioluminescence imaging. Mice received a total of four doses at 4mg/kg of
either the naked antibody (5E3), 5E3-MMAE or an isotype control (mIgG1-MMAE), ad-
ministered biweekly for two weeks (fig 5.19A). Disease activity was monitored by weekly
bioluminescence imaging. For 5E3-MMAE there was an initial near-complete elimination of
bioluminescence activity (fig 5.19B and C). However, following cessation of treatment these
mice relapsed (week 3) and all eventually succumbed to disease. Meanwhile, there was no
effect on tumour growth for either 5E3 alone or the isotype control. Overall, 5E3-MMAE
significantly improved survival compared with the two control groups (p=0.0004), demon-
strating the potent activity of 5E3-MMAE in vivo (fig 5.19D).
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Fig. 5.19 5E3-MMAE anti-myeloma activity in a myeloma orthometastatic xenograft model.
A Study treatment outline. 1x106 MM1S-MAC25 were injected i.v into sub-lethally irradiated
male NSG mice and disease establishment confirmed by bioluminescence imaging. Each
animal then received a total of four doses (i.v., at 4mg/kg for each dose) of either 5E3,
5E3-MMAE or mIgG1-MMAE (on day 13, 15, 19 and 22 post transplantation, termed ‘Study
day’ 0, 2, 6 and 9 respectively). Disease was monitored by weekly bioluminescence imaging.
B Bioluminescence imaging of the NSG xenografts showing the initial reduction in tumour
burden in the 5E3-MMAE treated mice compared with the mIgG1-MMAE and 5E3 alone
groups. C The average radiance of each mouse (region of interest (ROI)) for each treatment
group at each weekly imaging session. D Kaplan-Meier survival curves of NSG xenografts
in response to treatment. Graphs are shown as mean ± SEM.
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5.2.7 SEMA4A may play an essential role in myeloma cell biology
As discussed in the introduction, one of the potential mechanisms for resistance towards
targeted therapeutics is downregulation of the target. The role of SEMA4A as a ligand has
been extensively characterised. It’s role as a receptor, however, has been largely unexplored.
Recently, Sun et al reported that SEMA4A does exhibit signalling functionality and is in-
volved in regulating cell migration [327]. Our next aim was to investigate the functional role
of SEMA4A in myeloma cell biology and to determine if loss of this protein would provide
a viable mechanism for tumour escape.
To initially investigate the role of SEMA4A, I performed a stable RNA-mediated knock-
down of SEMA4A in the myeloma cell line, NCI-H929. NCI-H929 were lentivirally trans-
duced with one of three SEMA4A-targeting hairpins (shSEMA4A-136, shSEMA4A-636
and shSEMA4A-567) or with a luciferase-targeting hairpin (shLUC, non-targeting control).
Interestingly, despite the maintenance of antibiotic selection, I observed the emergence of a
small population of SEMA4Apos cells for all three hairpins (10.05%, 9.68% and 21.42% for
shSEMA4A-136, shSEMA4A-636 and shSEMA4A-567 respectively at day 80, fig 5.20A).
The emergence of this SEMA4Apos population, despite an antibiotic selection pressure,
suggested that loss of SEMA4A may be detrimental to cell viability. To further investigate,
I performed a RNAi competition assay in which SEMA4A was knocked-down in ≈ 50%
of the cell population and the proportion of remaining GFP+ cells analysed over time. The
two hairpins which provided the greatest knock-down (98% and 96% loss in MFI com-
pared to shLUC for shSEMA4A-636 and shSEMA4A-567 respectively) were cloned into
pLKO.1_GFP. The puromycin resistance gene in this vector has been replaced with a GFP
reporter to monitor hairpin expression by flow cytometry.
For both NCI-H929 and MM.1S there was an observed rapid decrease in the proportion of
GFP+ cells over time, with a decrease from 1.0 at day 4 to 0.29 (±0.034) and 0.16 (±0.007)
at day 16 for shSEMA4A-636 and -567 in NCI-H929 and to 0.082 (± 0.004) and 0.104
(±0.05) for MM.1S at day 16 (fig 5.20C). There was minimal to no loss in the proportion
of GFP+ cells in the SEMA4Aneg cell line K562, 0.710 (± 0.021) and 0.939 (± 0.053) for
shSEMA4A-636 or -567 respectively at day 16 compared to day 4. For both NCI-H929 and
K562 there was no effect of the non-targeting control (1.17 ± 0.049 and 1.071 ± 0.017 for
NCI-H929 and K562 respectively), whilst there was a modest loss of GFP+ cells in MM.1S
(0.716 ± 0.045) (fig 5.20C, n=3).
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Overall these results suggested that loss of SEMA4A conferred a competitive disadvan-
tage and that SEMA4A may play an essential role within myeloma cell biology. This loss of
fitness appeared to be at least partly mediated through loss of viability, with an increased
proportion of dead cells amongst the GFP+ population for both NCI-H929 and MM.1S
compared to the shLUC control as determined by flow cytometry (fig 5.21, n=1).
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Fig. 5.20 RNAi mediated knockdown of SEMA4A in HMCLs is associated with a competitive
disadvantage. A SEMA4A expression by flow cytometry at 52 and 80 days post viral
transduction for the four hairpins in antibiotic selection. B RNAi mediated knockdown
competition assay. NCI-H929, MM.1S and K562 were lentivirally transduced with two
SEMA4A hairpins or a control shRNA targeting luciferase. Representative histograms
showing SEMA4A expression by flow cytometry at day 8 in both the GFP+ and GFP−
populations. C The proportion of GFP+ cells was monitored over time by flow cytometry
and compared to the proportion of GFP+ cells present at day 4 post transduction (mean ±
SD, n=3).
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Fig. 5.21 RNAi mediated knockdown of SEMA4A in HMCLs is associated with a decrease
in cell viability RNAi mediated knockdown competition assay. NCI-H929, MM.1S and
K562 were lentivirally transduced with two SEMA4A hairpins or a control shRNA targeting
luciferase. GFP+ cell viability was analysed by flow cytometry using 7-AAD to discriminate
between live and dead cells over the timecourse of the competition assay.
5.2.8 Rescue of SEMA4A expression does not restore cell fitness
I next investigated whether re-expression of SEMA4A could restore cell fitness in SEMA4A
shRNA-expressing cells. I generated two bi-cistronic vectors, expressing either the wild-type
(WT) (pLenti6.2_hSEMA4A(wt)) or truncated SEMA4A (pLenti6.2_hSEMA4A∆C) and
a fluorescent reporter (blue fluorescent protein (BFP)) separated by a small T2A peptide
sequence. This truncated mutant lacks the intracellular domain, which has been shown by
Sun et al to be required for signal transduction [327]. These two constructs were designed to
investigate whether a) over-expression of the wild-type SEMA4A was sufficient to reverse the
observed phenotype and therefore that the shRNA effect was target-specific and b) whether
SEMA4A was acting as a receptor with intracellular domain-mediated signalling in myeloma
cells.
NCI-H929 and MM.1S were stably transduced with either the WT or mutant (SEMA4A∆C)
over-expression vectors or the empty parental vector (pLenti6.2/V5) before transduction
with a SEMA4A- or luciferase-shRNA vector. The SEMA4A shRNA used for this experi-
ment was shSEMA4A-636, which targets the three prime untranslated region (3’-UTR) and
therefore does not target the exogenous SEMA4A. As with the competition assay described
above, the proportion of GFP+ cells was monitored by flow cytometry over time. As seen
in figure 5.22A, both constructs restored SEMA4A expression at the cell surface following
knock-down. Although both constructs were expressed at a high level in both cell lines,
SEMA4A expression was only completely restored to the endogenous levels in NCI-H929.
The MFI ratio of endogenous SEMA4A in pLenti6.2/V5 expressing GFP− NCI-H929 cells
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was 86.6 ± 1.1 compared to 123.3 ± 10.22 for the mutant-expressing GFP+ cells and 163.0
± 16.02 (SD) for WT-expressing GFP+ cells. For MM.1S both WT (MFI ratio of 190.9
± 45.96 (SD)) and mutant SEMA4A (80.38 ± 8.95) were expressed at a lower level than
endogenous SEMA4A (227.4 ± 7.51) in the cells transduced with the empty parental vector.
I expected rescue of WT SEMA4A expression at the cell surface would prevent the loss of
GFP+ cells. Contrary to this, I did not observe any differences between the three constructs
and all of the groups exhibited a competitive disadvantage following hairpin transduction
compared to their non-hairpin expressing counterparts (GFP−) (fig 5.22B, n=2).
To generate the bi-cistronic vector, I used the T2A peptide sequence to mediate ’cleavage’
between our SEMA4A construct and the fluorescent reporter. This ’cleavage’ is mediated
by a ribosomal skip mechanism [334]. One consideration in using this method is that the
T2A peptide sequence may be insufficiently ’cleaved’, resulting in a SEMA4A-BFP fusion
construct that may interfere with signal transduction [334]. Although I had confirmed that
T2A was efficiently cleaved in 293T when initially generating the constructs, 2A ’cleavage’
is cell-type dependent [335] and I therefore hypothesised that the failure of the rescue of
the phenotype may be caused by insufficient T2A cleavage. Analysis of NCI-H929 lysates
by Western Blot revealed that a large proportion of the mutant SEMA4A was insufficiently
cleaved (fig 5.23). For both cell lines, however, WT SEMA4A appeared to be efficiently
cleaved from BFP.
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Fig. 5.22 Rescue of SEMA4A expression does not revert competitive disadvantage following
RNA-mediated loss of endogenous SEMA4A A RNAi mediated knock-down competition
assay. Empty vector (pLenti6.2/V5), SEMA4A WT or mutant (∆C) transduced NCI-H929
and MM.1S were lentivirally transduced with shSEMA4A-636 or a control shRNA targeting
luciferase. Representative histograms showing SEMA4A expression by flow cytometry
at day 8 in both the GFP+ and GFP− populations. B The proportion of GFP+ cells was
monitored over time by flow cytometry and compared to the proportion of GFP+ cells present
at day 4 post transduction (mean ± SD, n=3).
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Fig. 5.23 WT and mutant SEMA4A expression by Western Blot. Expression of the three
constructs (pLenti6.2/V5, hSEMA4A∆C and hSEMA4A(WT)) was analysed by Western
Blot to assess the efficiency of the T2A cleavage.
Another hypothesis for the failure of the rescue experiment was that the prolonged
over-expression of the rescue constructs prior to knockdown had a detrimental effect on
cell growth. As a result, the cells may have down-regulated the expression of downstream
signalling molecules, preventing the reversal of the competitive disadvantage. I therefore
next investigated whether the simultaneous expression of the rescue constructs and the
SEMA4A-targeting hairpins could prevent the loss of cell fitness observed previously (sec-
tion 5.2.7). MM.1S were stably transduced with one of two doxycyline-inducible hairpin
constructs (pLKO.1_TET _shLUC or pLKO.1_TET _shSEMA4A-636). Following antibiotic
selection, cells were lentivirally transduced with either the WT or mutant (SEMA4A∆C)
over-expression vectors or the empty parental vector (pLenti6.2/V5). Hairpin expression was
subsequently induced by the addition of doxycyline (1µg/ml) to the cell culture media and
the total cell counts were measured at days 7 and 14 by flow cytometry.
As seen in figure 5.24A both of the over-expression constructs restored SEMA4A ex-
pression at the cell surface following knockdown of endogenous SEMA4A (shSEMA4A-
636 +Dox). Although expression of the mutant construct was similar to endogenous
SEMA4A (MFI ratio of 169.3 for MM1S_shSEMA4A-636 + hSEMA4A∆C versus 193.6
for MM1S_shLUC + pLenti6.2/V5), expression of the WT SEMA4A was much greater
(MFI ratio of 646.8 for MM1S_shSEMA4A-636 + hSEMA4A(WT)). Despite rescue of cell
surface expression, neither WT nor mutant SEMA4A could restore cell fitness. Instead, both
constructs appeared to be highly cytotoxic, with a clear detrimental effect on cell growth
that was independent of endogenous SEMA4A knockdown (fig 5.24B and C). As a result, I
was unable to conclude that the observed hairpin effects were target-specific and as such the
essentiality of SEMA4A remains unclear.
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Fig. 5.24 Expression of exogenous SEMA4A is highly detrimental to cell growth.
A pLKO.1_TET _shLUC or shSEMA4A-636 expressing MM.1S cells were lentivirally
transduced with either an empty vector (V5), WT SEMA4A (WT) or mutant SEMA4A (∆C).
24 hours later, hairpin expression was induced with the addition of 1µg/ml doxycycline to
the cell culture media (+Dox). SEMA4A expression at days 7 and 14 was measured by flow
cytometry and expressed as the MFI ratio over the isotype control. B The total number of
cells in culture was determined by flow cytometry using fluorescent microbeads at day 7 C
and day 14. n=1.
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5.3 Chapter conclusions
Having identified a list of 16 potential monoclonal antibody targets, the aim of this chapter
was to further characterise these targets in order to identify a lead candidate. With an
interest in generating an ADC, I focussed on identifying a therapeutic target that was both
highly expressed on malignant plasma cells relative to other normal tissue and also rapidly
internalised to deliver a cytotoxic payload. From these investigations I identified SEMA4A
as a promising novel ADC target for the treatment of multiple myeloma.
5.3.1 Identification of a lead candidate
Multiple myeloma is a highly heterogenous disease, both at the inter-patient level but also
within the tumour, with numerous subclones present at all stages of disease [21]. Although I
had identified a number of potential targets by PMP, the number of samples profiled was rela-
tively small (n=8). The first aim of this chapter was to therefore characterise target expression
in a larger cohort of myeloma patients and to compare expression between malignant plasma
cells and other normal hematopoietic cells. This would enable us to not only determine if the
target is most highly expressed by plasma cells amongst all normal tissue but also if any of
the target antigens were restricted to a particular subclone.
The characterisation of some targets was hampered by the lack of commercially available
FCM antibodies, such as was the case for BTN2A1, EPHB2, LRRC8C, LRRC8D and PTRPG
for which there were no flow cytometry antibodies available. For PLXNA1 and PLXNC1,
the three antibodies tested exhibited weak target binding that was likely to be non-specific
(fig 5.1A) and so were determined to be unsuitable for target characterisation. In the case of
PLXNC1, it was confirmed that the poor correlation between flow cytometry and PMP was
not caused by a change in target expression by analysis of mRNA expression (fig 5.1B). Three
targets had suitable antibodies available but were not tested (ADAM17, EVI2B and ROR2).
Following patient sample analysis by flow cytometry, CD97 and SEMA4D expression was
determined to be similar or greater in normal leukocytes compared to malignant plasma cells
in the majority of samples (fig 5.2 and 5.5). One of the critical factors in target selection for
an ADC is tumour over-expression relative to other, normal tissue, reducing the likelihood of
off-tumour toxicities [336] and any potential ’sink’ effects [311]. For these reasons, I did not
pursue the two candidates which exhibited high levels of off-tumour expression.
Two of the potential targets (NEO1 and ROBO1) exhibited highly restricted plasma cell
expression, with minimal to no expression in other immune cell subsets (fig 5.3 and 5.4).
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Although ROBO1 expression in primary samples was low both by PMP and flow cytometry,
because of the clean target expression profile amongst leukocyte subsets by flow cytometry
and other normal tissue by mass spectrometry I further pursued this antigen as a potential
therapeutic target. Both ROBO1 and NEO1 appeared to be internalised by flow cytometry,
another critical factor for the development of an ADC, but did not induce cell death when
linked to a cytotoxic compound (fig 5.11). This may be explained by several reasons. The
most likely hypothesis for ROBO1 is that because the antibody used in this study exhibited
very weak binding, very few antibody-toxin conjugates were taken up by the cell, which
would have resulted in minimal cell death. Alternatively, the target antigen may not have been
internalised but was instead lost at the cell surface through other means, such as cleavage. A
third hypothesis is that the antigen-antibody complex was internalised but failed to traffic to
a suitable intracellular location. Finally, the secondary antibody itself may have dissociated
from the primary antibody or inhibited internalisation of the antigen-antibody complex. As
ADC internalisation is highly dependent on the properties of a specific antibody clone, the
failure of one clone to induce cell death does not discount a plasma membrane protein as an
ADC candidate and NEO1 still remains of interest. ROBO1, however, was discontinued as
a potential target following re-evaluation of target expression in both primary samples and
HMCLs in conjunction with the failure to induce cell death.
5.3.2 SEMA4A as an ADC candidate
By flow cytometry analysis, SEMA4A expression was highest in plasma cells in the majority
of samples. Although there was relatively high expression on monocytes and granulo-
cytes, there was no discernible expression on B cells and low to minimal expression on T
lymphocytes, protecting the adaptive immune system from any on-target cytotoxic effects.
Importantly, SEMA4A was not highly expressed on CD34+ stem cells (fig 5.7C). Therefore,
if there were any ADC-related toxicities to the SEMA4Apos haematopoeitic cells, these
pluripotent stem cells would be able to reconstitute the bone marrow. For one of the patients
profiled by PMP, I was able to obtain a second BMA sample two years later. Flow-cytometric
analysis of this sample suggested that SEMA4A expression was relatively unchanged over
the course of disease progression. This was consistent with our observations in the flow
cytometry profiling of samples with no notable difference in the mean expression at diagnosis
compared with relapse and progression (fig 5.6). IHC revealed that SEMA4A exhibited
clean off-tumour expression with no detectable expression in normal, healthy tissue except
within the lymph node and tonsil. From this, it was concluded that SEMA4A was most
likely restricted to immune cell populations (fig 5.13B). Although SEMA4A mutations have
been reported to be involved in retinitis pigmentosa, a genetic disease associated with loss
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of vision, I was unable to detect cell surface SEMA4A expression in the RPE-1 cell line.
This is in accordance with other published reports that suggest that under normal conditions,
SEMA4A in RPE cells is localised intracellularly and under oxidative stress is secreted via
exosomal release [324]. As expected, these cells were unaffected by a SEMA4A-targeted
ADC (fig 5.14).
Similarly to NEO1 and ROBO1, SEMA4A was rapidly internalised following antigen
binding, with 50% loss of cell surface SEMA4A over two hours. Importantly the antibody-
antigen complex was not recycled back to the cell surface (fig 5.9). Antigen internalisation
was confirmed by immunofluorescence and the antigen-Ig complex appeared to be partially
localised with LAMP-1 positive lysosomes (fig 5.10) suggesting that the internalised antibody
is trafficked to the lysosome. This is considered to be an ideal subcellular localisation for
ADCs as a number of cytotoxin linkers rely on either the acidic environment of the late
endosome/lysosome or lysosomal-specific proteases for degradation [247]. Using a ’piggy
back’ system, a SEMA4A-targeting antibody in conjunction with a saporin-linked secondary
antibody induced extensive cell death (47 to 56% over 72 hours) in two antigen-expressing
cell lines. Importantly, a third cell line that did not express SEMA4A was unaffected (fig
5.12).
Having characterised SEMA4A as a promising target in vitro, the next aim of this chapter
was to investigate the potential of SEMA4A as an ADC candidate in vivo. Whilst the use of
a ’piggy back’ system enables the rapid screening of antibody clones in vitro for preliminary
proof of principle, there are several disadvantages to this system [337] and I was unable to
achieve greater than 56% loss of viability in NCI-H929 and MM.1S (at 1nM) using either
the Fab-ZAP or Strep-ZAP kit. This was likely because I was unable to increase the primary
antibody concentration above 1nM as the ratio of unbound primary antibody began to out-
compete secondary-bound-primary antibody for SEMA4A. Saporin is also not used clinically
and so in order to have greater understanding of the properties of a lead SEMA4A-targeting
ADC, I opted for a directly conjugated ADC to evaluate activity in vivo. Using the direct
conjugates, I was able to test the antibody at a higher dose and achieved greater maximal
cell death (66 to 92% cell death at 0.1nM in MM.1S and NCI-H929 respectively) (fig 5.18).
As 5E3-MMAE was more potent in vitro and did not appear to exhibit any non-specific
activity, I decided to proceed with this conjugate. In vivo 5E3-MMAE showed promising
anti-tumour activity with an initial reduction in tumour burden during dosing and overall
significantly improved survival for treated mice compared with both control groups (fig 5.19).
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Finally, I have begun to investigate the role of SEMA4A in myeloma cell biology.
An initial stable RNAi-mediated knock-down experiment suggested that loss of SEMA4A
may be detrimental to HMCL fitness with the emergence of a SEMA4Apos population (fig
5.20A). A competitive disadvantage following loss of SEMA4A in SEMA4Ahi cell lines was
confirmed using a competition assay, in which I observed the rapid decline in proportion
of SEMA4A-hairpin expressing cells compared to shLUC expressing cells (fig 5.20C) that
was associated with an increase in cell death (fig 5.21). To confirm that this observed
phenotype was not the result of a hairpin off-target effect, I performed a rescue experiment
in which endogenous SEMA4A was knocked-out and shRNA-resistant wild-type or mutant
(intracellular domain deficient) SEMA4A re-expressed. Unexpectedly, I failed to observe
a reversion of the competitive disadvantage following rescue of SEMA4A expression (fig
5.22). This was unlikely to be due to insufficient rescue of expression (fig 5.22B) or cleavage
of the BFP reporter (fig 5.23). Instead, the failure to reverse the observed phenotype may be
due to the apparent toxicity of the rescue constructs, with both WT and mutant SEMA4A
having a detrimental effect on cell growth (fig 5.24B and C). From these experiments, I was
unable to conclude that SEMA4A plays an essential role in myeloma biology.
Chapter 6
Discussion and Future Perspectives
Despite the recent improvements in patient survival due to novel therapeutics, it is still largely
considered that myeloma is incurable, and patients will eventually relapse. Recently, the
focus of future myeloma treatment has shifted towards more targeted therapeutics, such
as monoclonal antibodies. These antibodies are a promising strategy for the treatment of
malignancies and have demonstrated significant successes in a wide range of both solid and
haematological cancers. Although there are a few proteins that have been well characterised
as potential targets, it is likely that there are many more novel targets that have not yet been
identified due to the limitations of currently available techniques. These limitations include
their low abundance, the difficulty in isolating these proteins from the membrane and the
limited availability of antibodies for characterisation. The overall aim of this thesis was to
use PMP to identify a novel antibody drug conjugate target for the treatment of myeloma.
6.1 The myeloma cell surface proteome
The first aim of this thesis was to characterise the myeloma cell surface proteome using PMP.
Although this technique has been used successfully in the past on cell lines [288][338], our
initial concerns were that the mildly acidic conditions required for PMP would be highly
detrimental to the viability of the fragile myeloma cells ex vivo. Despite the challenges faced
in obtaining a sufficient number of patient samples, I observed no technical difficulties apply-
ing this technique to primary myeloma cells. Using PMP, I quantified a total of 2,714 proteins
across the 18 samples, 2,077 of which were identified by two or more unique peptides (fig
3.8). Of these proteins, 1,319 were determined to be plasma membrane proteins using a
combination of gene ontology and UniProt annotations (79.5% enrichment as determined
by protein abundance). 488 had an extracellular domain and therefore represented potential
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monoclonal antibody targets of interest. Although I have tried to be as inclusive as possible
using both the GOCC and UniProt databases for protein annotations, it is highly possible
that there are several plasma membrane proteins missed. As discussed in the introduction,
membrane proteomics has been traditionally challenging, and the number of plasma mem-
brane proteins identified have been both small and highly variable. Using PMP, I was able
to consistently achieve a high level of enrichment over both cell lines and primary samples.
Although several MS analyses have been undertaken in myeloma, the number of plasma
membrane proteins identified has been typically low, and few have been quantitative. Dytfeld
et al [299][261] also used isobaric tags for mass spectrometry multiplex analysis of primary
samples, quantifying 399 to 944 total proteins across several studies. However, Dytfeld et al
did not enrich for the PM, and it is highly possible that less than 15% of these proteins are
plasma membrane proteins [284]. Whilst Xie et al [339] did enrich for the plasma membrane,
using biotin for affinity-purification, they only reported the identification of 156 proteins
using two cell lines. Using a similar technique, Zhao et al reported the identification of
663 plasma membrane proteins in a human lung epithelial cell, but this was not quantitative
[286]. The results presented in this thesis, therefore, represent the first quantitative analysis
of the whole myeloma cell surface proteome, providing a substantial improvement over
other published reports (including studies undertaken in other cell types), both in terms
of the enrichment and in the total numbers of plasma membrane proteins identified and
quantified. This dataset represents an invaluable tool to aiding target discovery, as well as
our understanding of myeloma cell biology.
However, it should be noted that there are a few caveats to this dataset. Firstly, although
the majority of cell surface proteins are predicted to be glycosylated, not all are [279], and
these may have been excluded from our dataset. Secondly, although I was able to select HM-
CLs that represent the majority of the genetic events that occur in myeloma, because nearly
all cell lines are of the non-hyperdiploid subgroup, the hyperdiploid group (which comprises
nearly half of the myeloma cell population) is not represented at all in our HMCL PMP.
Conversely, thus far, only one of the patients profiled by PMP exhibits an IgH rearrangement
by FISH analysis (6 out of 8 analysed to date). Finally, because of the difficulties in obtaining
healthy, age-matched BMAs or sufficient PC numbers from the in vitro differentiation of B
cells, I was unable to profile normal plasma cells. Although I concluded that this would not
hinder target discovery significantly, it may limit the identification of biomarkers that are
associated with plasma cell transformation or disease progression. In lieu of this, I have used
the extensively characterised HMCLs to identify proteins that are associated with high-risk
cytogenetics and may be involved in driving the disease. By comparing protein expression
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between subgroups, I identified 11 proteins associated with del(17p)/TP53 mutations, includ-
ing VAV1. Interestingly, VAV1 was reported as playing a dual pro- and anti-apoptotic role
that was dependent on p53 availability and it may be possible there is a feedback loop for this
protein [340]. I also observed several proteins linked with the t(11;14) subgroup, including
ENTPD1 (p=7e-6, q=0.0072, fig 3.13) which was validated in a larger sample of HMCLs
by RNA expression analysis. Overall though, the total number of proteins associated with
underlying genetic perturbations was low, most likely as a result of the limited number of
samples for each subgroup. For seven out of the eight patients profiled by PMP we have
banked CD138+ cells and it is hoped it will be possible to use these for gene expression
profiling. Using this additional data, it will be possible to expand the number of samples
within each sub-type and enable the identification of other plasma membrane proteins asso-
ciated with high-risk cytogenetics. These proteins not only represent potential biomarkers
for high-risk that are more accessible than FISH analysis or GEP but may help elucidate the
downstream sequelae of common genetic events.
Interestingly, although I failed to identify any proteins significantly associated with the
t(4;14) subgroup, using unsupervised clustering I identified a clear t(4;14) plasma membrane
protein signature (fig 3.16). Meanwhile, the t(11;14) and t(MAF) subgroups were less well
defined, possible because these subgroups were smaller (only 1 sample for t(14;20)) but
also because cyclin D and c-Maf are frequently dysregulated in a translocation-independent
manner [34][35]. Aside from subtype, I also observed a clear contrast between HMCLs
and primary samples, with upwards of 500 proteins identified as significantly differentially
expressed with a FDR of 0.01% (fig 3.18). This was not entirely unexpected. Although
these cells recapitulate the major mutational events in myeloma, they represent advanced
relapsed/refractory disease and are highly proliferative in comparison to their primary coun-
terparts, as shown by the gene enrichment analysis performed (fig 3.18). Furthermore, as
discussed, cell lines are typically non-hyperdiploid and represent those patients with a poorer
prognosis. Whilst this doesn’t detract from using HMCLs as a model for myeloma, it should
be noted that there are limitations to using these cell lines for target discovery. This was
highlighted by ROBO1 and EPHB2, both of which were predicted to be highly expressed
in myeloma by the HMCL PMP. Subsequent analysis of patient samples revealed that these
were in fact not so highly expressed in primary disease.
One of the predominant arguments for the use of proteomic profiling over RNA analysis
is the poor correlation between transcript and protein levels. As anticipated, I observed a
very poor correlation between RNA and protein abundance across the ten cell lines (ranging
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from 0.13 to 0.21 across all proteins, (fig 3.12)), corresponding with what has been reported
previously [258]. However, both Wilhelm and Edfors [302][305] have recently proposed
that although the RNA translation and protein degradation rates may vary greatly between
different transcripts, these factors remain surprisingly constant for any given protein across
multiple tissue types. Therefore, using a RNA-to-protein (RTP) conversion factor, the abun-
dance of any protein can be predicted from transcript expression. Using a training set of
nine of the ten HMCLs, I determined a RTP factor for each protein quantified by PMP and
demonstrated that this factor could accurately predict the abundance of any given protein in
the tenth HMCL using only RNAseq data (Pearson correlation coefficient of 0.78 to 0.89,
fig 3.12). Using a combination of our results obtainined by PMP and the publicly available
RNAseq dataset, I have determined a RTP conversion factor for over 2,000 proteins.
Whilst mass spectrometry analysis has provided substantial insight into our understand-
ing of the myeloma cell proteome, these techniques are still limited by both the associated
prohibitive costs and the large number of cells required per analysis. Comparatively, next
generation sequencing is not only cheaper but also requires considerably fewer cells and is
better suited for high-throughput analysis. During this project, one of the challenges faced
was obtaining a suitable number of CD138+ cells for PMP analysis and many samples were
discarded because of low cell counts. Although it would be imperative to first validate these
values, it would be possible to use a combination of RNAseq data and the RTP ratios to
analyse the cell surface proteome of a much greater cohort of patient samples in an unbiased
and comprehensive manner. These low CD138+ samples are also likely to be of considerable
interest, representing MGUS, SMM or early-stage myeloma patients with low infiltration and
those patients that have recently undergone treatment but have retained a small population
of therapeutic-resistant cells. In addition, it would be possible to profile the cell surface
proteome of normal plasma cells, enabling the identification of proteins involved in plasma
cell transformation. Furthermore, myeloma is a highly heterogenous sub-clonal disease.
Because of the large sample size requirements, analysis by mass spectrometry only informs
us of the population-average and subsequent studies are required to determine sub-clonal
protein expression. Single-cell proteomic techniques are beginning to emerge but are still
very much in their infancy. Although, Budnik recently reported the mass spectrometry-based
profiling of a single cell [341], the majority of single-cell techniques rely on antibodies to
target specific proteins and are limited to the detection of tens to hundreds of proteins [342].
In comparison, single cell RNA sequencing (scRNAseq) is now a well-established technique
and is comparatively low-cost. In combination with the RTP factor, scRNAseq could be used
to accurately predict the myeloma cell surface proteome on a sub-clonal scale. This would
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enable us to track the clonal evolution of the tumour over the course of the disease and to
identify biomarkers associated with the drug-resistant minor sub-clones.
Aside from profiling the myeloma tumour on a sub-clonal and high-throughput scale, the
calculated RTP factors could be used to characterise the plasma membrane proteome in other
cell types. Although I was initially interested in using the in vitro plasma cell differentiation
protocol to generate normal controls for our study, I also considered the possibility of using
PMP to quantify cell surface protein expression changes during plasma cell differentiation.
However, as discussed, the low cell counts associated with this protocol meant I did not
proceed with this. Using our calculated RTP ratios, it would now be possible to predict
protein abundance from transcript levels using much fewer cells. This would provide further
insight into plasma cell generation, which to our knowledge has not yet been performed on a
proteomic scale (excluding one study which used cell lines to represent different stages of
plasma cell differentiation [343]). This may also help elucidate the mechanisms involved
in determining the longevity of a plasma cell. In addition, because the RTP factor has
been shown to be considerably stable over multiple tissue types [305], this may allow the
direct comparison of off-tumour expression between targets instead of relying on whole-cell
proteomic data, which although useful for this study, is limited by the low number of proteins
and tissue types profiled.
Overall, I have profiled a total of 18 samples and consider that this dataset provides
us with a comprehensive analysis of the myeloma cell surface proteome. The fact that
only a few changes occurred between the first and second PMP of the two cell lines (fig
3.10), which were profiled more than a year apart, and that I was able to correlate this
data with flow cytometry (fig 3.11), suggests that this data can be considered to be highly
representative of the cell surface proteome. Through the combined analysis of our PMP
dataset and other whole-cell proteomic databases, I identified 20 plasma membrane proteins
that represented potential monoclonal antibody targets, four of which had already been
described as therapeutic targets for myeloma (table 3.5). This approach also identified the
two monoclonal antibody targets currently FDA approved for the treatment of myeloma
(CD38 and SLAMF7), giving us confidence in this technique and our analytical approach.
Several of these top hits were proteins that have already been identified in other malignancies,
both solid and haematological. CD97, for instance, has been shown to promote the migration
and invasiveness of hepatocellular carcinoma [344]. While EPHB2 is associated with a poor
prognosis in breast cancer [345] and ROBO1 has been reported to be promote the prolifer-
ation and survival of osteosarcoma [346]. Interestingly, the SLIT2/ROBO1 axis has been
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implicated in the inhibition of osteoblast differentiation and was identified in two separate
studies as a candidate gene in myeloma, associated with a t(4;14) subgroup and mutated in 5
out of 67 patients [22][347]. NEO1 dysregulation has been reported in a number of human
tumours, including glioma, medulloblastoma, breast cancer, cervix cancer, pancreas cancer
and colorectal [348]. Other proteins have been associated with regulation of the immune
system and may promote tumour evasion, including BTN2A1 which has been identified as
a ligand for dendritic cells [349] and ADAM17 which may be involved in the shedding of
immune-regulating proteins, such as MICA [350].
6.2 Recombinant protein production and purification of
remaining targets
As it was anticipated that not all of our candidate proteins would have reliable antibodies
available, the second aim of this thesis was to establish a recombinant protein mammalian ex-
pression system. This would enable the production of the protein required for the generation
of key, proprietary antibodies for target validation but also for any potential lead candidates
to take forward into pre-clinical testing. Thus far, I have successfully cloned five proteins
and purified three to homogeneity. Despite successfully cloning and expressing full-length
SEMA4A in both HEK-293T and HMCLs (fig 5.23), I experienced difficulties expressing
high levels of truncated SEMA4A in the cell culture media (fig 4.7). This is likely due to
the compositional instability of this construct, which may improve with the addition of a
stabilising tag. Alternatively, as I plan to use this recombinant protein for phage-display, it
may be simpler to use target-expressing cell lines instead of purified protein.
6.3 SEMA4A as a novel myeloma target
From our list of 16 novel targets, I was only able to characterise a few because of the limited
availability and reliability of commercial antibodies. Of those that were characterised, only
three exhibited comparatively higher expression on myeloma cells and were assessed as
ADCs.
Although naked antibodies have demonstrated clinical success, these antibodies are fre-
quently used in combination with chemotherapy to achieve therapeutic efficacy. Elotuzumab,
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for instance, fails to demonstrate any single agent activity but does act synergistically with
lenalidomide and dexamethasone to significantly improve both progression-free and overall
survival [241]. ADCs, which combine the specificity of unconjugated antibodies with the
cytotoxicity of chemotherapeutics, are becoming increasingly popular. Out of the three pro-
teins I assessed, SEMA4A, which met the ideal properties of an ADC target, was identified
as a lead candidate. By flow cytometry, SEMA4A was determined to be highly expressed
in nearly all patient samples and did not appear to be expressed outside of the lymphoid
organs by IHC (fig 5.13). Furthermore, following antibody binding, SEMA4A was rapidly
internalised to deliver a cytotoxic agent in a target-specific manner (fig 5.12). Although
SEMA4A mutations are associated with retinitis pigmentosa, I did not observe any expression
on RPE-1 cells, despite the addition of oxidative stress (fig 5.14). Notably, I did observe
SEMA4A expression on monocytes and granulocytes and a small subset of T cells, although
in nearly all cases SEMA4A expression was greater on myeloma cells (fig 5.7). ADC toxicity
is directly proportional to target expression. The higher the expression, the more ADC can
be internalised to deliver the toxin. Only the highest SEMA4A-expressing cell lines were
sensitive to 5E3-MMAE (fig 5.18). Based on our observations with BM068, which showed
similar expression to KMS-12-BM, I would expect monocyte and granulocyte expression
levels to be comparable to the cell lines in which I did not observe any ADC cytotoxic
activity. Of course this is highly dependent on the sensitivity of the cell type to the conjugated
toxin and it may be that similar to alemtuzumab [351], a naked antibody for the treatment of
chronic lymphocytic leukaemia, a prophylactic antibiotic will be necessary with this antibody.
Importantly, I observed minimal SEMA4A expression on CD34+ cells and therefore, if there
were any ADC-related toxicities to the SEMA4Apos haematopoeitic cells, these pluripotent
stem cells would be left untouched and would be able to reconstitute the bone marrow. CD46
was recently reported as a potential ADC target for myeloma [223]. Similar to SEMA4A,
they observed notable expression on monocytes and granulocytes. Reassuringly, they ob-
served no off-tumour toxicity within the haematopoietic compartment, and this target is now
set to enter human clinical trials in spring 2019 (NCT03650491, [221]).
Having confirmed the selective and potent activity of the SEMA4A-ADC in vitro, I
also tested 5E3-MMAE activity in vivo in an orthometastatic xenograft model. NSG mice
bearing luciferase-expressing MM.1S tumours received one of three treatments: 5E3-MMAE,
isotype control (mIgG1-MMAE) or the unconjugated antibody (5E3) for a total of four doses
at 4mg/kg (i.v.). 5E3-MMAE demonstrated potent activity in vivo, with a near-complete
elimination of bioluminescence activity during treatment, although all mice did subsequently
relapse and eventually succumb to disease. This delay in tumour growth translated to a
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significant improvement in survival for all 5E3-MMAE treated mice over the control groups.
These results are highly promising and demonstrate the potential for a SEMA4A-targeting
antibody for the treatment of myeloma. As the mice used in this study are immune-deficient,
the effects of a SEMA4A-targeting ADC on the haematopoeitic compartment is currently
unknown. As such, a future tolerability study in immunocompetent mice is planned. Because
5E3 exhibits cross-reactivity, targeting both human and murine SEMA4A, this will enable us
to assess any off-tumour target-specific toxicity, such as on monocytes and granulocytes as
well as on retinal tissue.
Interestingly, SEMA4A is located at 1q22, within the predicted minimally amplified
region for gain 1q. It would be of considerable interest to determine if myeloma cells with
dup(1q), a poor prognostic marker associated with relapsed/refractory disease, also exhibit
SEMA4A gene amplification. As the 1q amplification is routinely assessed by FISH during
patient diagnosis, this would prove an invaluable marker for patient stratification and per-
sonalised medicine. Although I have the FISH results for six of the eight patients profiled
by PMP confirming dup(1q), I do not have exact copy numbers and have not yet been able
to determine a correlation between copy number gains and SEMA4A expression, although
the highest expressing patient sample by PMP was positive for 1q amplification. There are a
few datasets available, including the CoMMpass Study (https://research.themmrf.org), which
would enable us to correlate 1q gains with SEMA4A gene amplification in a much larger
cohort than our eight samples.
Several reports have suggested that monoclonal antibody resistance can in part be me-
diated through target downregulation, as is seen for both rituximab (CD20) in B lymphoid
malignancies and daratumumab (CD38) for myeloma [328][329]. CD38 expression strongly
correlates with ADCC and CDC activity, and cell surface downregulation provides a mecha-
nism for tumour escape from immune-mediated killing. However, some patients with CD38
downregulation are still responders, and it has been hypothesised that loss of CD38 reduces
myeloma cell contact with the BM stromal cells and may contribute to reduced growth
and survival [329]. The report that SEMA4A can function as a receptor [327] led us to
hypothesise that dysregulated SEMA4A may contribute to myeloma cell biology and that
loss of this protein may not represent a viable mechanism of resistance.
RNA-interference (RNAi) is a frequently used method for RNA knock-down. However,
it can also be highly non-specific, and off-target effects are a common problem, requiring the
use of multiple targeting hairpins as well as control hairpins. Using two targeting hairpins, I
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observed that loss of SEMA4A conveyed a substantial competitive disadvantage and these
cells were rapidly lost in a co-culture with SEMA4A-expresssing cells. This effect appeared
to be target specific as I did not observe the same effect using a control hairpin (shLuciferase)
or in a third SEMA4Aneg cell line (K562) (fig 5.20). To further prove that these effects were
target-specific, I attempted a knockdown and rescue experiment, in which the endogenous
SEMA4A is knocked-down and exogenous, shRNA-resistant SEMA4A is re-introduced
to reverse the phenotype. Unfortunately, I was unable to reverse the competitive disadvan-
tage, with either mutant or WT SEMA4A and I was unable to conclude that the observed
phenotype was SEMA4A-specific (fig 5.22B). Although expression rescue experiments can
be considered the ultimate proof for an observed shRNA effect, these experiments are not
without limitations, including the challenges involved in expressing the correct level of
exogenous protein and the presence of splice variants. Datler et al were similarly unable
to reverse the observed phenotype following RNAi, despite using a total of 19 hairpins to
demonstrate that mitochondrial depolarisation only occurred in the presence of CKMT1 gene
silencing [352]. I confirmed that exogenous SEMA4A was expressed at the cell surface of
the rescue cells and although it was lower than endogenous SEMA4A for MM.1S, it was
similar for NCI-H929 and this is unlikely to be the reason behind the failure to rescue the
phenotype. I also demonstrated that at least the WT SEMA4A was completely cleaved from
the BFP reporter. However, following T2A cleavage, some additional residues are left on
the first protein [353]. The loss of as few as four amino acids from the termini of a receptor
can completely abolish receptor signalling [354] and it may be that these additional amino
acids interfered with correct protein folding and signal transduction. In addition, it can’t be
excluded that there is an un-described alternatively spliced transcript that is dissimilar to our
rescue constructs but is essential for myeloma cell survival.
Another possible reason for the failure of the rescue experiment was that the prolonged
over-expression of the rescue constructs prior to knockdown had a detrimental effect on
cell growth. To test this hypothesis, I used doxycycline-inducible hairpins to induce the
simultaneous knockdown of endogenous SEMA4A and over-expression of the WT or mutant
SEMA4A constructs. Following transduction, there was a substantial reduction in cell growth
for both the WT and mutant SEMA4A-expressing cells compared to the cells transduced
with the empty parental vector (fig 5.24). This observed effect was independent of hairpin
expression. The results of this experiment may explain why the initial knockdown and rescue
experiment failed and suggests that the over-expression of SEMA4A is highly toxic. Protein
over-expression may negatively impact cell viability and/or growth for several reasons. One
reason is that the over-expression of protein overwhelms the cell with the high resource
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burden required for protein production. Alternatively, high expression of the protein may
modulate numerous signalling pathways, over-stimulating the normal physiological pathway
and promoting promiscuous interactions and sequestration of essential proteins [355]. As a
result, I am unable to conclude that the observed phenotype reported in this thesis is the result
of an on-target effect. As an alternative, I have begun to investigate a CRISPR/Cas9-mediated
knockout of SEMA4A which may help elucidate the essentiality of SEMAA in myeloma
cell lines.
6.4 Conclusion
• Using plasma membrane profiling to selectively enrich for an quantify cell surface
proteins, I have quantified over 1,300 plasma-membrane or associated proteins. This
represents a substantial improvement over other published studies, both in the total
number of identified membrane proteins but also in the number of cell surface pro-
teomes quantitatively analysed. From this unique dataset, I have identified 16 novel
myeloma therapeutic targets.
• I have established a recombinant protein production system that will enable us to
generate the tool antibodies necessary to validate these proteins and have successfully
purified protein for three of our candidates.
• From this dataset, I identified SEMA4A as a lead candidate based on a combination
of high on-tumour and low off-tumour expression. Furthermore, an ADC against
this target has been shown to be highly efficacious in high SEMA4A-expressing cell
lines both in vitro and in vivo. The work presented in this thesis supports further
investigation into SEMA4A as a novel target for the treatment of myeloma and to this
extent, we have established an ongoing collaboration with CMAL (Cancer Research
UK-Medimmune Alliance Laboratory).
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